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Abstract 
Background: Lung disease is a common complication of human immunodeficiency virus 
(HIV) infection in children and adolescents. As antiretroviral programmes have 
strengthened and HIV diagnosed earlier, survival of perinatally HIV-infected children has 
improved. Therefore, an increasing number of perinatally HIV-infected children are 
surviving into adolescence, with development of chronic multisystem disease including 
chronic lung disease (CLD). However, there is limited information on the determinants, 
spectrum and progression of lung disease. Lung function testing, an objective, non-invasive, 
reproducible tool, is useful in characterising CLD and in monitoring disease progression.  
Aim: To investigate the spectrum, determinants and progression of lung function in 
perinatally HIV-infected adolescents on antiretroviral therapy (ART) in Cape Town, South 
Africa. Specific objectives included describing the spectrum and determinants of lung 
function; investigating cardiopulmonary dysfunction and investigating progression of lung 
function over two years. 
Methods: The study population was from a prospective cohort, the Cape Town Adolescent 
Anti-retroviral cohort (CTAAC), that enrolled 515 perinatally HIV-infected adolescents on 
ART and 110 age-matched HIV-uninfected adolescents followed six-monthly for two years 
in Cape Town, South Africa. Eligibility criteria were adolescents, aged 9-14 years, with 
perinatally acquired HIV, who had been on ART for at least six months. Comprehensive lung 
function testing was done, and clinical and lung function data collected at baseline, 12 and 
24 months.  
Results: At baseline, HIV-infected adolescents had lower forced expiratory volume in 1 
second (FEV1), forced vital capacity (FVC), FEV1/FVC, diffusing capacity for carbon 
xiii 
 
monoxide, respiratory system compliance and functional residual capacity; and higher 
airway resistance and lung clearance index compared to HIV-uninfected adolescents, 
p<0.05 for all. At 24 months, FEV1 and FVC remained lower in the HIV-infected compared 
to the uninfected, p<0.05 and had similar growth-related change over time in both groups. 
Previous pulmonary tuberculosis (PTB) or severe lower respiratory tract infections (LRTI) 
was associated with reduced FEV1 and FVC, p<0.05 for both. Impaired cardiopulmonary 
function was detected in 13% of HIV-infected adolescents and 8% of HIV-uninfected 
adolescents, p=0.136. Past PTB was significantly associated with a low cardiopulmonary 
function, OR 2.3, 95%CI 1.2-4.4. 
Conclusion: Perinatally HIV-infected adolescents had lower lung function and higher 
resistance and ventilation inhomogeneity compared to age-matched HIV-uninfected 
adolescents at baseline. Lung function tracked, remaining lower at two years. Previous PTB 
or severe LRTI were predictors of lower lung function. Co-existent cardiopulmonary 
dysfunction occurred in a minority. 
These data highlight respiratory disease risk in this vulnerable group and may inform policy 
to strengthen strategies to prevent and manage HIV-associated lung or cardiopulmonary 
disease. 
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Four of the chapters (2–5) of this thesis are presented as published manuscripts.  
Chapter 1 encompasses an overview of the burden of HIV disease and the spectrum of HIV-
associated chronic lung disease in adolescents and the utility of lung function in the 
diagnosis of chronic lung disease. Study methodology is also detailed in this chapter. 
Chapter 2 (published manuscript) comprises a comprehensive review of published data on 
lung function (over and above the literature included in the individual papers) in HIV-
infected children and adolescents and summarises studies that have been done in Africa, 
USA, Europe and Asia.  
Chapter 3 (published manuscript) describes the spectrum and determinants of 
comprehensive lung function parameters (flow, volume, compliance, resistance, 
ventilation inhomogeneity) in perinatally HIV-infected adolescents with a comparator 
group of age-matched HIV-uninfected adolescents. 
Chapter 4 (published manuscript) further explores the prevalence and determinants of co-
existent cardiopulmonary dysfunction in perinatally HIV-infected adolescents on ART.  
Chapter 5 (published manuscript) describes the progressive changes in spirometry over 
two years in perinatally HIV-infected adolescents compared to HIV-uninfected age-
matched controls. It also addresses the associations of low lung function, factors amenable 
to public health interventions.  
Chapter 6 is a summary of the study findings and recommendations. 
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Chapter 1:  
1. Introduction 
1.1 HIV prevalence in children and adolescents  
In 2017, there were 36.9 million people living with HIV globally of which 1.8 million were 
children less than 15 years old. Among these children, 59% had access to antiretroviral therapy 
(ART). [1]  
There were 2.1 million adolescents aged 10-19 years living with HIV globally in 2017. Among 
40 countries with available data, only about 43% of adolescents aged 10-19 years living with 
HIV received ART in 2017. Of the 250 000 adolescents (ages 15-19 years) who were newly 
infected with HIV in 2017, 66% were female. [2]  
In Eastern and Southern Africa, there were 77 000 new HIV infections among children (<15 
years) in 2016. There has been a 56% reduction in new infections among children in this region 
since 2000. Fifty-one per cent of children less than 15 years were accessing ART in Eastern and 
Southern Africa. [3] Adolescent girls and women aged 15-24 years accounted for 25% of new 
HIV-infections in sub-Saharan Africa. 
In South Africa, 280 000 children, aged 0-14 years, were living with HIV, of which 58% were on 
ART in 2017. [4] There were 13 000 new infections and 8 600 deaths attributable to acquired 
immune deficiency syndrome (AIDS) among children aged 0-14 years. There were 1.3 million 
orphans, aged 0-17 years, as a result of AIDS in 2017. [4]  
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1.2 Chronic lung disease in HIV-infected children and adolescents 
With the more widespread availability of ART, HIV has now become a chronic disease. [5] The 
adolescent age group is among the most vulnerable to HIV in sub-Saharan Africa. [3] HIV 
chronic lung disease (CLD) is a common sequela of HIV infection. [6, 7] Diagnosis of CLD 
requires clinical, radiological, pulmonary function testing or histopathological diagnosis. The 
syndrome of chronic lung disease reported in HIV-infected adolescents includes irreversible 
airway obstruction, chronic respiratory symptoms and exercise intolerance.  
The spectrum of chronic lung disease is worse in adolescents where there was delayed 
initiation of ART, [8, 9] emphasising that early ART initiation is beneficial to mitigate the 
damage that HIV or opportunistic infections (OIs) have on the lung. 
1.2.1 Clinical spectrum of chronic lung disease 
In 116 adolescents with vertically transmitted HIV in Zimbabwe (69% on ART), Ferrand et al. 
[10] reported 66% had chronic respiratory symptoms and 55% with non-tuberculous chronic 
lung disease had chest computed tomography scan findings of bronchiolitis obliterans.  
Chronic lung disease was reported to be more prevalent in HIV-infected than HIV-uninfected 
children (71% vs 27%) in a cohort of 194 children who had respiratory symptoms persisting for 
more than one month. [11] In a subset of 42 patients who underwent invasive investigation 
for CLD, Jeena et al. [11] reported lymphocytic interstitial pneumonitis in 57%, tuberculosis in 
29% and non-specific interstitial pneumonitis in 14%. Tuberculosis (TB), diagnosed by 
histology, was common in a cohort of HIV-infected children in South Africa with chronic 
respiratory symptoms and significant peripheral lymphadenopathy. [12] This was also found 
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in a Zimbabwe cohort of 32 older children and adolescents with delayed HIV diagnosis where 
Ferrand et al. [13] reported 59% had TB.  
Increased asthma prevalence in a cohort of HIV-infected children on ART has been reported. 
[14] The diagnosis of asthma was, however, based on the use of asthma medication which may 
have led to overdiagnosis, as asthma medications are commonly used for symptom relief in 
HIV-related chronic lung disease. Shearer [15] reported a higher rate of bronchodilator 
reversibility in HIV-exposed uninfected youth compared to HIV-infected youth (17% vs 9%, 
p=0.05). Asthma symptoms and use of asthma medications and atopic dermatitis were also 
reported to be higher in HIV-infected children compared to HIV-exposed but uninfected 
children. [16] This may be due to the immune reconstitution of CD4 T cells which regulate the 
type II inflammatory pathway in asthma. 
The aetiology of CLD is broad, ranging from chronic infection to non-infective causes. With the 
advent of ART, the incidence of opportunistic infections has reduced substantially. [7] Further, 
Kaposi’s sarcoma, lymphocytic infectious pneumonia (LIP), Pneumocystis jirovecii pneumonia 
(PCP) infection have a markedly reduced incidence in the ART era. [17] Bronchiolitis obliterans 
on chest tomography scan (CT scan) has been identified as the commonest radiological 
manifestation in CLD in HIV-infected adolescents. [10, 18] 
1.2.2 Lung function abnormalities in chronic lung disease 
The spectrum of lung function abnormalities in HIV-related chronic lung disease may present 
as an obstructive pattern on spirometry (bronchiectasis, bronchiolitis obliterans), restrictive 
pattern (chronic PCP, tuberculosis, lymphocytic interstitial pneumonitis (LIP), bronchiectasis) 
or mixed obstructive-restrictive pattern due to combinations of these. Interstitial pneumonitis, 
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LIP, PCP are likely to lead to a reduced diffusion factor for carbon monoxide (DLCO), table 1. 
Diffusion abnormalities though rarely reported in this age group have been reported in 
younger children [19] who had a faster clearance of radiolabelled aerosol and the faster 
clearance correlated with chronic respiratory symptoms in older children. Other less reported 
lung function abnormalities include reduced lung compliance [20] and increased airway 
resistance in HIV-infected children. [21] 
Other clinical entities with non-specific lung function abnormalities that have been 
encountered in HIV-associated CLD include recurrent lower respiratory tract infections [9] and 
immune reconstitution inflammatory syndrome (IRIS). [7] Growth impairment in HIV-infected 
children (stunting or wasting) may also affect lung growth and lung function. 
There is scarce longitudinal lung function data in HIV-infected adolescents on ART. Possible 
reasons for decreased lung function and decline over time as shown in previous HIV-infected 
adult studies includes immune activation in HIV leading to alveolitis. [22] Opportunistic 
infections (OIs) like PCP or TB have been reported to cause a decline in FEV1, FVC and DLCO. 
[23, 24] HIV per se has been considered responsible for the decline in lung function after 
controlling for other respiratory infections. [25] Increased HIV viral load accelerates lung 
function decline, [25] and achievement of viral suppression by ART may preserve lung function 
at near or equivalent levels to HIV-uninfected individuals. 
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Table 1: Spectra of chronic lung disease in HIV infected adolescents [7] and associated lung 
function abnormality 
Infective causes Lung function abnormality 
Pulmonary Tuberculosis (PTB) Mixed obstructive-restrictive pattern on spirometry 
or purely restrictive (if fibrosis) 
Persistent and recurrent pneumonia due to 
recurrent viral and bacterial infections 
Restrictive pattern on spirometry or mixed 
obstructive-restrictive pattern 
Opportunistic infections like PCP* Reduced DLCO  
Post-infectious bronchiolitis obliterans Obstructive or mixed pattern spirometry 
Non-infective causes  
Bronchiectasis Obstructive or mixed pattern spirometry 
Lymphocytic interstitial pneumonitis (LIP) Reduced DLCO 
Immune reconstitution inflammatory 
syndrome (IRIS) following ART or TB therapy 
Mixed obstructive-restrictive pattern spirometry or 
restrictive pattern 
Malignancy e.g. pulmonary Kaposi’s sarcoma Restrictive pattern spirometry 
Pulmonary hypertension Reduced DLCO 
Non-specific interstitial pneumonitis Reduced DLCO 
* PCP-Pneumocystis jirovecii pneumonia; DLCO diffusion factor for carbon monoxide; ART antiretroviral therapy  
 
2. Use of lung function to measure chronic lung disease 
Different lung function tests measure various aspects of pulmonary function hence 
comprehensive measures are needed. These tests may aid in diagnosing and monitoring CLD. 
They include spirometry and bronchodilator response test, carbon monoxide single breath 
lung diffusion test, multiple breath nitrogen wash-out, forced oscillation and six-minute walk 
test as detailed in table 2. 
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Table 2: Lung function parameters 
Test Measurement Disease definition 
Spirometry FEV1, FVC, FEF2575, FEV1/FVC Obstructive or restrictive 
disease 
Single breath 
diffusion for CO 
DLCO, KCO Interstitial lung disease, 
emphysema 
Multiple breath 
washout test 
FRC, LCI Obstructive lung disease and 
ventilation homogeneity 
Forced 
oscillation 
Technique 
Resistance and compliance Respiratory system resistance 
and compliance  
Six-minute walk  Distance walked, SaO2, HR, RR, BP before and 
after test and measure of dyspnoea in six 
minutes (Borg scale) 
Cardiopulmonary functional 
status 
Forced expiratory volume in 1s (FEV1), forced vital capacity (FVC), forced expiratory flow between 25-75 sec of 
vital capacity (FEF2575), transfer factor for carbon monoxide (TLCO), carbon monoxide transfer coefficient (KCO), 
functional residual capacity (FRC), lung clearance index (LCI), Oxygen saturation (SaO2), blood pressure (BP), heart 
rate (HR), respiratory rate (RR) 
 
2.1 Spirometry 
Spirometry provides information on dynamic lung volumes and airflow and can identify 
patterns of lung disease. The commonly used outcomes in spirometry are forced vital capacity 
(FVC), forced expiratory volume in the first second (FEV1), FEV1/FVC ratio, and forced 
expiratory flow between 25 and 75% of vital capacity (FEF25-75), which can be seen on the 
spirogram in figure 2 The test requires that the patient understands what is expected, can 
follow the instructions and uses maximal effort to comply with the current paediatric 
spirometry standards. [26, 27] Information on the reversibility of airway obstruction after 
bronchodilator is useful to differentiate asthma from non-reversible airway obstructive 
disease. Airflow in restrictive disorders is usually reduced in proportion to the reduction in lung 
volumes; thus, the ratio of FEV1/FVC remains unchanged or is increased (>80%). In obstructive 
disorders, airflow is reduced more than lung volume and thus FEV1/FVC decreases. [28, 29] 
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Mixed obstructive-restrictive diseases are suspected when reductions in the magnitude of 
forced expiratory flow appear disproportionately large in relation to reduction in the FEV1/FVC 
ratio. [28] Declines in FVC caused by airway closure and gas trapping are accompanied by 
increases in the residual volume/total lung capacity (RV/TLC) ratio. Classically, RV/TLC remains 
unchanged in restrictive disorders. [28] TLC is reduced in restrictive diseases. In obstructive 
diseases, FRC will be increased. Spirometry does not measure RV, TLC or FRC (figure 1), other 
lung function tests and radiological tests may be required to confirm true restrictive or 
obstructive disease. Recent grading of severity of airway obstruction published in 2014 
reported values of FEV1 >-2 z-scores normal as per the reference standards, [30] whereas  mild 
dysfunction is ≤2 z-scores and severe dysfunction ≥3 z-scores. The Global Lung Initiative (GLI) 
[31] has provided reference equations for use in multi-ethnic groups in ages 3-95 years and 
introduced reporting references as the lower limit of normal (LLN), which denotes 1.64 SD, z-
scores and per cent predicted. 
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Figure 1: Lung volumes and lung capacities [32] 
 
 
Figure 2: Forced expiratory and inspiratory flow volume loop [33] 
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2.2 Single breath test for carbon monoxide 
Transfer factor for carbon monoxide of the lung (TLCO) or diffusion factor for carbon monoxide 
(DLCO), measured by single breath test, is a measure of the impedance to gas flow across the 
alveolar-capillary interface. It measures the rate at which carbon monoxide is transferred from 
the lung to the pulmonary capillary bed and is a reflection of the efficiency of diffusion across 
the capillary-alveolar surface. TLCO is the volume of carbon monoxide (CO) transferred from 
alveolar gas to blood (VCO) in mm/min divided by the difference between mean alveolar-
capillary CO pressure (PACO) and mean pulmonary-capillary CO pressure (PaCO). 
TLCO = VCO÷ (PACO-PaCO)  
Current standards when performing the test are specified in the ATS/ERS guidelines. [34, 35] 
TLCO below the lower limit of normal (LLN) can be due to emphysema, interstitial lung 
diseases, congestive heart failure, alveolar proteinases, bronchiectasis, bronchiolitis 
obliterans, anaemia among others. TLCO may be elevated in exercise, in patients with right to 
left shunts, polycythaemia and acute pulmonary haemorrhage. [28, 36] The GLI has provided 
reference values for ages 3-95 years [37]; 85% of participants were Caucasians. TLCO has been 
used to diagnose and monitor diffusion impairments in patients with chronic pulmonary 
diseases. 
2.3 Multiple breath washout (MBW) test 
Functional residual capacity (FRC) and lung clearance index (LCI) can be measured by inert gas 
washout tests, the most commonly used measure being the nitrogen (N2) multiple breath 
washout test. FRC measurement is a marker of normal lung growth but may also be increased 
in severe obstructive lung disease. [38] The total amount of nitrogen washed from the lungs 
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provides a measure of the patient’s resting FRC. FRC equals the product of the washout volume 
divided by the nitrogen concentration of air in the lungs. The current standards for lung volume 
measurement have been specified by Robinson et al. [39] 
Lung clearance index is a measure of ventilation homogeneity and has been found to be an 
early marker of lung function impairment in children with cystic fibrosis. [40] LCI is the ratio of 
cumulative expired washout volume (CEV) and FRC. The CEV reflects the sum of the tidal 
volumes required to reduce the concentration to 1/40th of the concentration of the inert gas 
prior to the washout. In children with the non-homogenous lung disease, washout takes longer 
and requires more tidal breaths and thus the LCI is elevated compared to healthy children. In 
healthy people, LCI values do not change through later childhood and adult life. [28] Although 
reference equations exist for MBW in adolescents, [41] there are no appropriate reference 
ranges for African youth using N2 MBW. 
2.4 Forced oscillation technique (FOT) 
FOT measures the impedance of the respiratory system and is measured during tidal breathing. 
External pressure oscillations are delivered at the airway opening and flow and pressure 
changes are measured to obtain the impedance (Zrs), and its component parts resistance (Rrs), 
and reactance (Xrs.) of the respiratory system. The current standards when performing FOT 
are spelt out by Oostveen et al. [42] Rrs depends on the resistive behaviour of the respiratory 
system and the reactive component, Xrs depends on the elastic and inert behaviour of the 
respiratory system. FOT has been used to diagnose airway obstruction and assess 
bronchodilator responses in asthma. [43-45] Rrs and Xrs are reported to be abnormal in 
children with chronic lung disease. [46-48] Xrs has been used to monitor improvement in cystic 
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fibrosis after a pulmonary exacerbation. [28] Calogero et al. [49] have provided reference 
values for respiratory impedance and bronchodilator responsiveness in Caucasian children 2-
13 years of age, but currently, no reference ranges exist for African children and adolescents. 
2.5 Six-minute walk test 
The six minutes’ walk test assesses functional status in chronic heart and or lung disease and 
has been used to monitor treatment response or to predict hospitalisation or mortality. 
Despite its utility in adults, six-minute walk test is not commonly performed in children due to 
lack of standardised guidelines and reference values in Paediatrics. Past studies have 
documented reference values for use in healthy children and adolescents. [50-52] 
2.6 Study Methodology 
2.6.1 Aim 
To investigate the spectrum and determinants of lung function and progression over two years 
in perinatally HIV-infected adolescents on ART in Cape Town, South Africa. 
2.6.2 Specific objectives 
1. To describe the spectrum and determinants of lung function in perinatally HIV-infected 
adolescents on ART in Cape Town, South Africa. 
2. To investigate the prevalence and determinants of cardiopulmonary dysfunction in 
HIV-infected adolescents on ART.  
3. To describe the progression of lung function over two years in HIV-infected adolescents 
on ART and to determine risk factors associated with low lung function over time.  
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2.6.3 Study design 
This was a prospective study of children enrolled in the Cape Town Adolescents Antiretroviral 
cohort (CTAAC). CTAAC aims to investigate chronic diseases in HIV-infected adolescents and 
markers of disease severity or progression. Enrolment of the study subjects began in October 
2013 and was completed in March 2015. 
2.6.4 Setting 
The study was carried out at the Red Cross War Memorial Children’s Hospital, Research Centre 
for Adolescent and Child Health (REACH). 
2.6.5 Study population 
Five hundred and fifteen HIV-infected adolescents and 110 healthy age, sex, ethnicity matched 
HIV-uninfected adolescents were enrolled and followed for two years. The HIV-infected 
participants were recruited from seven ART clinics within Cape Town namely Nolungile, 
Gugulethu, Cross Roads, Mitchell’s Plain, Infectious disease clinics at Red Cross War Memorial 
children’s and Tygerberg hospitals and Adolescent HIV clinic at Groote Schuur hospital. The 
HIV-uninfected adolescents were from Masiphumelele Youth Centre, a voluntary social service 
institution, located in a township in Cape Town. 
2.6.6 Inclusion criteria 
All participants enrolled in CTAAC study were eligible for inclusion. Eligibility criteria for CTAAC 
were HIV-infected adolescents, aged 9-14 years, who had been on ART for at least six months 
and who are resident in Cape Town area and where informed consent and assent for 
participation had been provided. The comparator group were healthy HIV-uninfected age-
matched adolescents, where informed consent and assent was provided and had no known 
pre-existing lung disease. 
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2.6.7 Routine health care and follow up 
All adolescents in this cohort were receiving routine health care at primary health care sites 
and/or clinics according to the Western Cape Department of Health Guidelines. If impaired 
lung function was detected as part of the study, this information was communicated back to 
the primary health care provider enabling the primary health care provider to adjust 
management according to standard care guidelines. Participants were followed up six-monthly 
from enrolment at REACH. 
2.6.8 Data collection 
The following measures were taken:  
 Clinical parameters-signs and symptoms of respiratory disease, e.g. cough, wheeze, 
digital clubbing, intercurrent illness, intercurrent hospital visits/admissions, history of 
pulmonary tuberculosis and lower respiratory tract infections, history of smoking either 
passive or active, history of doctor-diagnosed asthma and anthropometry data, i.e. 
weight, height, body mass index (BMI). Clinical data were collected at baseline and 
annually. Clinical examination was conducted by a qualified medical officer. A 
standardised respiratory questionnaire (Appendix 1) was administered at enrolment 
and six-monthly. Data extraction from hospital records for past lower respiratory tract 
infections requiring hospitalisation or PTB was done at enrolment. 
 Laboratory measures of disease, collected annually, included full blood count, HIV viral 
load (CAP method/Roche COBAS Ampliprep, Germany) and CD4 cell count (Beckman 
Coulter FC500 MPL analysers, USA and sputum microbiology. 
 Lung function at baseline and progression over two years 
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The lung function testing at enrolment included spirometry, single breath carbon 
monoxide diffusion test (TLCO), multiple breath nitrogen washout (MBW), forced 
oscillation technique (FOT), bronchodilator response test and 6MWT. The testing at 24 
months which is longitudinally reported was spirometry with bronchodilator 
responsiveness. 
 Echocardiography to assess cardiac function at enrolment. 
Cardiac function testing was assessed by echocardiography, performed by a trained 
research echocardiographer using either a Philips IE33 or CX50 echo machines (Phillips, 
Netherlands) using standardised techniques. [53, 54] 
2.6.9 Lung function testing 
Lung function testing included spirometry, FOT, six-minute walk test, N2 multiple breath 
washout, single breath diffusion test for carbon monoxide and bronchodilator response 
testing. All testing was done according to the American Thoracic Society and European 
Respiratory Society (ATS/ERS) standards. [27, 32, 34, 35, 38, 42, 55] Spirometry, single breath 
diffusion test for carbon monoxide and multiple breath washout test was done using NDD 
EasyOne Pro machine (NDD, Switzerland) and for the FOT, a custom-made setup (University of 
Szeged, Hungary). 
2.6.10 Bronchodilator testing 
After performing DLCO and MBW tests, bronchodilator (400 µg of salbutamol) was given via 
MDI-spacer and FOT and spirometry was repeated after 15 minutes. 
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2.6.11 Evaluation of results 
Lung function results were evaluated using z-scores, per cent predicted and lower limit of 
normal according to the Global Lung Initiative [31, 37]. The association of low lung function 
with socio-demographic factors, HIV-related factors and other clinical factors was investigated 
using Directed acyclic graphs. [56] 
2.6.12 Ethical considerations 
This study was approved by the Faculty of Health Sciences Human Research Ethics Committee, 
University of Cape Town (REC Ref: 051/2013), see Appendix 2. Consent from a parent or legal 
guardian and assent from the participant were obtained in the participant’s first language by 
a trained study counsellor during enrolment, Appendix 3. The study was on a voluntary basis 
and participants were aware they could opt out of the study at their own will. Confidentiality 
was maintained by ensuring study participants were assigned unique study codes and hard 
copies of data locked in cabinets with restricted access and the computerised records were 
password restricted. 
Potential risks in this sub-study were minimal, e.g. minimal discomfort involved when 
phlebotomy and lung function procedures were performed. Phlebotomy was done by trained 
nurses. Standardised phlebotomy kits were made available. We also ensured sterilisation of 
the sensor on the machine used for lung function was done daily with alcohol swabs. Lung 
function testing was done by a trained respiratory technologist. A new spirette (mouthpiece) 
was allocated to each study participant for each visit and was disposed of after use.  
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Results of lung function tests were availed to the participant’s primary health care provider. 
Participants needing specialist review were referred to a pulmonologist. The study potential 
benefits outweighed the minimal study risks. 
Pertaining to the use of vulnerable population, i.e. adolescents, HIV infected, low 
socioeconomic status, the study was carried out in accordance with standard operating 
procedures published in January 2013 by Faculty of Health Sciences, Human Research Ethics 
committee that addresses research in a vulnerable population. The participants were 
reimbursed R80 for short visits and R200 for long visits predominantly to cover the costs of 
transportation  
2.6.13 Sample size and power calculation 
We used Satterthwaite’s test to estimate power for a two sample means test, assuming 
unequal variances. Mean and standard deviation (SD) was obtained from a convenience 
sample of the whole cohort; mean (SD) of FEV1 for HIV- uninfected and HIV-infected of 1.85 
(0.50) and 1.56 (0.45), respectively and mean (SD) of DLCO of 18.40 (4.20) and 16.50 (3.38) of 
HIV-uninfected and HIV-infected, respectively. With the 515 HIV-infected adolescents and 110 
HIV-uninfected adolescents already enrolled in the CTAAC cohort, the study had a power of 
98% to describe the spectrum of lung function of HIV-infected adolescents on ART, with a type 
1 error rate of 5%. 
2.6.14 Data analysis  
Data analysis and monitoring were undertaken continuously over the study period. Data were 
analysed with Stata Version 15.0. 
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An initial one-way analysis was conducted to assess the distribution of each variable. 
Continuous variables were summarised using mean and standard deviation for normally 
distributed variables and median and inter-quartile range (IQR) for non-normally distributed 
variables. Categorical variables were summarised with percentages in each category. 
A two-way analysis including graphs, plots and tables were used to look for an association 
between the outcome and the exposure of interest, including potential confounders. Group 
differences for continuous variables were evaluated using T-test for normally distributed 
variables or Wilcoxon test or Kruskal-Wallis test for non-normally distributed variables. Group 
differences for categorical variables were evaluated using the Chi-Square. The final analysis 
utilised multivariate linear regression analysis for continuous outcomes or multivariate logistic 
regression for binary outcomes. Linear mixed effect modelling was used to explore longitudinal 
changes over two years in lung function. The impact of potential predictors and confounders 
was assessed using appropriate regression analysis. 
For objective 1:  
To describe the spectrum and determinants of lung function in HIV-infected adolescents on 
ART in Cape Town, South Africa. 
Summary statistics included means, standard deviation (SD) or median, interquartile range 
(IQR) and z-scores. Linear regression was used to investigate the determinants of lung function. 
For objective 2: 
To investigate cardiopulmonary function in HIV-infected adolescents on ART.  
This was summarised using mean (SD) and median (IQR). Logistic regression was used to 
compute determinants of cardiopulmonary function. 
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For objective 3:  
To investigate the progression of lung function over two years in HIV-infected adolescents on 
ART. 
This was done using cross-sectional time-dependent analysis to assess the patterns in mean 
lung function over time in the cases and controls. To explore lung growth in this population we 
controlled for baseline lung function and described lung function longitudinally as a change in 
z-score expected for age, height and gender. The impact of potential predictors and 
confounders was assessed using mixed model regression analysis.  
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Abstract 
Background: The advent of anti-retroviral therapy has led to improved survival of HIV-infected 
children to adulthood, and to HIV becoming a chronic disease in older children and 
adolescents. Chronic lung disease is common among adolescents. Lung function measurement 
may help to delineate the spectrum, pathophysiology and guide therapy for HIV-related 
chronic lung disease.  
Aim: The aim was to review the available data on the spectrum and determinants of lung 
function abnormalities and the impact of antiretroviral therapy on lung function in perinatally 
HIV-infected children and adolescents. 
Methods: Electronic databases, “PUBMED” and “African wide” and “CINAHL” via EBSCO Host, 
using the MeSH terms, “Respiratory function” AND “HIV” OR “Acquired Immunodeficiency 
Syndrome” AND “Children” OR “Adolescents” were searched for relevant articles on lung 
function in HIV-infected children and adolescents. The search was limited to English language 
articles published between January 1984 and September 2017. 
Results: Eighteen articles were identified which included studies from Africa, USA and Italy, 
representing 2051 HIV-infected children and adolescents, 68% on antiretroviral therapy, age 
50 days to 24 years. Lung function abnormalities showed HIV-infected participants had 
increased lower airway expiratory obstruction that was irreversible and reduced functional 
aerobic impairment on exercise, compared to HIV-uninfected participants. Mosaic 
attenuation, extent of bronchiectasis, history of previous pulmonary tuberculosis or previous 
lower respiratory tract infection and cough for more than one month were associated with low 
lung function. Pulmonary function tests in children established on antiretroviral therapy did 
not show aerobic impairment and had less severe airway obstruction. 
Conclusion: There is increasing evidence that HIV-infected children and adolescents have high 
prevalence of lung function impairment, predominantly irreversible lower airway obstruction 
and reduced aerobic function. 
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Background 
Improved survival of perinatally HIV-infected children to adolescence has occurred with the 
scale-up of paediatric antiretroviral therapy (ART) and prevention of mother to child 
transmission (PMTCT) programmes. This has led to a large cohort of youth living with vertically 
transmitted HIV in sub-Saharan Africa. [1] Of the 2.3 million children living with HIV globally, 
43% are on ART. [2, 3] In 2016, seven million people were reported to be living with HIV in 
South Africa, of which 350,000 were between 10-19 years old. [2]  
HIV-related chronic lung disease (CLD) is a major cause of morbidity and mortality. [4, 5] In the 
post-ART era, the spectrum of CLD has changed from lymphocytic interstitial pneumonitis (LIP) 
being most predominant to bronchiolitis obliterans and bronchiectasis being more prevalent 
patterns. [5, 6] The spectrum of chronic lung disease in HIV infection has broad clinical 
phenotypes. For example, bronchiolitis obliterans or bronchiectasis may present as an 
obstructive or mixed pattern on spirometry, [5] while chronic Pneumocystis jirovecii 
pneumonia (PCP), pulmonary tuberculosis (PTB) or LIP have a restrictive or pattern spirometry. 
Interstitial pneumonitis, LIP and PCP are likely to lead to a reduced diffusion capacity for carbon 
monoxide (DLCO). 
Comprehensive lung function measures are therefore needed to delineate the spectrum of 
CLD, monitor progression and to guide therapy and treatment response. These include 
measurements of lung capacities and flow such as spirometry and bronchodilator response 
testing, measure of lung volumes with plethysmography, measure of resistance and 
compliance with tests such as the forced oscillation technique (FOT), interrupter technique or 
single-breath occlusion technique, measure of gas diffusion with single-breath carbon 
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monoxide lung diffusion test to assess alveolar-capillary membrane function, measurement of 
ventilation distribution with multiple breath nitrogen wash-out test (MBW), cardiopulmonary 
functional assessment with six-minute walk test (6MWT) and exercise (treadmill) testing. 
The aim of this study was to review the available data on the spectrum and determinants of 
lung function abnormalities in perinatally HIV-infected children and adolescents. 
Methodology 
A review of published literature was done by searching “PUBMED”, “African wide” and 
“CINAHL” via EBSCO Host using the MeSH terms “Respiratory function” AND “HIV” OR 
“Acquired Immunodeficiency Syndrome” AND “Children” OR “Adolescents”; full search terms 
are shown in table 1. Search was limited to English language, and publication date January 
1984 - September 2017. Articles involving infants, child, adolescents or youth, HIV-infected or 
exposed and lung function testing were included. Articles on adult studies or healthy 
populations were excluded. Where full articles could not be retrieved on Endnote, we 
requested the full article from the corresponding author by email. In addition to database 
searches, other relevant references from previous original articles were hand-searched 
through google scholar. Data regarding patient characteristics, lung function test used, and 
outcome were abstracted and summarised in table format. 
Results 
The process of the literature search is shown in Figure 1. After combining all the search terms, 
146 articles were found; eight additional articles were obtained by hand-searching, figure 1. 
One hundred and thirty-six studies were excluded because they were unrelated to lung 
function or were not related to the population of interest or only a conference abstract was 
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available. Eighteen full articles were found and are included in this review, table 2. Included 
studies were published between July 1997 and September 2017. Of the 18 included studies, 
11 were from Africa, six from USA and one from Italy. Three studies were done in infants (of 
which two also included HIV-exposed uninfected infants), [7-9] two were done in children <8 
years [10, 11] and 13 were done in adolescents and youth (9-24 years), table 2. Eleven studies 
had a comparator group (control), table 2. All the HIV- infected participants were perinatally 
infected.  
Baseline characteristics of participants differed among studies with median age ranging from 
50 days to 24 years. Number of participants in each study ranged from 100 to 600 with a total 
of 2051 HIV-infected participants pooled from all studies. Severity of disease differed; Ferrand 
et al. [6] reported 66% had chronic cough, McHugh et al. [1] reported 54% had chronic cough. 
Githinji et al. [12] reported 3.5% had clubbing while Mwalukomo reported 22% with digital 
clubbing. [13] 
Participants were reported to have been on ART in 75% of the studies, table 2. Duration of ART 
was reported in five studies and ranged from 2-8 years. [12, 14-16] In three studies, no 
participant was on ART, table 2; two of these studies were done in sub-Saharan Africa [1, 17] 
and one in Italy in the pre-ART era. [11] 
Lung function measures reported were spirometry with bronchodilator response testing and 
exercise testing (with treadmill or incremental shuttle walk test or 6MWT. One study included 
comprehensive lung function testing including forced oscillation technique (FOT) and MBW 
test. [12]  
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Spirometry testing was standardised in all studies as per American Thoracic Society/European 
Respiratory Society criteria. [18] Definition of restrictive pattern spirometry varied across 
studies with most reporting reduced forced vital capacity (FVC) as a spirometry pattern. 
Definition of obstructive pattern also varied across studies with some studies using the lower 
limit of normal of forced expiratory volume in 1sec/ forced vital capacity (FEV1/FVC), as per the 
global lung initiative reference [19] and others using FEV1/FVC less than 80%. Shearer et al. 
[20] had a broad inclusion criteria of obstructive spirometry pattern including FEF25-75 <65% or 
FEV1/FVC less than 80%.  
Assessment and definition of bronchodilator responsiveness varied among the studies. Criteria 
for bronchodilator responsiveness (BDR) in most studies was change in FEV1>12%. Shearer et 
al. [20] used albuterol and a change of ≥10% in FEV1. Three studies used 2.5 mg nebulized 
salbutamol [1, 13, 16] while the rest used 400 µg inhaled salbutamol. 
Of the ten studies reporting spirometry findings, table 2, nine reported obstructive spirometry 
pattern, of which six studies demonstrated low rates of bronchodilator reversibility; and in five 
studies with a comparator group, this rate of irreversible obstruction spirometry was higher in 
the HIV-infected. Rylance et al. [16] reported 11 (35%) out of 31 HIV-infected children with 
obstructive spirometry had positive bronchodilator responsiveness, while Githinji et al. [12] 
reported 15% of HIV-infected had bronchodilator responsiveness compared to 8% HIV-
uninfected adolescents, p=0.058. Mwalukomo et al. [13] reported 31.9% of the HIV-infected 
participants had bronchodilator responsiveness. Shearer et al. [20] reported similar rates of 
obstructive pattern spirometry between HIV-infected youth and HIV-exposed uninfected 
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youth (22% vs 21%), but a lower rate of bronchodilator responsiveness in the HIV-infected 
youth, 17% vs 9%, p=0.05). 
Two studies reported diffusion tests, table 2, found to be lower or impaired in the HIV-infected 
group compared to the uninfected. Airway obstruction and reduced diffusion capacity were 
consistent findings across age-groups from childhood [10, 11] to adolescence, table 2. 
Seven studies reported exercise tests for cardiopulmonary function status (6MWT or treadmill 
test), table 2, which showed that HIV-infected participants had functional aerobic impairment 
except for one study where no difference in distance walked or oxygen desaturation was 
reported after exertion, table 2. 
Determinants of lung function were reported in three studies. [5, 6, 12, 13] History of previous 
lower respiratory tract infection or pulmonary tuberculosis was associated with reduced FEV1 
and DLCO. [12] Cough >one month was 2.9 times more likely to be associated with abnormal 
spirometry, 95% CI 1.21-7.10. [13] Mosaic attenuation and extent of bronchiectasis were 
significantly associated with reduced FEV1, (r=-0.52 and r=-0.50, p<001, respectively). [5] 
One study reported MBW and FOT besides spirometry, table 2, where HIV-infected 
adolescents had increased resistance, lower compliance, reduced functional residual capacity 
and increased lung clearance index compared to HIV-uninfected adolescents.  
Two studies involved HIV-exposed uninfected children. [7, 9] and one study had HIV-exposed 
uninfected youth as a comparator group. [20] Forced expiratory flow was about 20% less in 
the HIV-exposed group but this difference was not significant. [21]  
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A summary of all studies included in this review is presented in table 2. Overall, results showed 
that HIV-infected participants had reduced flow and volume and functional aerobic 
impairment on exercise, reduced compliance, increased respiratory system resistance and 
reduced diffusion capacity compared to HIV-uninfected participants. Participants who had 
longer ART duration had less severe respiratory symptoms, less severe lower airway 
obstruction and no aerobic impairment. 
Discussion 
This review provides evidence of impairments in lung function in perinatally HIV-infected 
children and youth which were predominantly irreversible lower airway obstruction, reduction 
in exercise tolerance and reduced diffusion capacity. [1, 6, 15, 16] Fixed airflow obstruction 
was the most commonly reported finding, irrespective of ART status, table 2. 
Irreversible airway obstruction is likely to be a response to airway epithelium injury by 
opportunistic infections (OIs) or from HIV, repair of which can lead to proliferation of 
granulation tissue, fibrosis of airways and subsequent obliteration of the lumen. [22] 
Bronchiolitis obliterans, which may result in irreversible lower airway obstruction, has been 
reported as a predominant pathology, evidenced by radiological manifestation of mosaic 
attenuation on chest tomography in HIV-infected adolescents with delayed access to ART. [5, 
6] Systemic inflammatory markers have also been found to be increased in uncontrolled HIV 
or following repeated infections. [23] Lung infections like PCP [24] have been associated with 
increased metalloproteinases and chronic airflow obstruction in adults but none of the studies 
in this review reported prior PCP in participants.  
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ART has been reported in HIV-infected adults to be independently associated with irreversible 
airway obstruction, but the mechanism remains unproven. [25, 26] A direct effect of ART on 
inflammation in the lung and airways by reduction of peroxisome-proliferator-activated 
receptor has been reported in adults. [27]  
Bronchodilator reversibility was reported to be present in 15-35% of participants. Despite the 
available evidence that irreversible airway obstruction is common in HIV-infected children, use 
of inhaled asthma medications has been reported to be widely used in HIV-infected children 
and adolescents. [28] Although bronchodilator reversibility was more common in HIV-exposed 
uninfected youths than in the HIV-infected youths, Shearer [20] reported that self-reported 
asthma diagnosis was higher in HIV-infected youths than uninfected. This may be due to 
constellation of symptoms of asthma-like respiratory illness, e.g. wheeze and cough in HIV-
infected population and physician use of inhalers in the patients who present with such 
symptoms.  
Differences in disease severity across study populations were more likely a result of varying 
duration of HIV infection and ART use. Those who had a duration of ART therapy of more than 
seven years reported lower prevalence of respiratory symptoms [12] than those who initiated 
ART in later childhood. [1, 6] Chronic lung diseases like bronchiectasis and bronchiolitis 
obliterans are likely to have occurred by the time of ART initiation in most of these studies 
reporting higher prevalence of chronic cough and wheeze. [1, 5, 6] 
Functional aerobic impairment was more common in HIV-infected participants than 
uninfected. [1, 16, 17, 29, 30] Those on ART were reported to have done better on exertion 
than those not on ART. [15] The exercise intolerance may have been due to impaired 
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ventilation-perfusion mechanics with possible heart dysfunction, though no study in this 
review reported cardiac function. The cardio-pulmonary function status results across studies 
were inconsistent due to patient selection differences, with Githinji et al. [12] reporting no 
significant difference in exercise status between the HIV-infected adolescents and the 
uninfected and Chisati et al. [17] reporting low aerobic endurance in the HIV-infected group. 
These differences may be explained by differences in the cohorts and ART use; all children in 
the former cohort were stable on ART for a median duration of 8 years whereas none of the 
youth in the latter study were on ART.  
While adult studies [25, 31] have reported diffusion impairment as predominant lung function 
abnormality, diffusion impairment in HIV-infected children and adolescents has not been 
commonly investigated. However, HIV-infected adolescents on ART were reported to have 
lower diffusion capacity compared to HIV-uninfected adolescents [12] suggesting that HIV or 
opportunistic infections may impair oxygen diffusion either by thickening of alveolar-capillary 
membrane due to interstitial inflammation or post-inflammation fibrosis or due to reduced 
surface area for gas exchange like in HIV-related bronchiectasis or bronchiolitis obliterans. 
Alveolar-capillary membrane integrity may be damaged by HIV and/or opportunistic infections 
well before the presence of clinical symptoms as reported by Alderson et al. [10] Emphysema, 
unlike in adults, was not documented as a common presentation in HIV-infected adolescents 
in Zimbabwe. [5, 6] Inflammation of the alveolar-capillary membrane by opportunistic 
infections like PCP and other AIDS related complications have also been documented. [31, 32] 
Low diffusion capacity has been reported in adult patients who had previous TB in a South 
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Africa cohort. [33] One study reported that pulmonary tuberculosis was associated with 
reduced DLCO in HIV-infected adolescents. [12] 
The evidence on impact of HIV in-utero on infants born to HIV-infected mothers is evolving 
with only a few studies to date investigating HIV-exposed uninfected infants. These found no 
difference in spirometry pattern or forced expiratory flow on thoraco-abdominal compression 
between HIV-unexposed infants and HIV-exposed uninfected infants. [9, 20] Gray, [7] 
however, reported increased tidal volumes in HIV-exposed uninfected infants compared to 
unexposed infants soon after birth.  
Although accelerated lung function decline has been shown in HIV-infected adults, [34, 35] 
published data on longitudinal lung function changes in HIV-infected children and adolescents 
are lacking. HIV per se has been reported to cause decline in lung function after controlling for 
other respiratory infections. [31] Bacteria pneumonia in HIV has been associated with 
permanent declines in FEV1, FVC, FEV1/FVC and DLCO. [36] Pneumonia and pulmonary 
tuberculosis were reported to be more common in HIV-infected adolescents than uninfected 
in two of the studies [12, 16] A result of pre-natal and postnatal origin of adult chronic 
obstructive airway disease as reported in several studies, [7, 37, 38] remains to be proven by 
longitudinal studies where these HIV-infected children and adolescents are followed to 
adulthood.  
Limitations of this review include heterogeneity among studies and lack of reporting by some 
studies on duration of ART. The studies were also carried out in different eras of PMTCT and 
ART roll-out, where ART was initiated at varying CD4 counts or clinical stages. [39] Description 
of obstructive and restrictive spirometry patterns was not uniform across studies with most 
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studies reporting reduced FVC as a spirometry pattern per se and one study also including 
FEF25-75 in the definition of obstructive spirometry. Determinants of lung function were also not 
widely reported. Almost all studies were cross sectional with very limited data on longitudinal 
changes in lung function over time. 
Conclusion  
There is increasing evidence that HIV-infected children and adolescents have high prevalence 
of lung function impairment, predominantly irreversible lower airway obstruction and reduced 
aerobic function. Lung function impairment was milder in cohorts of adolescents/children who 
had had earlier access to ART. Lung function impairment starts early in life in the absence of 
ART as evidenced by the papers published in the pre-ART era. Achievement of viral suppression 
through ART may preserve lung function, though at a lower level compared to HIV-uninfected 
individuals. ([1, 12, 20, 34]  
Future directions 
There is a need for longitudinal studies on lung function in HIV-infected children and 
adolescents in the post-ART era into adulthood as there is increasing evidence that chronic 
obstructive pulmonary disease has its origins in early life. [38] There is also need for more 
studies comparing lung function among HIV-infected, HIV-exposed uninfected and HIV-
uninfected children and adolescents, to provide evidence on how exposure to maternal virus 
in-utero may affect lung function and how early intervention with ART in HIV-pregnant 
mothers may help to preserve lung function in infants and children.
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3Table 1: Search strategy for review of lung function in HIV-infected children and adolescents 
Database MeSH Key words 
PUBMED Respiratory 
Function Tests 
Lung function test OR pulmonary function test OR Respiratory Function Tests 
 HIV OR Acquired 
Immuno-
deficiency 
Syndrome 
HIV OR human immunodeficiency virus OR AIDS OR Acquired immunodeficiency syndrome 
OR Acquired Immuno-deficiency Syndrome or Acquired Immunodeficiency Syndrome 
  Children OR pediatric OR paediatric OR neonates OR Adolescents OR teenagers OR youth OR 
young people OR infants 
   
Search, Query, Items found, Time 
#35, "Search ("Respiratory Function Tests"[Mesh]) OR (Respiratory Function Tests) OR 
pulmonary function test) OR lung function test)) AND ("Acquired Immunodeficiency 
Syndrome"[Mesh]) OR "HIV"[Mesh])) OR (HIV) OR human immunodeficiency virus) OR 
AIDS) OR Acquired immunodeficiency syndrome) OR Acquired Immuno-deficiency 
Syndrome) OR Acquired Immunodeficiency Syndrome) AND (Children) OR pediatric) OR 
paediatric) OR Adolescents) OR youth) OR young people) OR infants) OR teenagers) OR 
neonates) Sort by: [relevance]", 146,08:58:16 
#34, "Search ("Respiratory Function Tests"[Mesh]) OR (Respiratory Function Tests) OR 
pulmonary function test) OR lung function test) AND ("Acquired Immunodeficiency 
Syndrome"[Mesh]) OR "HIV"[Mesh]) OR ((HIV) OR human immunodeficiency virus) OR 
AIDS) OR Acquired immunodeficiency syndrome) OR Acquired Immuno-deficiency 
Syndrome) OR Acquired Immunodeficiency Syndrome) Sort by: [relevance]", 659,08:54:18 
#33, "Search (Children) OR pediatric) OR paediatric) OR Adolescents) OR youth) OR young 
people) OR infants) OR teenagers) OR neonates Sort by: [relevance]", 4074285,08:53:22 
#32, "Search infants Sort by: [relevance]",1118057,08:51:23 
#31, "Search young people Sort by: [relevance]", 805914,08:51:04 
#30, "Search youth Sort by: [relevance]", 1839127, 08:50:35 
#29, "Search teenagers Sort by: [relevance]", 1822104, 08:50:16 
#28, "Search Adolescents Sort by: [relevance]", 1843588, 08:49:54 
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#27, "Search neonates Sort by: [relevance]", 572698, 08:49:40 
#26, "Search paediatric Sort by: [relevance]", 413775, 08:49:16 
#25, "Search pediatric Sort by: [relevance]", 612753, 08:48:58 
#24, "Search Children Sort by: [relevance]", 2174198,08:48:33 
#23, "Search ("Acquired Immunodeficiency Syndrome"[Mesh]) OR "HIV"[Mesh]) OR ((HIV) 
OR human immunodeficiency virus) OR AIDS) OR Acquired immunodeficiency syndrome) 
OR Acquired Immuno-deficiency Syndrome) OR Acquired Immunodeficiency Syndrome) 
Sort by: [relevance]", 424852, 08:47:05 
#22, "Search (HIV) OR human immunodeficiency virus) OR AIDS) OR Acquired 
immunodeficiency syndrome) OR Acquired Immuno-deficiency Syndrome) OR Acquired 
Immunodeficiency Syndrome Sort by: [relevance]", 424852, 08:46:36 
#21, "Search Acquired Immunodeficiency Syndrome Sort by: [relevance]", 88073, 08:44:20 
#20, "Search Acquired Immuno-Deficiency Syndrome Sort by: [pubsolr12]", 88141, 
08:44:00 
#19, "Search Acquired immunodeficiency syndrome Sort by: [relevance]", 88073, 08:43:37 
#18, "Search AIDS Sort by: [relevance]", 250617, 08:43:14 
#17, "Search human immunodeficiency virus Sort by: [relevance]", 328144, 08:42:43 
#16, "Search HIV Sort by: [relevance]", 316415, 08:42:22 
#15, "Search ("Acquired Immunodeficiency Syndrome"[Mesh]) OR "HIV"[Mesh] Sort by: 
[relevance]", 152381, 08:41:48 
#14, "Search ("Respiratory Function Tests"[Mesh]) OR (Respiratory Function Tests) OR 
pulmonary function test) OR lung function test) Sort by: [relevance]", 224085, 08:40:33 
#13, "Search "Respiratory Function Tests"[Mesh] Sort by: [relevance]", 213706, 08:40:04 
#12, "Search (Respiratory Function Tests) OR pulmonary function test) OR lung function 
test Sort by: [relevance]", 224085, 08:38:54 
#11, "Search Respiratory Function Tests Sort by: [relevance]", 218117, 08:38:08 
#10, "Search pulmonary function test Sort by: [relevance]", 222124, 08:37:37 
#9, "Search lung function test Sort by: [relevance]", 221928, 08:37:11 
#8, "Search ""Acquired Immunodeficiency Syndrome"[Mesh] Sort by: [relevance]", 74419, 
08:36:14 
#4, "Search "HIV"[Mesh] Sort by: [relevance]", 88572, 08:29:34 
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African wide 
and CINAHL 
via EBSCO 
Host 
 lung function OR lung function test* OR pulmonary function OR pulmonary function test* 
OR Respiratory Function OR Respiratory Function Test* 
  HIV OR human immunodeficiency virus OR AIDS OR Acquired immunodeficiency syndrome 
OR Acquired Immuno-deficiency Syndrome or Acquired Immunodeficiency Syndrome 
  Child* OR pediatric OR paediatric OR neonat* OR Adolescent* OR teenage* OR youth OR 
young people OR infant*OR young adult* 
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4Table 2: Summary of studies on lung function in HIV-infected children and adolescents  
Author, Journal Symptoms 
Study 
design & 
country 
Participant 
characteristics 
Lung 
function 
test 
Summary of results 
Desai et al., [5] 2017 
Clin Infec Dis 
 
- 25% chronic 
cough 
- 5% wheeze 
- 18% resting 
hypoxia 
Cross-
sectional, 
Zimbabwe 
HIV-infected adolescents, 
median age 11 years, 
n=193, ART duration 5 
years 
spirometry 
with BDR* 
- Mosaic attenuation and 
bronchiectasis on HRCT 
strongly correlated with 
FEV1, r=-0.52, and r=-0.50, 
p<0.001 respectively 
Shearer et al., [20] 
2017 
J Allergy Clin & 
Immuno 
 
- 34% had history 
of physician-
diagnosed 
asthma 
Cohort, 
USA 
218 HIV-infected, all on 
ART; 152 HIV-uninfected 
exposed; median age 17 
years 
Spirometry 
with BDR 
- Obstructive spirometry 
pattern similar in both 
groups (22% vs 21%). 
- 17% HIV-exposed 
uninfected youth had 
positive BDR vs 9% in HIV-
infected youth, p=0.052 
Githinji et al. [12] 
2017 
Annals of ATS 
- 10% had history 
of asthma  
- 4% had 
clubbing  
- 15% anytime 
cough 
Cohort study, 
South Africa 
515 HIV-infected 
adolescents, median age 
12 years; mean ART 
duration 8 years, and 110 
HIV-uninfected 
Spirometry 
with BDR, 
FOT, 
N2MBW, 
Single breath 
CO  
6MWT 
- Flow, volume, compliance, 
diffusion capacity lower in 
HIV-infected than 
uninfected; Higher 
resistance and LCI in HIV-
infected compared to 
uninfected, p<0.05  
- No cardiorespiratory 
function impairment on 
exercise testing in both 
groups 
Gray D. et al. [7] 
2017 
Thorax 
- Birth cohort 129 infants HIV-exposed 
uninfected; 546 infants 
born to HIV-uninfected 
Tidal 
breathing 
and flow 
volume loops 
- HIV-exposed infants had 
higher tidal volumes 
compared to infants born to 
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mothers; median age 50 
days 
HIV-uninfected mothers, 
p=0.04 
McHugh et al. [1] 
2016 
AIDS 
- 54% chronic 
cough 
- 16% reported 
dyspnoea 
Cross-
sectional, 
Zimbabwe 
385 HIV-infected children, 
median age 11 years, 
none on ART 
Spirometry 
with BDR, 
shuttle walk 
test 
- 10% obstructive spirometry; 
1.3% BDR 
- 18% reduced FVC 
- 10% desaturated to <88% 
on exercise 
Rylance et al. [15] 
2016 
Arch dis child (poster 
abstract) 
- Those receiving 
ART, 15% had 
dyspnoea 
- 15% had daily 
cough 
Cross-
sectional 
385 HIV-infected ART-
naïve;202 on ART; 
median age 11 years 
Spirometry  
6MWT 
- Proportion of abnormal 
spirometry similar in ART-
exposed and ART-naïve 
group (25.6% vs 24.3%) 
- Less distance in 6MWT in 
ART-naïve group, p<0.001 
Mwalukomo et al. 
[13] 2016 
Peds Inf Dis 
- 8% had history 
of wheeze 
- 22% had finger 
clubbing 
- 20% had resting 
hypoxia 
Cross-
sectional, 
Malawi 
160 HIV-infected; median 
age 11 years 
71% on ART median 
duration 3.5 years 
Spirometry 
with BDR 
- 18% obstructive spirometry, 
20% reduced FVC; 32% had 
+ BDR 
Rylance et al. [16] 
2016 
AIDS 
- 15% had 
chronic cough 
- 15% had 
dyspnoea 
- 5% had wheeze 
Cross-
sectional, 
Zimbabwe  
150 HIV-uninfected;202 
HIV-infected;median age 
11 years 
ART mean duration 5 
years 
Spirometry 
with BDR, 
Shuttle walk 
test 
- Lower FEV1, FVC, and FEF50 
in HIV-infected, p<0.05. 11 
(35%) out of 31 with 
obstructive spirometry had 
+ BDR 
- Less distance walked in HIV-
infected, p<0.001  
Chisati et al. [17] 
2015 
Malawi Med. Journal 
- Cross-
sectional, 
Malawi 
55 HIV-infected youth, 
not on ART and 78 
uninfected youth, mean 
age 24 years 
Treadmill 
exercise test 
- Lower VO2max (aerobic 
endurance) in HIV-infected 
compared to uninfected, 
p=0.01 
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Masekela et al. [14] 
2012 
Int J Tuberc Lung Dis 
- Cross-
sectional, 
South Africa 
35, 6-18 years with HIV-
related bronchiectasis, all 
on ART 
Spirometry 
with BDR 
- Median FEV1 was 53% 
Ferrand et al. [6] 
2012 
Clin Inf Dis 
- 35% resting 
hypoxia 
- 66% recurrent 
cough 
- 10% clubbing 
Cross 
sectional, 
Zimbabwe 
116 adolescents mean 
age 14 years, vertically 
HIV-infected,  
69% ART mean duration 
20 months 
Spirometry 
with BDR, 
200 m brisk 
walk 
- 45% had FEV1<80%; 47% 
had CXR abnormalities, 55% 
had mosaic attenuation on 
HRCT 
Samadi et al. 2012 
(unpublished data)  
 - Cross-
sectional, 
South Africa 
56 HIV-infected on INH 
prophylaxis, 7-10y, none 
on ART 
Spirometry 
with BDR 
- 21% had abnormal 
spirometry; 18% had 
positive BDR 
Cade et al. [29] 2002 
Ped Rehab 
 Cross-
sectional, 
USA 
15 HIV-infected 
adolescents,14 on ART & 
15 matched HIV-
uninfected, median age 
18 years 
Treadmill 
exercise test 
- Peak oxygen consumption, 
treadmill duration and 
oxygen pulse were lower in 
HIV infected adolescents 
compared to uninfected, 
p<0.05 for all 
Colin A et al. [9] 
2001 
AJRCCM 
- 
 
Cohort, USA 285 HIV-exposed 
uninfected infants born 
to HIV-infected mothers, 
92 HIV-unexposed 
uninfected infants 
Vmax FRC by 
rapid 
thoracic 
compression 
- Forced expiratory flow was 
≈20% less in the HIV-
exposed group but this 
difference was non-
significant 
Keyser et al. [30] 
2000 
Arch Phys Med 
Rehabil 
 
- Cross-
sectional, 
USA 
17 HIV-infected mean age 
18 years; all on ART 
treadmill 
exercise test 
- Peak oxygen consumption 
was lower than expected 
(functional aerobic 
impairment)  
Platzker et al. [8] 
2000 
AJRCCM 
- Cohort, USA 41 infants born to HIV-
infected mothers (34% of 
HIV-infected infants), 
mean age 24 months 
Thoraco-
abdominal 
compression 
- Respiratory system 
compliance reduced and 
declined more after TAC in 
HIV-infected, p=0.003 
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- Higher resistance in HIV-
infected infants compared 
to uninfected, p=0.03 
Alderson et al. [10] 
1999 
Radiology 
- Cohort, USA 132 HIV-infected children, 
mean age 47 months and 
160 HIV-exposed 
uninfected infants; mean 
age 10 months 
Lung 
diffusion 
capacity 
using 99mTc 
DTPA 
- HIV-infected children had 
faster clearance of 99mTc 
DTPA compared to HIV-
exposed uninfected 
children, p<0.05, in the 
absence of clinical 
symptoms 
De Martino et al. 
[11] 1997 
Paeds Pulm 
- Prospective 
longitudinal 
cohort, Italy 
54 children, median age 
64 months, with perinatal 
HIV infection, none on 
ART and 315 healthy 
controls 
Interrupter 
technique 
- Airway resistance greater in 
HIV-infected than 
uninfected, p<0.001 
+BDR: positive bronchodilator responsiveness in FEV1>12%; FEV1: forced expiratory volume in 1s; FVC: forced vital capacity; FEF2575: forced expiratory 
flow between 25-75 sec of vital capacity; 99mTc DTPA: diethylene triamine pentaacetic acid; 6MWT: six-minute walk test; FOT: forced oscillation technique; 
N2MBW: nitrogen multiple breath was-out test; CO: carbon monoxide; HRCT: high resolution chest tomography 
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Abstract 
Rationale: Lung disease is a common cause of mortality and morbidity in HIV-
infected adolescents, but there is limited information on the spectrum of lung 
function impairment in adolescents on antiretroviral therapy.  
Objectives: To investigate lung function in HIV-infected adolescents on antiretroviral 
therapy in the Cape Town Adolescent Antiretroviral Cohort.  
Methods: A total of 515 South African adolescents aged 9 to 14 years, stable on 
antiretroviral therapy for at least six months, underwent baseline lung function 
testing. Measures included spirometry, nitrogen multiple breath washout, forced 
oscillation technique, six-minute walk test, single breath carbon monoxide diffusion 
testing, and bronchodilator response testing. A comparator group of 110 age and 
ethnically matched HIV-uninfected adolescents was also tested. 
Results: For the HIV-infected adolescents (mean (SD) age 12 (1.6) years, 52% male), 
the median (IQR) duration of antiretroviral therapy was 7.6 (4.6-9.2) years. The 
median (IQR) nadir CD4 was 510.5 (274-903) cells/mm3. HIV-infected adolescents 
had significantly lower forced expiratory volume in 1 sec (FEV1), forced vital capacity 
(FVC), FEV1/FVC, diffusing capacity for carbon monoxide (DLCO), respiratory system 
compliance, and functional residual capacity (FRC) than HIV-uninfected adolescents 
(p<0.05 for all associations). HIV-infected adolescents had higher airway resistance 
and lung clearance index than HIV-uninfected adolescents (p<0.05 for all 
associations). Although generally small in magnitude, these differences remained 
significant after adjusting for age, sex and height. In addition, age, sex, height, and 
history of past lower respiratory tract infection or pulmonary tuberculosis were 
associated with reduced lung function. 
Conclusions: Perinatally infected South African HIV-infected adolescents on 
antiretroviral therapy have lower lung function than uninfected adolescents. History 
of severe lower respiratory tract infection or pulmonary tuberculosis is associated 
with lower lung function. 
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Background 
Respiratory disease is the major cause of morbidity and mortality in HIV-infected 
children and adolescents. This burden of disease occurs predominantly in sub-
Saharan Africa. [1] South Africa has the world’s greatest burden of HIV infected 
people with an estimated 6.1 million persons infected, including 410 000 children 
under 15 years. [2] Since 2004, access to paediatric antiretroviral therapy has 
expanded globally, resulting in improved survival of HIV-infected children. [3] In 
South Africa, the number of children less than 15 years of age receiving antiretroviral 
therapy increased from 4200 in 2004 to 152 000 in 2011. [4] In response to 
treatment, the incidence of opportunistic infections has declined dramatically [5] 
Accordingly, HIV is evolving into a chronic illness among adolescents. [3]  
HIV-associated chronic lung disease is common [5-7] but there is limited information 
on the determinants, spectrum or progression of chronic lung disease in perinatally 
infected adolescents. Studies of lung function in HIV-infected children in pre-
antiretroviral therapy era have reported increased airway resistance, [8] while a few 
studies in children on antiretroviral therapy found airway obstruction, [6, 9-12] and 
increased  bronchodilator responsiveness. [13, 14] Studies of adults on antiretroviral 
therapy [15-17] have documented irreversible airway obstruction, reduced diffusion 
capacity and increased bronchodilator response with the most prominent being 
diffusion impairment. [17, 18] Studies of comprehensive lung function testing in HIV-
infected adolescents on antiretroviral therapy are limited, despite a high burden of 
respiratory disease. 
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The aetiology of HIV-associated chronic lung disease is broad, ranging from chronic 
infection to non-infective causes. [5] Diagnosis of chronic lung disease is made in 
South Africa by clinical criteria, imaging and lung function tests. Measurement of 
lung function offers an objective, reproducible, non-invasive measure of lung 
disease. Comprehensive lung function measures strengthen the ability to detect and 
diagnose the spectrum of lung function impairment.  
The aim of this study was to investigate the spectrum and determinants of lung 
function in HIV-infected adolescents on antiretroviral therapy in Cape Town, South 
Africa. Some of the results of these studies have been previously reported in the 
form of an abstract. [19] 
Methods 
Study subjects 
Patients at the Research Centre for Adolescent and Children Health at Red Cross 
Children’s Hospital, South Africa Study subjects were recruited between August 
2013 to April 2015 into a prospective study, the Cape Town Adolescent Anti-
retroviral cohort (CTAAC), a longitudinal cohort study of HIV-infected adolescents 
on antiretroviral therapy. Eligibility was limited to adolescents, aged 9-14 years, with 
vertically transmitted HIV, who had been on antiretroviral therapy for at least 6 
months, knew their HIV status, and where informed parental consent and 
participant assent was obtained. After enrolment, patients followed up monthly. 
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Lung function measures 
Lung function measurements (Appendix 4) were generally performed on eligible 
subjects at the time of enrolment in CTAAC. Lung function testing was deferred if 
the participant had an acute respiratory illness. Testing, therefore, represented 
baseline lung function measured at a time when the participant was well.  
Age, sex and ethnicity matched HIV-uninfected adolescents without known pre-
existing lung disease were enrolled from the Masiphumelele Youth Centre, a 
community based vocational centre in Cape Town to serve as controls. Perinatal HIV-
exposure of the HIV-uninfected participants was not known. 
Lung function testing included spirometry [forced expiratory volume in one sec 
(FEV1), forced vital capacity (FVC) and FEV1/FVC ratio]; single breath carbon 
monoxide diffusion test (DLCO); multiple breath nitrogen washout (multiple breath 
washout) measuring functional residual capacity (FRC) and ventilation homogeneity 
with the lung clearance index; the forced oscillation technique (forced oscillation 
technique testing) measuring respiratory system resistance and compliance; and the 
six-minute walk test. Spirometry was repeated 15 minutes after administering 
400 µg salbutamol via a metered dose inhaler equipped with a spacer.  
Lung function testing was performed using the NDD Easyone Pro LAB (NDD, 
Switzerland) for spirometry, single breath carbon monoxide diffusion test, and 
multiple breath washout. Forced oscillation technique testing was completed using 
custom-made equipment (University of Szeged, Hungary). [20] All testing adhered 
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to the American Thoracic Society/European Respiratory Society (ATS/ERS) 
guidelines. [21-27]  
The highest FVC and FEV1 from any of the acceptable manoeuvres was reported. Z-
standardization for spirometry outcome variables was performed with Global Lung 
Initiative (GLI) software using African-American reference population. [28] 
Bronchodilator response was considered positive if there was an increase in FEV1 of 
≥12% after bronchodilator administration. [22] The lower limit of normal (LLN) was 
calculated using the African-American reference cohort in GLI software, -1.64 
standard deviations (SD) below the mean. [28] 
Forced oscillation technique testing was performed first with the participant seated, 
nose clip on, cheeks firmly supported and breathing quietly through a mouthpiece 
and filter, as per consensus guidelines for testing. [25] Three 20-sec epochs were 
collected. Tests were considered acceptable if breathing was regular and free from 
leak or glottic closure. We collected a minimum of three repeatable tests, defined 
as visually overlapping spectral recordings within 10% of each other. The analysis 
model used was frequency range 10-20 Hz for respiratory system resistance (R) and 
4-26 Hz for respiratory system compliance (C). In the absence of appropriate 
reference ranges, we used our HIV-uninfected adolescents as the reference 
population. 
We followed ATS/ERS recommendations for acceptability of single breath CO 
testing. [24] We performed a minimum of two trials which met quality control 
standards and were within 3 ml/min/mmHg or 10%. Up to four attempts could be 
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done per session. Diffusion factor for carbon monoxide (DLCO) was adjusted for the 
patient’s haemoglobin done on the day of lung function testing. The average of two 
best manoeuvres was taken for analysis. LLN was estimated using the Kim and Hall 
Equations. [29] 
Multiple-breath washout testing adhered to international recommendations. [23, 
27] Tests were considered acceptable if there was regular breathing pattern, 
especially for five tidal breaths before washout and first four breaths of washout, 
devoid of sighs, apnoea or leaks, and complete washout. We ensured adequate time 
between tests (at least 4 minutes) for gas concentration to equilibrate. Multiple-
breath washout repeatability was defined by three technically acceptable tests with 
FRC within 10% of highest value and only excluded test if FRC differed by >25% of 
the median. For lung clearance index repeatability, we excluded test if lung 
clearance index differed by >1 FRC turnover (TO) from the median. Where there 
were two technically acceptable tests, we confirmed FRC repeatability if FRC is 
within 10% of the highest value, and lung clearance index was within one turnover. 
In the absence of appropriate reference ranges for African adolescents for multiple 
breath washout, we used the HIV-uninfected adolescents as the reference 
population. 
For the six-minute walk test, participants were instructed to walk to and fro for six 
minutes. This was done in the research centre where two marked cones had been 
placed 30 m apart, as per standardised recommendations. [26] Heart rate, 
respiratory rate, blood pressure, Borg scale for dyspnoea and oxygen saturation was 
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recorded before and at the end of testing. Distance covered in meters was recorded 
at the end of the test, with published reference data used as normative values. [30] 
Demographic data 
Demographic and exposure data were measured at enrolment. Smoking history was 
self-reported by questionnaire completed by the adolescent and by the parent or 
guardian. Passive smoke exposure was regarded if either respondent reported a 
smoker in the household; active smoking was attributed if the study participant self-
reported smoking. Antiretroviral therapy adherence data was collected via 
questionnaires to both participant and caregiver and graded according to the 
respondent’s subjective rating of adherence as either good or poor. Other covariates 
were extracted from medical records or measured at the study visit. Participants 
were screened for respiratory symptoms using a validated respiratory questionnaire 
derived from the International Study of Asthma and Allergies in Childhood study. 
[31] 
Statistical analysis 
Data were analysed using STATA 12.0, (StataCorp, College Station, Texas, USA). Lung 
function measures were summarised with mean (with SD) or median (with 
interquartile ranges, IQR). We used our HIV-uninfected controls as the reference 
population for normative values for lung clearance index and forced oscillation 
technique testing outcome variables in the absence of reference data in African 
adolescent populations. Z-scores for height and weight were calculated using LMS 
(lambda-mu-sigma) growth charts. [32]  
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Comparison of lung function between HIV-infected and uninfected subjects was 
computed using independent two sample t-test with equal variances, where data 
were normally distributed and Wilcoxon sum rank test for data that was not 
normally distributed. Z-test was used to compute differences between two 
proportions. All statistical tests were 2-sided at α=0.05. Univariable and 
multivariable linear regression was done to explore associations of lung function 
outcomes using the following covariates: HIV status, age, sex, height z-score, 
smoking status, CD4 count and viral load at the time of first study visit, antiretroviral 
therapy adherence, antiretroviral therapy duration, past lower respiratory tract 
infections, pulmonary tuberculosis (pulmonary TB) and self-reported respiratory 
symptoms.  
Ethical approval was obtained from the Faculty of Health Sciences, University of 
Cape Town Human Research and Ethics Committee. Informed consent and assent 
were obtained from study participants and a parent or guardian. 
Results 
A total of 567 HIV- infected adolescents and 114 demographically matched HIV-
uninfected control subjects were enrolled from August 2013 to April 2015. Fifty-six 
(9.9%) participants did not perform lung function testing and were excluded from 
this analysis, providing 515 HIV-infected adolescents and 110 HIV-uninfected 
adolescents with lung function results (figure 1).  
The success rate for spirometry testing in HIV-infected adolescents was 97% and 
88% for single breath test for CO, but 38% for multiple breath washout (figure 1). 
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The mean (SD) age of participants was 12 (1.7) years; 52% were male (table 1). 
Median (IQR) duration of antiretroviral therapy was 7.6 (4.6-9.2) years. Median (IQR) 
nadir CD4 count was 510 (274-903) cells /mm3.  
Past pulmonary TB was reported in 37% of HIV-infected adolescents, compared to 
none of the HIV-uninfected adolescents (table 1). Prior Pneumocystis jirovecii 
pneumonia (PCP) was only reported in 1.4% of cases. Prior pneumonia was more 
commonly reported in HIV-infected than uninfected adolescents. Passive smoke 
exposure occurred in 25% of HIV-infected children, with a similar prevalence in the 
HIV-uninfected group (table 1). Seventy-seven (15%) HIV-infected adolescents had 
a history of a self-reported cough as compared to 7.3% HIV-uninfected adolescents 
(p=0.033). HIV-infected adolescents had more reported wheeze than HIV-uninfected 
adolescents, although the difference was not statistically significant (10.9% vs 5.5%, 
p=0.084), table 1. Eighteen (3.5%) HIV-infected participants had digital clubbing 
compared to only one uninfected adolescent. There was no difference between 
respiratory rate or oxygen saturation between the two groups. 
HIV-infected adolescents had lower z-FVC compared to HIV-uninfected adolescents, 
(table 2). Overall, 75 (15%) HIV-infected adolescents and nine (8%) HIV-uninfected 
had a positive bronchodilator response, p=0.077, (table 2). There was no difference 
in the distance walked or oxygen saturation after six-minute walk test between the 
two groups, (table 3). 
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HIV infection was associated with lower z-FEV1 (coefficient -0.52; 95%CI -0.79 to -
0.26), lower z-DLCO (coefficient -0.23; 95%CI -0.35 to -0.11), lower z-FRC (coefficient 
-0.62; 95%CI -0.87 to -0.36), lower z-compliance (coefficient -0.21;95%CI -1.61 to -
0.80) and increased z-lung clearance index (coefficient 0.84; 95%CI 0.34 to 1.34 and 
increased z-resistance at 8Hz (coefficient 0.42, 95%CI 0.22 to 0.62), (table 4). 
The associations of lung function outcomes in HIV-infected adolescents are shown 
in tables S1-7. History of LRTI and PTB were associated with lower z-FEV1, after 
adjusting for smoking, ART duration and HIV status, coefficient -0.30; 95%CI -0.57 to 
-0.04 and -0.25; 95%CI -0.50 to -0.00 for previous LRTI and PTB respectively, (table 
S1). Longer ART duration was associated with a decrease in z-Reactance at 8Hz 
(coefficient -0.06; 95%CI -0.11 to-0.02), (table S6). History of LRTI was associated 
with increased z-LCI (coefficient 0.55; 95%CI 0.05 to 1.04; adjusting for HIV, smoking, 
ART duration and history of PTB). History of PTB was associated with lower z-DLCO 
(coefficient -0.13; 95% CI -0.23 to -0.02, adjusting for HIV, smoking, ART duration 
and history of PTB), (table S2).  Smoke exposure was not associated with lung 
function, (tables S1-S7). 
On average those who had digital clubbing had lower z-FEV1 compared to those who 
had no clubbing while controlling for smoking, HIV infection, history of past LRTI and 
pulmonary TB, table 5 (coefficient -1.17, 95% CI -1.78 to -0.56). History of self-
reported wheeze and asthma was significantly associated with lower z-FEV1, 
(coefficient 0.92, 95%CI -1.27 to -0.56 and coefficient -1.00, 95%CI -1.34 to -0.65), 
respectively, (table 5). 
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Discussion  
This study provides comprehensive lung function data on a large cohort of 
unselected perinatally HIV-infected adolescents established on antiretroviral 
therapy, showing that lung function outcomes are impaired compared to HIV‐
uninfected adolescents including expiratory flow volumes, ventilation homogeneity, 
resistance and compliance. Although the mean z-FEV1 and z-FVC in the HIV-infected 
adolescents were within normal limits, they were significantly lower than in the HIV-
uninfected. Further, the lung clearance index was increased in HIV-infected children 
reflecting ventilation impairment. The higher resistance and lower compliance 
found in HIV-infected adolescents suggests smaller airways or chronic inflammation.  
Overall lung function impairment was mild in the HIV-infected cohort compared to 
the uninfected patient cohort. The HIV‐infected cohort represented a relatively 
healthy group of perinatally infected adolescents with minimal symptoms, which 
may partly explain the relatively mild lung function impairment.  
Other African studies in Malawian and Zimbabwean HIV‐infected adolescents [6, 11, 
33] have reported more severe symptoms and lung function impairment. In a study 
[6] of 116 Zimbabwean HIV-infected adolescents (69% on antiretroviral therapy), 52 
(45%) were reported to have an FEV1<80%. A cross-sectional study of 145 Malawian 
HIV-infected adolescents of which 72% were on antiretroviral therapy, reported 18% 
to have obstructive disease. [11] Patient selection, with more severely symptomatic 
children being selected for lung function, may have influenced measurements in 
these studies.  
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The relatively preserved lung function in our cohort may also be a result of long-
term antiretroviral therapy use, good adherence to antiretroviral treatment, and 
access to health care enabling timely diagnosis and treatment of intercurrent 
infections. Although our HIV‐infected adolescents had been on antiretroviral therapy 
for approximately 8 years, the median age of initiation of antiretroviral therapy 
occurred only at around 5 years of age, suggesting that use of antiretroviral therapy, 
even when initiated late in childhood, is an important strategy to preserve lung 
health. The reasons for documented low lung function in HIV‐infected children may 
be related to prior illness, or HIV infection specifically. Opportunistic infections (OIs) 
have been reported to increase cytokines in serum and sputum, so promoting HIV 
mediated chronic airway inflammation. [15] 
Only a minority of adolescents had bronchodilator responsiveness, similar to that 
reported in a Malawian study. [11] Several mechanisms may predispose to 
irreversible airway damage in this group including recurrent infection, fibrosis and 
increased oxidative stress mediated by downregulation of glutathione pathways by 
the HIV virus. [34] Irreversible airway damage may also reflect bronchiolitis 
obliterans which has been commonly reported in a Zimbabwean cohort. [6]  
In our cohort, previous respiratory tract infection was common and associated with 
lower lung function. Previous lower respiratory tract infection or pulmonary TB was 
strongly associated with reduced lung function, both of which were more common 
in HIV‐infected participants. This is consistent with data from HIV‐uninfected children 
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showing lower respiratory tract infection in childhood to be associated with lower 
lung function in later life. [35, 36] 
Bacterial pneumonia in HIV-infected adults has been associated with permanent 
declines in FEV1, FVC, FEV1/FVC and DLCO. [37] Opportunistic infections like 
Pneumocystis jirovecii pneumonia have also been associated with increased 
metalloproteinases and chronic airflow obstruction in HIV infected adults. [38] Very 
few HIV-infected adolescents reported prior PCP in this cohort. Further HIV-infected 
adolescents had higher airway resistance possibly due to smaller airways from 
impaired growth, repeated lower respiratory tract infections, OIs or increased airway 
inflammation. Higher airway resistance has been demonstrated in HIV‐infected 
children before widespread use of antiretroviral therapy. [8] 
Although low lung function on spirometry was common in HIV‐infected adolescents, 
diffusion abnormalities were uncommon. Very few children were active smokers and 
only approximately a quarter reported passive smoke exposure; in contrast, HIV-
infected adult studies have reported diffusion impairment in the context of high 
smoke exposure. [17] The absence of an association between passive smoking and 
lung function outcomes may possibly reflect underreporting of smoke exposure 
which was self‐reported. The lack of association could also reflect a shorter term, 
lower dose exposure among adolescents compared to that reported in the adult 
emphysema literature. Diffusion abnormalities reported in both smoking and non‐
smoking HIV‐infected adults have been explained by the presence of radiological 
emphysema due to loss of capillary blood volume. [39]  
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Emphysema may not be important in the aetiology of chronic lung disease in HIV-
infected adolescents given the imaging findings that have been previously published 
that show predominantly bronchiolitis obliterans. [6] Other mechanisms postulated 
include alveolar-capillary membrane inflammation due to opportunistic infections 
like PCP or pulmonary TB. [18, 39] The lower DLCO in HIV‐infected adolescents in our 
study cohort may represent a loss of alveolar volume, because of previous 
respiratory infection or ongoing inflammation.  
The six‐minute walk test is an insensitive measure of cardiopulmonary compromise 
which only becomes impaired in moderate to severe disease. Therefore, the finding 
that the distance walked and arterial oxygen saturation on the six-minute walk test 
was similar in HIV-infected children and controls probably reflects the lack of severe 
cardiorespiratory compromise and relatively mild lung disease.  
Limitations 
One limitation of the study is that childhood history of prior lower respiratory 
infection or pulmonary TB were based on recall. Despite this, there was a strong 
association between prior lower respiratory tract infection or pulmonary TB and 
impaired lung function.  
A second limitation is a lack of appropriate normative reference values in African 
population for lung function, but the study is strengthened by the inclusion of an 
age‐matched control group. Further, the use of the GLI African‐American data for 
spirometry normal values provided an appropriate reference standard.  
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We did not obtain official birth records on the HIV‐uninfected participants to 
establish HIV exposure perinatally; however, given the very long time from exposure 
to enrolment in this cohort, any possible residual effect of HIV exposure on lung 
health is unclear and likely to be minimal. As the cohort was enrolled at 9-14 years 
of age, it is impossible to obtain data on HIV exposure in-utero in HIV-negative 
individuals during pregnancy. A decade ago, it was not routine to test pregnant 
woman and the enrolled adolescents will not know if they were HIV exposed. Even 
if we tested their mother’s now, there would be no way of knowing whether they 
were HIV-infected at the time of pregnancy. A further limitation is that few children 
met the strict criteria for multiple breath washout quality analysis as any who had 
sighs, glottis closure or hyperventilation during testing were excluded. This occurred 
in both HIV‐infected adolescents and controls. However, success rates in performing 
spirometry were more than 95% and there were also high rates of success for DLCO, 
forced oscillation technique testing and six‐minute walk test.  
Another limitation is the inability to correlate lung function with precise radiological 
abnormalities as we did not obtain radiological imaging due to concerns about 
exposure to radiation and cost. These findings may not be generalizable to other 
settings in sub-Saharan Africa where adolescents may be more severely 
symptomatic and have more delayed access to antiretroviral therapy and to health 
care. Nevertheless, the results suggest that antiretroviral therapy may be effective 
for preserving lung health even when started late in childhood.  
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Conclusions 
South African HIV‐infected adolescents on antiretroviral therapy have significantly 
lower lung function than HIV‐uninfected adolescents. Despite being well controlled 
on antiretroviral therapy, the study showed mild lung function impairment in HIV-
infected adolescents, though significantly lower compared to age-matched HIV-
uninfected. Previous lower respiratory infection and pulmonary TB were associated 
with lower lung function. With the growing number of perinatally HIV-infected 
adolescents in Africa facing improved survival and wellbeing on antiretroviral 
therapy, investigating the implications of these findings on long term respiratory 
health in this population is a priority which we are currently undertaking. 
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5Table 1: Characteristics of the study population 
 HIV-infected  
n=515 
HIV-uninfected 
n=110 
P-value 
Age, years 12.0 (1.6) 11.8 (1.8) 0.355 
Height for age z-score -1.3 (1.0) -0.5 (1.1) <0.001 
Weight for age z-score -0.8 (1.1) 0.1(1.2) <0.001 
Male, n (%) 266 (52.1) 48 (45.3) 0.127 
Smoke exposure, n (%) none 379 (74.3) 83 (78.3) 0.388 
passive  127 (24.9) 20 (18.9) 0.185 
active 2 (0.4) 1 (0.9) 0.458 
Past lower respiratory tract 
infection, n (%) 
147 (28.8) 1 (0.9) <0.001 
Past pulmonary TB, n (%) 301 (37.1) 0 (0) <0.001 
PCP, n (%) 7 (1.4%) 0(0) 0.220 
History of cough, n (%) 77 (15.0) 8 (7.3) 0.033 
History of wheeze, n (%) 56 (10.9) 6 (5.5) 0.084 
History of asthma, n (%) 51 (9.9) 7 (6.4) 0.246 
Shortness of breath, n (%) 17 (3.3) 2 (1.8) 0.411 
Clubbing, n (%) 18 (3.5) 1 (0.9) 0.152 
Respiratory rate, breaths/min 21.5 (3.4) 20.8 (5.1) 0.189 
Oxygen saturation (%) 98.6 (0.9) 98.8 (0.5) 0.063 
CD4 nadir count, (cells/mm3), n=442 510.5 (274-903)   
CD4 current, (cells/mm3), n=510 713 (561-957.5)   
Viral load zenith, (copies/mL), n=195 226 (40-3927)   
Antiretroviral therapy duration, 
(years), n=497  
7.6 (4.6-9.2)   
Age at antiretroviral therapy 
initiation, (years) 
5.0 (3.5)   
Poor antiretroviral therapy 
adherence, n (%) 
51 (10.8)   
Values are mean (SD) or median (IQR); P value computed by two-sample test for proportions or independent 
two-sample T-test. lower respiratory tract infection, lower respiratory tract infections; pulmonary TB, pulmonary 
tuberculosis; antiretroviral therapy, antiretroviral therapy; PCP, Pneumocystis jirovecii pneumonia 
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6Table 2: Baseline lung function tests 
Spirometry 
HIV-infected  
n=499 
HIV-uninfected  
n=106) 
P-value 
FEV1 z-score -1.0 (1.3) -0.5 (1.0) <0.001 
FVC z-score  -1.1 (1.3) -0.8 (1.04) 0.064 
FEV1/FVC z-score 0.2 (1.4) 0.9 (1.2) <0.001 
+BDR, n (%) 75 (15) 9 (8) 0.006 
Single breath CO diffusion test n=454 n=98  
DLCO z-score -0.6 (0.5) -0.3 (0.7)  0.002 
DLCO /VA z-score 0.7 (1.1) 0.5 (1.2) 0.078 
Multiple breath washout (med/IQR) n=193 n=41  
FRC z-score -0.6 (-1.1 to -0.2) -0.2 (-0.8- 0.7) 0.001 
LCI z-score 0.6 (-0.2-1.6) -0.2 (-0.8- 0.9) 0.002 
Forced oscillation technique testing 
(med/IQR) 
n=397 n=104 P-value 
z- score Resistance at 8Hz 0.4 (-0.2 to 0.9) -0.1 (-0.7 to 0.7) <0.0001 
z- score Reactance at 8 Hz -0.2(-1.0 to 0.3) 0.2 (-0.5 to 0.7) 0.0001 
z- score mean respiratory system 
resistance 
0.3 (-0.2 to 0.8) -0.1 (-0.8 to 0.7) 0.0001 
z- score compliance -0.2 (-0.5 to 0.3) 0.2 (-0.3 to 1.3) <0.0001 
Values are mean (SD) unless otherwise indicated. P values computed by T-test or Wilcoxon sum rank test depending 
on data normality. forced oscillation technique testing and multiple breath washout compared to control data; 
Spirometry reference equation: GLI 2012 [28] DLCO referenced to Kim et al., 2012 [29] 
FEV1, forced expiratory volume in 1s; FVC, forced vital capacity;  LCI, lung clearance index; FRC, functional residual 
capacity; DLCO, transfer factor for carbon monoxide; VA, alveolar volume  
 
 
7Table 3: Six-minute walk test  
Six-min walk test HIV-infected  
n=339 
HIV-uninfected  
n=99 
P-value 
Distance walked, metres 433.7 (57.0) 443.5 (60.5) 0.138 
Pulse before test, beats per min 78.1 (12.2) 83.0 (13.5) <0.001 
Pulse after test, beats per min 82.3 (13.9) 87.2 (14.4) 0.002 
Oxygen saturation after test (%) 98.7 (0.8) 98.8 (0.6) 0.473 
MAP before test (mmHg) 77.6 (7.9) 81.4 (7.9) <0.001 
P-value computed using independent two-sample T-test. MAP, mean arterial pressure 
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8Table 4: Effect of HIV-infection on lung function 
variable coefficient P value 95%CI 
zFEV1 (n=605) 
HIV status 
 
-0.52 
 
<0.001 
 
-0.79 to -0.26 
z-DLCO (n=552) 
HIV infection 
 
-0.23 
 
<0.001 
 
-0.35 to -0.11 
z-score FRC (n=234) 
HIV infection 
 
-0.62 
 
<0.001 
 
-0.87 to -0.36 
z-score LCI (n=234) 
HIV infection 
 
0.84 
 
0.001 
 
0.34 to 1.34 
z-score Resistance at 8Hz (n=501) 
 
HIV infection 
 
0.42 
 
<0.001 
 
0.22 to 0.62 
z-score Reactance at 8Hz (n=501) 
HIV infection 
 
-0.51 
 
<0.001 
 
-0.77 to -0.25 
z-score Compliance (n=501) 
HIV infection 
 
-1.21 
 
<0.001 
 
-1.61 to -0.80 
P value adjusted for HIV infection: linear regression 
FEV1, forced expiratory volume in 1s; lung clearance index, lung clearance index; FRC, functional residual 
capacity; DLCO, transfer factor for carbon monoxide. 
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9Table 5: Effect of self-reported respiratory symptoms on lung function in HIV-infected 
adolescents  
 z-FEV1 z-DLCO z-LCI 
Symptoms Coeff* 95% CI Coeff* 95% CI Coeff* 95% CI 
History of asthma -1.00 -1.34 to -0.65 -0.01 -0.16 to 0.15 0.48 -0.18 to 1.14 
History of wheeze -0.92 -1.27 to -0.56 -0.01 -0.17 to 0.15 -0.11 -0.78 to 0.55 
History of cough -0.30 -0.61 to 0.01 0.10 -0.04 to 0.25 0.54 -0.07 to 1.15 
Digital clubbing -1.17 -1.78 to -0.56 -0.36 -0.64 to -0.08 0.01 -1.32 to 1.34 
* Adjusted for HIV status, smoking, history of lower respiratory tract infections, history of pulmonary TB and 
antiretroviral therapy duration 
Coeff, coefficient; CI confidence interval, LCI, Lung clearance index; FEV1, forced expiratory volume in 1s; DLCO, 
transfer factor for carbon monoxide 
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DLCO, transfer factor for carbon monoxide 
4Figure 1: Cohort description 
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Supplementary Material  
10Table S1: Associations of z-FEV1 in HIV-infected adolescents 
  Univariable analysis Multivariable analysis n=465 
  N Coeff 95%CI Coeff 95%CI 
Smoking None 457 ref - - - 
 Passive 148 0.09 -0.15 to 0.33 0.11 -0.17 to 0.39 
 Active 3 -0.95 -2.42 to 0.52 -1.65 -3.49 to 0.20 
HIV status  Yes 503 -0.52 -0.79 to -0.25 Omitted*  
CD4+ T-cell count 
(cells/mm3) 
 501 0.00 -0.00 to 0.00 - - 
HIV viral load 
(copies/mL) <50 
 502 
383 
 
ref 
   
50-1000  55 -0.45 -0.82 to -0.07   
1001-10000  37 -0.45 -0.89 to -0.01 - - 
>10000  27 -0.67 -1.18 to -0.15   
ART duration (Y)  486 -0.02 -0.03 to -0.00 -0.03 -0.07 to 0.02 
Age at ART initiation (Y)  494 -0.01 -0.04 to 0.03   
ART adherence Good 382 ref - - - 
 Poor 116 0.16 -0.11 to 0.44 - - 
History of LRTI No 395 ref - - - 
 Yes 146 -0.45 -0.70 to -0.21 -0.30 -0.57 to -0.04 
History of PTB No 290 ref - - - 
 Yes 305 -0.39 -0.59 to -0.18 -0.25 -0.50 to -0.00 
Y: years; FEV1: forced expiratory volume in 1 second; PTB: pulmonary tuberculosis; ART: antiretroviral 
therapy; LRTI: lower respiratory tract infection; *HIV status omitted because of collinearity 
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11Table S2: Associations of z-DLCO in HIV-infected adolescents 
  Univariable analysis Multivariable analysis n=415 
  N Coeff 95%CI Coeff 95%CI 
Smoking None 409 ref - - - 
 Passive 137 0.04 -0.07 to 0.15 -0.01 -0.13 to 0.10 
 Active 2 -0.16 -0.94 to 0.63 -0.02 -0.75 to 0.71 
HIV status  Yes 549 -0.23 -0.35 to -0.11 Omitted*  
CD4+ T-cell count 
(cells/mm3) 
 449 -0.00 -0.00 to 0.00 - - 
HIV viral load 
(copies/mL) <50 
 450
344 
 
ref 
 - - 
50-1000  50 -0.03 -0.18 to 0.13   
1001-10000  33 -0.03 -0.22 to 0.16 - - 
>10000  23 -0.07 -0.29 to 0.15   
ART duration (Y)  443 -0.01 -0.02 to 0.01 -0.00 -0.02 to 0.01 
Age at ART initiation (Y)  443 0.04 0.02 to 0.05 - - 
ART adherence Good 339 ref - - - 
 Poor 107 0.03 -0.09 to 0.15 - - 
History of LRTI No 359 ref - - - 
 Yes 129 -0.11 -0.22 to -0.00 -0.08 -0.19 to 0.03 
History of PTB No 266 ref - - - 
 Yes 270 -0.18 -0.27 to -0.08 -0.13 -0.23 to -0.02 
Y: years, DLCO: diffusion factor for carbon monoxide; PTB: pulmonary tuberculosis; ART: antiretroviral 
therapy; LRTI: lower respiratory tract infection; *HIV status omitted because of collinearity 
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12Table S3: Associations of z-FRC in HIV-infected adolescents 
  Univariable analysis Multivariable analysis n=183 
  N Coeff 95% CI Coeff 95% CI 
Smoking None 164 - - - - 
 Passive  68 0.03 -0.20 to 0.26 -0.07 -0.30 to 0.16 
 Active 1 0.29 -1.29 to 1.87 0.58 -0.94 to 1.90 
HIV status  233 -0.61 -0.87 to -0.35 Omitted*  
CD4+ T-cell count 
(cells/mm3) 
 191 -0.00 -0.00 to 0.00 - - 
HIV viral load 
(copies/mL) 
<50 
  
147 
 
- 
 
- 
- - 
50-1000  20 -0.07 -0.40 to 0.26   
1001-10000  9 0.18 -0.29 to 0.66   
>10000  15 -0.17 -0.55 to 0.21   
ART duration (Y)  188 -0.01 -0.04 to 0.02 -0.01 -0.04 to 0.03 
Age at ART initiation (Y)  188 0.04 0.01 to  0.07   
ART adherence Good 140 -  - - 
 Poor 50 0.14 -0.09 to 0.37  - - 
History of LRTI No 150 - - - - 
 Yes 57 -0.15 -0.37 to 0.07 -0.10 -0.34 to 0.13 
History of PTB No 112 - - - - 
 Yes 115 -0.26 -0.46 to -0.05  -0.02 -0.24 to 0.19 
Y: years; FRC: functional residual capacity; PTB: pulmonary tuberculosis; ART: antiretroviral therapy; LRTI: 
lower respiratory tract infection; *HIV status omitted because of collinearity 
 
 
 73 
 
13Table S4: Associations of z-LCI in HIV-infected adolescents 
  Univariable analysis Multivariable analysis n=183 
  N Coeff 95% CI Coeff 95% CI 
Smoking None 164 - - - - 
 Passive  68 0.06 -0.36 to 0.48 0.16 -0.32 to 0.65 
 Active 1 4.49 1.56 to 7.42 3.5 0.54 to 6.54 
HIV status  233 0.85 0.35 to 1.35 Omitted*  
CD4+ T-cell count 
(cells/mm3) 
 191 -0.00 -0.00 to 0.00 - - 
HIV viral load 
(copies/mL) 
<50 
  
147 
 
- 
 
- 
- - 
50-1000  20 0.57 -0.16 to 1.31   
1001-10000  9 0.07 -0.99 to 1.12   
>10000  15 0.13 -0.71 to 0.96   
ART duration (Y)  188 0.12 0.05 to 0.19 0.10 0.03 to 0.18 
Age at ART initiation (Y)  188 -0.08 -0.14 to  -0.02   
ART adherence Good 140 -  - - 
 Poor 50 -0.23 -0.74 to 0.28  - - 
History of LRTI No 150 - - - - 
 Yes 57 0.82 0.36 to 1.27 0.55 0.05 to 1.04 
History of PTB No 112 - - - - 
 Yes 115 0.46 0.07 to 0.85  0.08 -0.38 to 0.54 
Y: years; LCI: lung clearance index; PTB: pulmonary tuberculosis; ART: antiretroviral therapy; LRTI: lower 
respiratory tract infection; *HIV status omitted because of collinearity 
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14Table S5: Associations of z-Resistance at 8Hz in HIV-infected adolescents 
  Univariable analysis Multivariable analysis n=366 
  N Coeff 95% CI Coeff 95% CI 
Smoking None 378 - - - - 
 Passive  115 -0.06 -0.26 to 0.13 -0.04 -0.26 to 0.18 
 Active 3 0.17 -0.89 to 1.23 0.72 -0.53 to 1.98 
HIV status  497 0.43 0.23 to 0.62 Omitted*  
CD4+ T-cell count 
(cells/mm3) 
 391 0.00 -0.00 to 0.00 - - 
HIV viral load 
(copies/mL) <50 
  
292 
 
 
- 
 
- 
 
- 
 
- 
50-1000  46 0.18 -0.10 to 0.45   
1001-10000  32 -0.27 -0.60 to 0.05   
>10000  22 0.15 -0.23 to 0.53   
ART duration (Y)  386 0.02 -0.01 to 0.05 0.02 -0.02 to 0.05 
Age at ART initiation (Y)  386 -0.05 -0.08 to  -0.03 - - 
ART adherence Good 298 -  - - 
 Poor 90 -0.03 -0.24 to 0.18  - - 
History of LRTI No 327 - - - - 
 Yes 112 -0.01 -0.21 to 0.19 -0.11 -0.32  to 0.09 
History of PTB No 247 - - - - 
 Yes 238 0.17 0.01 to 0.34  0.02 -0.17 to 0.21 
Y: years; PTB: pulmonary tuberculosis; ART: antiretroviral therapy; LRTI: lower respiratory tract infection; 
*HIV status omitted because of collinearity 
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15Table S6: Associations of z-Reactance at 8Hz in HIV-infected adolescents 
  Univariable analysis Multivariable analysis n=366 
  N Coeff 95% CI Coeff 95% CI 
Smoking None 378 - - - - 
 Passive  115 0.16 -0.09 to 0.42 0.14 -0.16 to 0.44 
 Active 3 -1.79 -3.19 to -0.40 -2.85 -4.61 to -1.08 
HIV status  497 -0.52 -0.78 to -0.26 Omitted*  
CD4+ T-cell count 
(cells/mm3) 
 391 -0.00 -0.00 to 0.00 - - 
HIV viral load 
(copies/mL) <50 
  
292 
 
 
- 
 
- 
 
- 
 
- 
50-1000  46 -0.40 -0.79 to -0.00   
1001-10000  32 0.08 -0.39 to 0.54   
>10000  22 -0.17 -0.72 to 0.38   
ART duration (Y)  386 -0.07 -0.12 to -0.03 -0.06 -0.11 to -0.02 
Age at ART initiation (Y)  386 0.09 0.06 to 0.13 - - 
ART adherence Good 298 -  - - 
 Poor 90 0.17 -0.13 to 0.47  - - 
History of LRTI No 327 - - - - 
 Yes 112 -0.32 -0.60 to -0.05 -0.10 -0.39 to 0.19 
History of PTB No 247 - - - - 
 Yes 238 -0.33 -0.54 to -0.11  -0.12 -0.39 to 0.39 
Y: years; PTB: pulmonary tuberculosis; ART: antiretroviral therapy; LRTI: lower respiratory tract infection; 
*HIV status omitted because of collinearity 
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16Table S7: Associations of z-Compliance in HIV-infected adolescents 
  Univariable analysis Multivariable analysis n=366 
  N Coeff 95% CI Coeff 95% CI 
Smoking None 378 - - - - 
 Passive  115 0.22 -0.19 to 0.62 0.12 -0.13 to 0.37 
 Active 3 -0.81 -3.01 to 1.40 -0.97 -2.42 to 0.47 
HIV status  497 -1.21 -1.62 to -0.80 Omitted*  
CD4+ T-cell count 
(cells/mm3) 
 391 -0.00 -0.00 to 0.00 - - 
HIV viral load 
(copies/mL) <50 
  
292 
 
 
- 
 
- 
 
- 
 
- 
50-1000  46 -0.28 -0.59 to 0.03   
1001-10000  32 0.08 -0.29 to 0.44   
>10000  22 -0.36 -0.80 to 0.07   
ART duration (Y)  386 -0.02 -0.05 to 0.02 -0.01 -0.05 to 0.02 
Age at ART initiation (Y)  386 0.04 0.02 to  0.07 - - 
ART adherence Good 298 -  - - 
 Poor 90 0.00 -0.24 to 0.24  - - 
History of LRTI No 327 - - - - 
 Yes 112 -0.32 -0.75 to 0.12 0.05 -0.18  to 0.29 
History of PTB No 247 - - - - 
 Yes 238 -0.59 -0.94 to -0.25  -0.12 -0.34 to 0.10 
Y: years; PTB: pulmonary tuberculosis; ART: antiretroviral therapy; LRTI: lower respiratory tract infection; 
*HIV status omitted because of collinearity 
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Abstract 
Introduction 
Antiretroviral therapy (ART) has reduced morbidity and mortality in sub-Saharan Africa, but 
the burden of coexistent cardiopulmonary disease in perinatally HIV-infected adolescents 
on ART has not been well described. The aim of this study was to investigate the prevalence 
and associations of cardiopulmonary dysfunction in adolescents with perinatally acquired 
HIV on antiretroviral therapy.  
Methods 
For this cross-sectional analysis, 515 perinatally HIV-infected adolescents ages 9-14 years 
on ART for at least six months, and a comparator group of 110 age-matched HIV-uninfected 
adolescents were tested between August 2013-April 2015 using echocardiography, six-
minute walk test (6MWT) and spirometry. Those with either abnormal spirometry or 
abnormal 6MWT and any right or left systolic or diastolic dysfunction or abnormal mean 
pulmonary arterial pressure were considered as having impaired cardiopulmonary 
function. Logistic regression was used to investigate determinants of impaired 
cardiopulmonary function. 
Results 
Overall, 474 adolescents with perinatally acquired HIV (mean [SD] age, 12 [1.6] years; 
median [IQR] ART duration, 7 [4.6-9.3] years; median [IQR] CD4 count, 712 [571-959] 
cell/mm3) and 109 HIV-uninfected adolescents (mean (SD) age 11.8 (1.8) years, had 
successful cardiac and lung function testing. Impaired cardiopulmonary function was 
detected in 13% of adolescents with perinatally acquired HIV and 8% of HIV-uninfected 
adolescents, p=0.136. Among adolescents with perinatally acquired HIV those with low 
tricuspid annular plane systolic excursion (TAPSE) had lower mean z-FEV1, 1.9 (1.4). versus 
-1.6 (1.3), p = 0.07, but this difference was not statistically significant. Height (OR 0.7, 95%CI 
0.5-0.9), body mass index (OR 0.7, 95%CI 0.5-0.9) and past pulmonary tuberculosis (OR 2.3, 
95%CI 1.2-4.4) were significantly associated with a low cardiopulmonary function. 
Conclusion 
Despite being on ART, cardiopulmonary dysfunction occurs in an appreciable proportion of 
perinatally HIV-infected adolescents but no significant difference to uninfected controls. 
This finding requires further exploration. Factors associated with dysfunction may be 
amenable to public health interventions to reduce cardiopulmonary disease in this 
population.  
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Introduction  
With improved survival of adolescents with perinatally acquired HIV on antiretroviral 
therapy (ART), HIV has become a chronic disease, with perinatally infected children 
surviving into adolescence and adulthood. [1] HIV-related cardiac disease [2-4] and/or 
chronic lung disease has been reported in sub-Saharan Africa. [5, 6] Symptoms which can 
be attributed to either cardiac or lung disease like tachypnoea or dyspnoea can overlap 
posing a diagnostic challenge. 
In the pre-ART era, a high prevalence of cardiac abnormalities especially left ventricular 
dysfunction and cardiomyopathy were reported, [7] but a sharp decline has been found 
with the use of ART. [8, 9] Although ART has reduced the incidence and severity of acute 
pulmonary infections, lung function abnormalities are still highly prevalent. [10, 11] Right 
heart dysfunction may be secondary to chronic lung disease. Miller et al. [4] reported a 29% 
prevalence of right ventricle dilatation in a Zimbabwe cohort of perinatally HIV-infected 
adolescents (71% on ART, median duration of ART 20 months). Nearly 50% of this 
population had chronic lung disease.  
ART also has an impact on exercise tolerance, which is a marker of cardiopulmonary 
function status. HIV-infected children on ART in Malawi had better exercise tolerance 
compared with HIV-infected ART-naive children. [12] ART-naive HIV-infected children had 
worse symptoms of cough, dyspnoea, hypoxaemia and low exercise tolerance compared 
with those on ART. [13] Although ART is reported to improve cardiac function, exercise 
tolerance and lung function, children on ART still have lower lung function, [11] lower 
exercise tolerance [12] and lower cardiac function [14] compared to HIV-uninfected 
children. Most of these published studies were from the era when ART access was not 
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universal, was initiated based on clinical and immunological severity; hence the need for 
studies from well-established ART cohorts. 
Risk factors for cardiopulmonary dysfunction may include HIV immunosuppression, 
opportunistic infections, poor ART adherence, late age at initiation of ART, malnutrition or 
smoking. Other risk factors may be specific to cardiac dysfunction like dyslipidaemia. 
Further, transplacental exposure to drugs like zidovudine has been reported to impact fetal 
cardiac development. [15] Lung disease may lead to right heart strain and pulmonary 
hypertension progressing to cor-pulmonale. [16] Conversely, cardiac dysfunction as 
measured by a reduced left ventricular ejection fraction may result in fluid overload causing 
pulmonary oedema and subsequent poor lung compliance. HIV has also been documented 
to cause primary pulmonary hypertension in adults [17] and adolescents. [18]  
The aim of this study was to investigate the prevalence and determinants of 
cardiopulmonary dysfunction in perinatally HIV-infected adolescents on antiretroviral 
therapy.  
Methods 
A prospective study, the Cape Town Adolescent Anti-retroviral cohort (CTAAC), previously 
described [11], enrolled 515 perinatally HIV-infected adolescents on ART and 110 age-
matched HIV-uninfected adolescents. Patients were enrolled from August 2013 to April 
2015 and followed six-monthly at the Research Centre for Adolescent and Child Health at 
Red Cross War Memorial Children’s Hospital, South Africa.  
Participants were eligible for the study if they were adolescents aged 9-14 years, with 
perinatal HIV infection, had been on ART for at least six months and knew their HIV status. 
Informed parental consent and participant assent were obtained. Age-matched HIV-
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uninfected adolescents without known pre-existing lung or cardiac disease were enrolled 
from Masiphumelele Youth Centre in Cape Town, South Africa. Perinatal HIV exposure of 
the HIV-uninfected participants was unknown, but all tested negative for HIV prior to 
enrolment in the study. Ethical approval was obtained from the Human Research Ethics 
Committee of the University of Cape Town.  
Data presented here are from the enrolment visit. Data on demography, self-reported 
smoking history and cardiorespiratory symptoms, ART duration and adherence, previous 
pulmonary tuberculosis (PTB) and other lower respiratory tract infections (LRTI) were 
collected by validated questionnaires. A history of previous PTB or LRTI was extracted from 
hospital records and supplemented by participant or caregiver report. Respiratory 
symptoms of wheeze, shortness of breath were self-reported. Blood was taken for CD4 
count (Beckman Coulter®, USA) and HIV viral load (Roche COBAS Ampliprep, Germany). 
Adherence to ART was self-reported and measured using any missed doses in the last 30 
days. 
Lung function testing 
Lung function testing [11] included spirometry measuring forced expiratory volume in one 
second (FEV1), forced vital capacity (FVC) and FEV1/FVC as measures of dynamic lung 
volumes and airflow obstruction; and the six-minute walk test measuring effort tolerance. 
Lung function testing was deferred if the participant had an acute respiratory illness. 
Spirometry was done using the NDD Easyone Pro LAB (NDD, Switzerland). All testing 
adhered to the American Thoracic Society/European Respiratory Society (ATS/ERS) 
guidelines. [19-21] We reported the highest FVC or FEV1 from any of 3 acceptable 
spirometric attempts. The lower limit of normal (LLN) for spirometry outcome variables 
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was calculated using the African-American reference cohort in Global Lung Initiative (GLI) 
software, -1.64 standard deviations (SD) below the mean. [22] 
For the six-minute walk test, the participant was instructed to walk for six minutes, 
between two marked cones placed 30 metres apart, as per standardized recommendations 
[21] Heart rate, respiratory rate, blood pressure, Borg scale for dyspnoea and oxygen 
saturation were recorded before and at the end of testing. Distance covered in meters was 
recorded at the end of the test, with published reference data used as normative values. 
[23] 
Spirometry patterns were used to define abnormal lung function. Abnormal lung function 
was defined as either abnormal 6MWT or abnormal spirometry with obstructive (FEV1/FVC 
less than the lower limit of normal (LLN), restrictive (FVC<LLN with normal FEV1/FVC) or 
mixed pattern spirometry (FEV1<LLN, FEV1/FVC<LLN and FVC<LLN). Abnormal 6MWT was 
defined as desaturation>5% post exercise or oxygen saturation < 94% at rest after exercise.  
Cardiac function testing 
Cardiac function testing [24] was assessed by echocardiography, performed by a trained 
research echocardiographer using either a Philips IE33 or CX50 echo machines (Phillips, 
Netherlands) using standardized techniques. [25, 26] All echocardiographs were 
interpreted by a single cardiologist. A random subset of 10% was also read by a second 
blinded cardiologist. Both cardiologists were blinded to the HIV status of the participant. 
Inter-reader disagreements were resolved by consensus. 
Right ventricular (RV) systolic function was determined by calculating the percentage 
fractional area change (FAC) and the volumetric RV ejection fraction i.e. tricuspid annular 
plane systolic excursion (TAPSE). TAPSE was measured using M Mode echo [27] and FAC 
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was measured by a 2-D technique for tracing the area during systole and diastole by using 
the formula = (RV end-diastolic area - RV end-systolic area)/RV end-diastolic area X 100. 
[28] Pulmonary artery pressures (systolic and diastolic) were estimated using standard 
continuous and pulse wave Doppler methods. Cardiac dimensions were assessed in the 
standard manner either using direct measurement of 2-D images or M Mode recordings. 
TAPSE is a global parameter for right ventricular function which describes apex-to-base 
shortening. [29, 30] TAPSE has been found to be highly specific and easy method to 
estimate the right ventricular ejection fraction. [31, 32] FAC has better correlation with 
cardiac MRI derived RV systolic dysfunction. [33] 
Left ventricular (LV) systolic function was determined by measuring shortening fraction (M-
mode) and deriving ejection fraction using the Teichholz method [34] and the modified 
Simpson’s method. [35] Left ventricular diastolic function was measured using Doppler 
assessment of mitral inflow. Tissue Doppler techniques were used to measure mitral 
annular velocity.  
The following deﬁnitions were used to define abnormal findings:  
1. Right ventricular systolic dysfunction was defined as low TAPSE or low FAC. TAPSE 
z-score <2 (z-score was calculated based on published normal values). [36] Z-scores 
were normalised to body surface area. [37] A fractional area change measurement 
of the RV (FAC) ≤34% was considered abnormal. [38] 
2. Pulmonary hypertension: Mean pulmonary arterial pressure (mPAP) was calculated 
using the Chemla equation. [2, 39] (mPAP= (0.61 × PAPs) + 2 mmHg) was normal if 
less than 25 mmHg. [2] 
3. LV systolic dysfunction: Left ventricular shortening fraction (LVSF) ≤25%. [27] 
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4. LV diastolic dysfunction: E-wave/A-wave normal range was calculated according to 
age as per Eidem et al. [40] 
5. Cardiopulmonary dysfunction was defined as any right ventricle or left ventricle 
systolic or diastolic dysfunction or abnormal mean pulmonary arterial pressure and 
abnormal spirometry or abnormal 6MWT. 
Data analysis 
Descriptive statistics were used to describe characteristics of the study population and to 
summarise cardiopulmonary outcomes by HIV status. Comparison of cardiopulmonary and 
clinical outcomes by HIV status was compiled using the two-sample test of proportions. 
Independent two-sample t-test was used to compare lung function in the adolescents with 
perinatally acquired HIV between those with low TAPSE and normal TAPSE. A new variable, 
cardiopulmonary status was generated; those with either obstructive or restrictive or 
mixed spirometry or abnormal 6MWT and any right or left systolic or diastolic dysfunction 
or abnormal mean pulmonary arterial pressure were considered as an impaired 
cardiopulmonary function. Univariate and multivariate logistic regression was done using 
the cardiopulmonary function as the outcome variable.  
Results 
Five hundred and fifteen adolescents with perinatally acquired HIV and 110 HIV-uninfected 
controls had lung function testing. Four hundred and seventy-four adolescents with 
perinatally acquired HIV and 109 HIV-uninfected completed echocardiogram testing; 478 
APH, 104 uninfected adolescents completed six-minute walk test, figure 1. Mean (SD) age 
was 12 (1.6) years and 50% were male. Median (IQR) duration of ART was 7.6 (4.6-9.3) 
years. Median (IQR) CD4 count was 712 (571-959) cells/mm3, 77.9% had viral load<50 
copies/ml, table 1. Sixty per cent of the participants were on two nucleoside-reverse 
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transcriptase inhibitors (NRTI), 75% on abacavir and one non-nucleoside-reverse 
transcriptase inhibitors (NNRTI), 98% were on efavirenz. Median age at ART initiation was 
4.4 (2.0-7.0) years, with 29.7% initiating ART at <2 years of age. Cough and digital clubbing 
were more common in the adolescents with perinatally acquired HIV, p=0.05 for both, table 
1. History of shortness of breath occurred rarely in less than 5% of participants, table 1.  
Adolescents with perinatally acquired HIV with mixed pattern spirometry had a higher rate 
of RV dysfunction, figure 2. None of the uninfected adolescents had mixed pattern 
spirometry. Obstructive and mixed pattern spirometry was reported in five per cent of the 
HIV-infected adolescents, table 2. Right ventricle dysfunction (32%) was more common 
than left ventricular dysfunction (7%) in the adolescents with perinatally acquired HIV but 
not significant different to uninfected adolescents (26.6% of whom had RV dysfunction and 
5.5% LV dysfunction), table 2. Thirteen per cent of perinatally HIV-infected and 8.3% of 
uninfected adolescents had impaired cardiopulmonary function, table 2. Sixteen per cent 
of HIV-infected and 5% of uninfected adolescents had FEF25-75 less than the lower limit of 
normal for age, sex and height, table 2. A pictorial diagram that shows the proportions of 
the various cardiac and lung function abnormalities in the HIV-infected cohort is presented, 
figure 3. Only 2 HIV-infected children had pulmonary hypertension, table 2. Among 
adolescents with perinatally acquired HIV those with low TAPSE had lower mean z-FEV1, 
1.9 (1.4) versus -1.6 (1.3), p = 0.07, Table 3, but this difference was not statistically 
significant. 
The cardiopulmonary functional status as measured by distance walked in six-minutes, 
Borg scale and oxygen saturation were not different between the two groups, table 2. 
Mean Borg scale was 1.3 in both groups, table 2. Mean pulse rate and mean arterial 
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pressures were lower in the adolescents with perinatally acquired HIV compared to the 
HIV-uninfected, p<0.05 for all, table 2.  
Height (OR 0.7, 95% CI 0.5-0.9), body mass index (OR 0.7, 95%CI 0.5-0.9) and past 
pulmonary tuberculosis (OR 2.3, 95%CI 1.2-4.4) were significantly associated with low 
cardiopulmonary function, table 4. Those with digital clubbing had significantly higher odds 
for impaired cardiopulmonary function, OR 4.5, 95% CI 1.6-12.3, adjusted for age, sex, 
height and HIV status, table 5. 
Discussion 
This study provides comprehensive lung function and cardiac function data on a large 
cohort of perinatally HIV-infected South African adolescents on ART showing that a 
proportion of HIV-infected adolescents had cardiopulmonary dysfunction despite being on 
long-term ART and having well-controlled HIV disease. However, the prevalence of 
cardiopulmonary dysfunction was similar to the uninfected adolescents. This may be due 
to lack of validated local African reference values for cardiac function parameters or 
measurement error in the echocardiography measurements.  
Low FEF25-75, a marker of small airways disease, was significantly higher in the HIV-infected 
group, consistent with studies of HIV-infected adolescents in sub-Saharan Africa that have 
reported a predominance of small airways lung disease. [6, 41] However, we did not include 
low FEF25-75 in the definition of impaired cardiopulmonary function but used FEV1 or FVC as 
large airways disease is regarded as the standard measurement of clinically relevant lung 
disease. [42]  
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Height, Body Mass Index and previous history of pulmonary tuberculosis were associated 
with impaired cardiopulmonary function; and digital clubbing had higher odds of low 
cardiopulmonary function. Those with low TAPSE had lower lung function.  
Contrary to the few published studies [43-45] that showed reduced exercise capacity as 
measured by treadmill or six-minute walk test in HIV-infected adolescents, this study did 
not show any differences in distance walked nor oxygen saturation post-exercise between 
perinatally HIV-infected and uninfected adolescents. This may reflect differences in study 
populations, as in the current study, the perinatally HIV-infected adolescents were 
relatively well, established on ART and had good control of HIV disease. It may also be due 
to differences in the exercise test modalities or outcome measured; the current study 
reported distance walked and oxygen saturation before and after the test while other 
studies [44, 45] outcome measure was peak oxygen consumption (VO2max). [43] Further, 
the six‐minute walk test is an insensitive measure of mild cardiopulmonary compromise. It 
is a submaximal test and less predictive of VO2 max compared to the shuttle‐walk test. [46] 
The lower mean heart rate and arterial pressure observed in adolescents with perinatally 
acquired HIV requires further study. 
Right ventricular dysfunction was more common than left ventricular dysfunction in these 
data. However, this finding must be interpreted cautiously as the normal reference ranges 
used were from North America and symptoms of RV dysfunction in this cohort were 
minimal. Miller et al [4] in a Zimbabwe cohort reported 29% of right ventricular dysfunction 
in a cohort that had a high rate of abnormal lung function. [6] The prevalence of restrictive 
spirometry pattern in this cohort, table 2, was unexpected and requires further exploration 
in an ongoing longitudinal study. 
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The finding that body mass index, height and past pulmonary tuberculosis were associated 
with impaired cardio-pulmonary dysfunction may reflect the fact that stunting and 
opportunistic infections affect lung function and may lead to subsequent cardiac 
dysfunction. Pulmonary TB has also been associated with chronic obstructive pulmonary 
disease in adults with HIV. [47] Previous data [11] reported that PTB and previous 
pneumonia were more prevalent in HIV-infected adolescents and were both associated 
with low lung function. In addition, the higher likelihood of impaired cardiopulmonary 
dysfunction in those with digital clubbing may reflect lung disease leading to consequent 
heart dysfunction. Digital clubbing is well known to be associated with chronic cardiac or 
lung disease. [48] Similarly, nail clubbing was common in a Malawi cohort of HIV-infected 
adolescents with a high prevalence of chronic lung disease. [49]  
The strengths of this study include a large sample size of perinatally HIV-infected 
adolescents on ART with a comparative group of HIV-uninfected adolescents and the 
comprehensive lung and cardiac function tests. Our study was limited by the independent 
assessment of lung and cardiac function rather than a combined measure of 
cardiopulmonary function such as formal cardiopulmonary exercise testing. This would 
measure oxygen consumption and carbon dioxide excretion by sampling inspired and 
expired gas during exercise. [50] Such technology is expensive and inaccessible in most 
paediatric centres in South Africa. However, we used a broader definition of impaired 
cardiopulmonary function to include both heart and lung function parameters used in our 
study. The cardiac function measures, TAPSE and FAC, are limited by the absence of African 
reference parameters; normative values were derived from a Caucasian population. 
Nevertheless, the uninfected control group served as a comparator.  
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Conclusion 
This study indicates that cardiopulmonary dysfunction occurs in an appreciable proportion 
of African adolescents with perinatally acquired HIV despite being on antiretroviral therapy 
and having well-controlled HIV disease. However, the prevalence of cardiopulmonary 
dysfunction was similar in HIV-uninfected adolescents, which may reflect lack of validated 
local African reference values for echocardiography measurements. In turn, this study 
highlights the need for development of more sensitive markers of lung or heart disease in 
adolescents with perinatally acquired HIV, given the minimal symptoms that participants 
reported. The study identified risk factors for cardiopulmonary dysfunction such as prior 
PTB and impaired nutrition highlighting areas that may be amenable to public health 
interventions to optimise health.  
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17Table 1: Baseline characteristics of study population  
Variable HIV-infected n=474 HIV-uninfected 
n=109 
*P-value 
Age, years 12.0 (1.6) 11.8 (1.8) 0.257 
Male, n (%) 247 (51.7) 47 (45.2) 0.231 
Height z-score -1.3 (1.1) -0.5 (1.0) <0.001 
Respiratory rate, breaths/min 21.5 (3.5) 20.8 (5.1) 0.082 
Viral load category, copies/ml 
<50, n (%) 
50-1000, n (%) 
1001-10000, n (%) 
>10000, n (%) 
 -  
369 (77.9)   
46 (9.7)   
32 (6.8)   
26 (5.5)   
CD4 count, cells/mm3 712 (571-959) -  
WHO HIV staging at HIV 
diagnosis, n (%) 
   
I 
II 
III 
IV 
34 (7.2)   
47 (9.9)   
266 (56.1)   
105 (22.2)   
ART used 
NNRTI+2NRTI 
PI+2NRTI 
Others 
   
282 (59.5)   
175 (36.9)   
9 (1.9)   
Previous PTB, n (%) 287 (58.5) 2 (0) <0.001 
Previous severe LRTI, n (%) 134 (28.3) 1 (0.9) <0.001 
Tobacco smoke exposure, n (%) 119 (25.0) 22 (20.9) 0.279 
Poor ART adherence, n (%) 111 (23.4) -  
ART duration, years, n (%) 7.0 (3.0) -  
Age at ART initiation, years 4.4 (2.0-7.0)   
Shortness of breath, n (%) 16 (3.4) 2 (1.8) 0.402 
History of wheeze, n (%) 51 (10.8) 6 (5.5)  0.096 
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History of cough, n (%) 69 (14.6)  8 (7.3)  0.045 
History of doctor-diagnosed 
asthma, n (%) 
57 (12.0) 6 (5.5)  0.048 
Finger clubbing, n (%) 16 (3.5)  0  0.052 
Values are mean/SD except for age at ART initiation, viral load and CD4 which are median 
(IQR) *P-values derived from chi-square or two sample t-test 
ART antiretroviral therapy, PTB pulmonary tuberculosis, NNRTI non-nucleoside reverse 
transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, PI protease inhibitor, LRTI 
lower respiratory tract infections, WHO World Health Organization 
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18Table 2: Cardiopulmonary measurements by HIV status 
Variable, n (%) n HIV-infected  n HIV-uninfected  *P-value 
Restrictive 
spirometry  
474 110 (23.2) 109 23 (21.1) 0.637 
Obstructive 
spirometry  
474 23 (4.9) 109 4 (3.4) 0.596 
Mixed pattern 
spirometry  
474 22 (4.6) 109 0 0.022 
FEF25-75 below LLN 474 76 (16.0) 109 6 (5.5%) 0.004 
*Right ventricular 
dysfunction (low 
TAPSE and low FAC)  
474 154 (32.5) 109 29 (26.6) 0.232 
Pulmonary 
hypertension  
474 2 (0.46) 109 0 0.476 
Left ventricular 
diastolic dysfunction  
474 36 (7.6) 109 6 (5.5) 0.447 
Left ventricle systolic 
dysfunction  
474 1 (0.2) 109 0 0.631 
*Cardiopulmonary 
function (impaired)  
474 64 (13.5) 109 9 (8.3) 0.136 
Pulse before walk 
(mean/SD) 
478 78.6 (12.5) 104 82.9 (14.2) 0.002 
Pulse after walk 
(mean/SD) 
478 82.9 (13.8) 104 87.1 (15.0) 0.004 
Oxygen saturation 
before walk 
(mean/SD) 
478 98.4 (2.0) 104 98.6 (0.8)) 0.315 
Oxygen saturation 
after walk (mean/SD) 
478 98.3 (2.7) 104 98.4 (1.4) 0.675 
MAP before 6MWT 
(mean/SD) 
478 79.2 (7.7) 104 82.6 (8.1) <0.001 
 96 
 
MAP after 6MWT 478 83.0 (8.7) 104 86.6 (8.5) 0.001 
Borg scale before 
6MWT (mean/SD) 
478 0.1 (0.2) 104 0.04 (0.2) 0.577 
Borg scale after 
6MWT (mean/SD) 
478 1.3 (0.6) 104 1.3 (0.7) 0.737 
Distance walked in 6 
min (mean/SD) 
478 437.8 (60.4) 104 443.8 (60.7) 0.380 
*P-value derived from chi-square or two sample t-test 
TAPSE tricuspid annular plane systolic excursion, 6MWT six-minute walk test, MAP: mean arterial 
pressure (calculated from blood pressure), FAC fractional area change, Borg scale (perceived 
exertion scale) FEF25-75 forced expiratory flow at 25% and 75% of forced vital capacity, LLN lower 
limit of normal calculated from African-American reference values. [22] 
 
19Table 3: Lung function by Tricuspid Annular Plane Systolic Excursion (TAPSE) index in 
HIV-infected adolescents  
Lung 
function 
n Low TAPSE 
Mean/SD 
n Normal TAPSE 
Mean/SD 
P-value 
z-FEV1 114 -1.9 (1.4) 350 -1.6 (1.3) 0.07 
z-FVC 114 -2.0 (1.4) 350 -1.8 (1.3) 0.13 
z-FEV1/FVC 114 -0.0 (1.6) 350 0.2 (1.4) 0.16 
z-FEF25-75 114 -1.0 (1.8) 350 -0.8 (1.5) 0.09 
P-value from two sample t-test 
FEV1 forced expiratory volume in 1 sec; FVC forced vital capacity; FEF2575 forced expiratory flow 
at 25-75% of vital capacity; TAPSE Tricuspid Annular Plane Systolic Excursion 
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20Table 4: Associations of impaired cardiopulmonary function (n=569) in perinatally HIV-
infected and uninfected adolescents 
Variable Univariate 
Odd’s ratio 
*P-value 95% CI Multivariate 
Odd’s ratio 
P-value 95% CI 
Age 1.1 0.365 0.9 to 1.2 -   
Z-Height 0.8 0.017 0.6 to 0.9 0.7 0.010 0.5 to 0.9 
Z-BMI 0.7 <0.001 0.5 to 0.8 0.7 0.009 0.5 to 0.9 
ETS exposure 0.8 0.545 0.5 to 1.5 -   
Sex 0.8 0.419 0.5 to 1.3 -   
Past LRTI 1.6 0.124 0.9 to 2.7 1.4 0.321 0.7 to 2.5 
Past PTB 2.1 0.013 1.2 to 3.9 2.3 0.017 1.2 to 4.4 
Viral load 
copies/ml 
   -   
50-1000 0.8 0.677 0.3 to 2.2    
1001-10000 1.9 0.171 0.8 to 4.6    
>10000 1.7 0.331 0.6 to 4.6    
ART duration 1.1 0.062 1.0 to 1.2 1.1 0.228 0.9 to 1.2 
*Adjusted for HIV status. Logistic regression  
BMI body mass index, LRTI lower respiratory tract infection, PTB pulmonary tuberculosis, ART 
antiretroviral therapy, ETS environmental tobacco smoke 
21Table 5:  Association of respiratory symptoms/signs with impaired cardio-pulmonary 
function (n=569) in perinatally HIV-infected and uninfected adolescents 
 Univariate ^Multivariate 
Symptom OR 95% CI P-value OR 95% CI P-value 
Wheeze 1.5 0.7 to 3.2 0.249 1.4 0.7 to 3.0 0.369 
Shortness of breath 0.9 0.2 to 3.8 0.831 0.8 0.2 to 3.7 0.808 
Cough 1.6 0.8 to 3.0 0.180 1.5 0.8 to 2.9 0.253 
Digital clubbing 5.2 1.9 to 14.0 0.001 4.5 1.6 to 12.3 0.004 
*Asthma 1.5 0.7 to 3.2 0.249 1.3 0.6 to 2.7 0.445 
Symptoms are self-reported except digital clubbing *physician-diagnosed asthma ^adjusted for 
HIV status, age, sex, height. Logistic regression 
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6MWT six-minute walk test 
5Figure 1: Flow diagram for the study population  
 
 
6Figure 2: Spirometry pattern and right ventricle function  
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7Figure 3: Lung and cardiac functional abnormalities in perinatally HIV-infected adolescents 
RV right ventricle: LV left ventricle, FEF25-75 forced expiratory flow at 25% and 75% of forced vital 
capacity. LLN lower limit of normal calculated from African-American reference values. [22] 
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Abstract 
Background: Despite increased access to antiretroviral therapy (ART), lung disease remains 
common in HIV-infected adolescents. There is limited information on changes in lung 
function over time in perinatally HIV-infected adolescents on ART.  
Objective: To investigate the progression of spirometry findings over two years in HIV-
infected adolescents on ART in a prospective cohort, the Cape Town Adolescent Anti-
retroviral cohort (CTAAC). 
Methods: HIV-infected adolescents aged 9-14 years, with at least six months of ART, and a 
comparator group of healthy HIV-uninfected, age-matched controls were enrolled in 
CTAAC. Spirometry and bronchodilator testing was done at baseline, 12 and 24 months. 
Mixed-effect models were used to compute longitudinal changes in lung function. 
Results: Five hundred and fifteen HIV-infected adolescents mean (SD) age, 12 (1.6) years, 
50.4% male; and 110 HIV-uninfected adolescents, mean (SD) age 11.8 (1.8), 45.6% male, 
were tested at baseline, 477 (93%) HIV-infected and 102 (93%) HIV-uninfected at 12 
months and 473 (92%) HIV-infected and 97 (88%) uninfected adolescents at 24 months. 
Only 5.4% of the HIV-infected adolescents had HIV viral load >10000 copies/ml at baseline. 
FEV1 and FVC were lower in the HIV-infected compared to the uninfected adolescents and 
tracked with no deterioration or catch up over two years. Previous pulmonary tuberculosis 
(PTB) or lower respiratory tract infection (LRTI) was significantly associated with reduced 
FEV1 and FVC, p<0.05 for both. 
Conclusion: HIV-infected adolescents had lower lung function over two years than HIV-
uninfected. This study highlights the need for lung function surveillance and prevention of 
LRTIs and PTB in HIV-infected adolescents. 
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Background 
Perinatally acquired HIV has evolved into a chronic disease due to early diagnosis and 
improved access to antiretroviral therapy (ART) [1, 2] However, of the 2.1 million children 
under 15 years living with HIV only about 43% were on ART in 2017. [3] Over 90% of HIV-
infected adolescents live in sub-Saharan Africa (SSA) with only about 49% accessing ART. 
Chronic lung disease remains one of the most common concerns in HIV-infected 
adolescents in the ART era in SSA. [4]  
Normal lung growth begins in-utero and continues throughout childhood and adolescence 
till it reaches a plateau in the early twenties and begins to decline. [5, 6] Lung function 
tracks through life, with those starting at low lung function continuing along the lower 
centile into adulthood and also being associated with increased respiratory symptoms and 
illness. [7] However, most of the evidence on lung function in HIV-infected adolescents is 
from cross-sectional studies, with limited information on longitudinal lung function 
changes especially in the context of ART. Prior studies have shown that HIV-infected 
adolescents on ART have lower lung function compared to HIV-uninfected adolescents. 
[8, 9] Longitudinal studies are needed to understand the lung function trajectory in HIV-
infected adolescents and the impact of low lung function and the risk of later respiratory 
disease. The aim of this study was to investigate the progression and determinants of lung 
function over two years in HIV-infected adolescents on ART in a South African perinatally 
infected adolescent cohort. 
Methods 
Children were enrolled from October 2013 to March 2015 in a prospective cohort, Cape 
Town Adolescent Antiretroviral Cohort, CTAAC as previously described. [8] HIV-infected 
adolescents, aged 9-14 years on ART for more than 6 months, in whom informed parental 
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consent was obtained and assent provided, were enrolled and followed up 6-monthly. 
Informed consent and assent was renewed annually.  
Children were recruited from primary care clinics and hospital-based ART clinics in Cape 
Town, South Africa. HIV-uninfected age, sex, ethnicity matched comparator group, with no 
known pre-existing lung disease was also enrolled. The study was approved by the Faculty 
of Health Sciences, University of Cape Town Human Research Ethics Committee.  
Spirometry and bronchodilator testing was done at baseline, 12 and 24 months. Testing 
was done using NDD EasyOne Pro LAB (Switzerland). Testing adhered to ERS/ATS 
guidelines. [10, 11] A minimum of 3 trials to a maximum of 8 attempts were done per 
patient and at least 3 acceptable, reproducible best quality curves were selected by the 
respiratory technologist. The highest forced vital capacity (FVC) and forced expiratory 
volume in 1 second (FEV1) from any of the acceptable manoeuvres was reported. 400 µg 
salbutamol was given via spacer and testing repeated after 15 minutes. 
Global Lung Initiative (GLI) [6] African-American reference population was used to calculate 
the lower limit of normal for the spirometry outcome measures. Obstructive spirometry 
pattern was defined as FEV1 over FVC ratio less than the lower limit of normal (FEV1/FVC 
<LLN); restrictive spirometry pattern as FVC<LLN and normal FEV1/FVC ratio and a mixed 
pattern was defined as FEV1/FVC<LLN, FVC<LLN and FEV1<LLN. Bronchodilator response 
was defined as a change in FEV1 ≥12% after 400µcg salbutamol administered via MDI-
spacer. 
Clinical data including age, sex, height, weight, CD4 and viral load were collected annually. 
Questionnaires were administered semi-annually to study participants to collect data on 
ART adherence, smoking, isoniazid prophylaxis, respiratory symptoms and other 
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intercurrent events. ART adherence was calculated by assessing 30-day recall of any missed 
doses. Data on previous pulmonary tuberculosis (PTB) and past lower respiratory tract 
infection (LRTI), date of ART initiation, doctor-diagnosed asthma were extracted from 
hospital records and validated study questionnaires. Data on medications use was 
extracted from health records. 
Data analysis 
Two sample t-test was used to compute the comparison of lung function outcome between 
HIV-infected and uninfected at baseline and 24 months. Demographic and clinical factors 
were included to determine associations of lung function. The minimum covariates, age, 
height, sex, HIV, time, smoke exposure, previous PTB and previous LRTIs, figure 1S, were 
determined using Directed Acyclic Graphs. [12] Mixed-effects modelling was used to 
compute longitudinal changes over two years and determinants of lung function outcomes. 
Results 
Five hundred and fifteen HIV-infected adolescents, mean (SD) age, 12 (1.6) years and 110 
HIV-uninfected adolescents, mean age 11.8 (1.8) years, were tested at baseline, 477 (93%) 
HIV-infected and 102 (93%) HIV-uninfected at 12 months and 473 (92%) HIV-infected and 
97 (88%) uninfected adolescents at 24 months, with over 90% successfully tested, figure 1. 
Four hundred and eighty-three (96%) HIV-infected and 88 (83%) HIV-uninfected 
adolescents had successful bronchodilator testing at baseline, 437 (92.6%) HIV-infected 
and 91 (94.8%) HIV-uninfected had bronchodilator testing at 12 months and 402 (92.4%) 
HIV-infected and 88 (93.6%) HIV-uninfected adolescents had a successful bronchodilator 
test at 24 months, table 2. 
At two years of study, the median (IQR) duration of ART was 9.8 (6.8 to 11.3) years, table 
1a. The median (IQR) age at ART initiation was 4.3 (1.9 to 7.6) years. HIV-infected 
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adolescents were shorter and had lower BMI than HIV-uninfected controls at enrolment 
and at two years, p<0.001, table 1b. Only 5-6% of adolescents had HIV viral load 
> 10000 copies/ml at both baseline and 24 months, table 1a. History of hospitalisation for 
LRTI or past pulmonary tuberculosis (PTB) prior to enrolment visit was more common in 
HIV-infected adolescents compared to uninfected, P<0.001, table 1a. However, 
intercurrent hospitalisation for non-TB LRTI, ambulatory LRTI not requiring hospitalisation 
during the 24-month follow-up period was uncommon in both groups, table 1a. However, 
HIV-infected adolescents had a high incidence rate of intercurrent culture-positive PTB of 
3.2% compared to none in the HIV-uninfected adolescents in the two-year study period. 
Those with culture-positive Mycobacterium tuberculosis over the two years had on average 
0.23 lower FEV1 z-score (95% CI -0.57 to 0.10, p=0.174, adjusted for time and HIV status, 
data not shown) compared to those without intercurrent tuberculosis disease. 
More adolescents reported symptoms of cough or wheeze at enrolment than at the 2-year 
follow-up period, table 1b. Less than 7% of HIV-infected adolescents used asthma 
medications at baseline and over two years, table 1a. There was higher use of isoniazid 
prophylaxis in the HIV-infected adolescents at baseline than at two years, 115 (22.9%) and 
33 (7.6%) respectively, table 1a. Cotrimoxazole prophylaxis use was 10% at baseline and 
7.6% at two years in the HIV-infected, table 1a. Less than 20% of HIV-infected children 
reported chronic or recurrent respiratory symptoms at baseline and at two years, table 1b. 
Mean z-FEV1/FVC tracked lower in the HIV-infected over time, narrowing at 12 months, 
mean/SD -0.2 (1.3) in the HIV-infected and 0.0 (1.1) in the HIV-uninfected, p=0.231 (table 
2) but the means of the two groups were statistically different at 2 years, mean/SD -0.3 
(1.2) in the HIV-infected, 0.0 (1.0) in the HIV-uninfected, p=0.008, figure 2S. 
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Further, HIV-infected adolescents had lower z-FEV1 compared to the uninfected 
adolescents at all time points, table 2, with HIV-infected adolescents having on average 
0.52 z-FEV1 lower than the HIV-uninfected adolescents over two years, (95% CI -0.76 to -
0.27, p<0.001), table 3. Although HIV infection was associated with lower FEV1 or FVC, the 
change in either FEV1 or FVC at two years was similar between HIV-infected and uninfected 
adolescents as depicted by a near parallel slope, figure 2, and a non-significant interaction 
between HIV and time at two years for both, coefficient -0.03, 95% CI -0.17 to 0.23, p=0.764 
for FEV1 and coefficient -0.14, 95% CI -0.34 to 0.05, p=0.154 for FVC, table 1S. 
A history of pulmonary tuberculosis or severe LRTI prior to enrolment were significantly 
associated with impaired FEV1 z-score at two years (coefficient-0.27, 95% CI -0.50 to -0.03 
p=0.024 for PTB and -0.37, 95% CI -0.62 to -0.13, p=0.003 for LRTI) and FVC z-score 
(coefficient -0.27, 95% CI -0.49 to -0.05, p=0.015 for PTB and -0.30, 95% CI -0.53 to -0.06, 
p=0.013 for LRTI), adjusting for smoke exposure, time and HIV infection, tables 4 ,4Sa,4Sb. 
HIV-infected adolescents with past LRTI requiring hospitalisation had lower lung function 
compared to those with no prior severe LRTI, figure 3.  
FEV1/FVC z-score tracked lower at all time points in those who had history of severe LRTI 
compared to those without history of severe LRTI, figure 3S. Those who began ART before 
3 years of age had significantly lower rates of history of severe LRTI compared to those who 
began ART after 3 years, (47% vs 53% at baseline, p=0.006; 49% vs 51% at 12 months, 
p=0.002; 46% vs 54% at 24 months, p=0.019). 
HIV-infected adolescents who had ART initiated before 3 years of age had higher z-FVC, Z-
FEV1 and z-FEV1/FVC compared to those who had ART initiated above 3 years, as shown 
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on the lung growth curves, figure 4S, but this difference was not statistically significant, 
p>0.05 for all, table 5S.  
Over 65% of HIV-infected adolescents had a normal spirometry pattern at baseline, 12 and 
24 months, table 2S. Mixed spirometry pattern was more common in the HIV-infected 
compared to HIV-uninfected adolescents at each time point, table 2S and figure 4. 
Obstructive spirometry pattern increased from a prevalence of 4.8% at baseline to 8.1% at 
24 months, table 2S. Bronchodilator responsiveness at baseline was 16.1% and 11.4% in 
HIV-infected and HIV-uninfected adolescents respectively, table 2. This decreased to 6.2% 
and 5.7%, respectively, in the HIV-infected and uninfected at 24 months indicating an 
increase in fixed airway obstruction over the 24 months. On average, those with abnormal 
spirometry pattern had a higher odds of having either wheeze, shortness of breath, cough 
on most days, history of doctor diagnosed asthma, adjusted for HIV status, p<0.05 for all, 
table 5. History of doctor diagnosed asthma (OR 1.96, 95% CI 1.02 to 3.77) or past severe 
LRTI requiring hospitalisation (OR 1.72, 95% CI 1.02 to 2.91), adjusted for time and HIV 
status, were significantly associated with bronchodilator responsiveness, table 3S. 
Discussion 
This study provides novel 2-year follow-up data showing that spirometry in perinatally HIV-
infected adolescents established on ART tracks lower compared to uninfected adolescents. 
Prior LRTI requiring hospitalisation or PTB were associated with low FEV1 or FVC. 
Reassuringly this cohort had minimal chronic respiratory symptoms and few intercurrent 
ambulatory or hospitalised LRTIs during the two-year follow-up. The cohort was well 
established on ART with a mean duration of ART of nine years 
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The stable trajectory of spirometry outcomes over two years, suggests that damage to the 
lung reflected as lower lung function in the HIV-infected group may have occurred early in 
life due to uncontrolled HIV infection as ART was only initiated on average at 4 years of age 
in this cohort. In addition, it suggests that in HIV-infected adolescents well established on 
ART lung growth continues to occur and tracks similar to HIV uninfected youth. Early 
damage may have been caused by HIV-exposure in-utero in the developing lung or in the 
early childhood years prior to initiation of ART. This damage may be attributed to early 
childhood infection, by HIV associated inflammation and immune dysregulation or 
opportunistic infections in the HIV-infected group who had high rates of prior PTB or LRTI 
compared to HIV-uninfected participants, as has been reported in other studies. [9, 13] This 
is supported by the fact that previous LRTI or PTB were associated with lower lung function. 
The effect of HIV on lung function reduced after adjusting for LRTI and PTB suggesting that 
pulmonary infection may be a major mechanism by which HIV reduces lung function. 
Reduction of LRTI by early initiation of ART is possible as evidenced by low rates of severe 
LRTI in adolescents who had ART initiated before 3 years of age in this cohort. 
The incidence of culture confirmed tuberculosis in the HIV-infected adolescents was high 
over the study period. This is in keeping with published evidence [14] that while long-term 
ART is associated with a reduction in TB risk, the incidence remains high in HIV-infected 
populations. South Africa has a high HIV and TB burden [15] and previous reports have 
shown that adolescent age group has a higher rate of tuberculosis disease. [16] Of concern, 
was the very low use of cotrimoxazole or isoniazid prophylaxis as effective preventive 
interventions in this cohort. The low use of cotrimoxazole may reflect current program 
guidelines as prophylaxis is stopped after immune reconstitution, which had occurred in 
most participants, as reflected by the median CD4 count of around 700 cells/mm3. 
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The higher occurrence of obstructive and mixed pattern spirometry in the HIV-infected 
adolescents may be due to higher rates of bronchiectasis or post-infective bronchiolitis 
obliterans (BO) in the HIV-infected group. High rates of bronchiectasis in HIV-infected 
children have been reported. [4, 17] A study on chest computed tomography (CT) in HIV-
infected adolescents reported predominantly mosaic attenuation due to possible 
bronchiolitis obliterans that was inversely correlated with FEV1. [4] BO is a non-reversible 
condition due to fibrosis. In our study cohort, bronchodilator responsiveness at two years 
was less than 10%, suggesting irreversible airway pathology, possibly related to BO. Others 
have reported irreversible airway pathology in HIV-infected youth compared to HIV-
exposed uninfected youth. [18] The high rate of restrictive spirometry pattern in both the 
HIV-infected and HIV-uninfected adolescents at baseline may be for technical reasons as 
most participants had never done a lung function test before enrolment but became 
familiar with the technique of performing spirometry and were able to produce better 
quality tests in subsequent visits.  
The improvement of respiratory symptoms over the two-year period in our cohort may 
have been due to close follow up of study participants, good clinical management and 
appropriate treatment or referral when the participant was sick or symptomatic. This 
cohort also had good adherence to ART, reflected by most adolescents having low HIV viral 
load. 
Birth cohort studies from high-income countries in HIV-uninfected populations have shown 
that lung function tracks from childhood to adulthood. [7, 19-21] Therefore the lung 
function of HIV-infected adolescents, which was lower than the HIV-uninfected, is likely to 
continue to track along the lower centile over time, provided there are no further insults. 
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Longitudinal studies in HIV-infected children and adolescents are however lacking. With 
the expected physiological growth and development of the lung from in-utero to early 
adulthood, [5] it is unclear what effect HIV or opportunistic infections may have on normal 
physiological growth. In our study, there was no catch-up or deterioration over two years 
between the HIV-infected and the uninfected adolescents, but a longer follow-up period is 
needed. The lack of deterioration in lung function over the two years may reflect that this 
is a relatively healthy HIV-infected cohort (as evidenced by minimal respiratory morbidity 
in the 2-year period) who were, stable on ART for a mean duration of nine years.  
Strengths of the study include a prospective collection of objective measures of lung 
function, high cohort retention with close follow-up over two years, and a well-controlled 
HIV cohort. Limitations of the study are that data included spirometry only, but this is the 
most widely used measure of lung function; further bronchodilator responsiveness was 
also assessed in this study. In the absence of local South African adolescents’ spirometry 
reference equation, we used the GLI 2012 [6] African-American reference values, which 
have been shown to be acceptable for sub-Saharan Africa. [22] Further limitation was the 
lack of chest CT imaging to define lung abnormalities and correlate with lung function. 
These findings may not be generalizable to HIV-infected adolescent populations that are 
not well controlled on ART, where more severe lung function abnormalities have been 
found. [23, 24] However, as ART programmes are strengthened, increasing numbers of 
perinatally HIV-infected adolescents can be expected to be on therapy and to develop this 
spectrum of lung disease. 
Conclusions 
HIV-infected adolescents had lower spirometry at all time points compared to HIV-
uninfected adolescents over two years. Lung growth was, however, preserved in the HIV 
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infected group and similar in both groups. Previous pulmonary tuberculosis or previous 
LRTI were associated with reduced FEV1 and FVC. Those with ART initiated before 3 years 
of age had lower rates of past severe LRTI. There was a high incidence rate of culture 
confirmed tuberculosis in the HIV-infected adolescents. Interventions to prevent childhood 
LRTI or TB must be strengthened to optimise lung health. Further longitudinal studies on 
lung function in HIV-infected children and adolescents on ART are needed to show the long-
term effect of HIV or opportunistic infections on subsequent respiratory health and to 
enable timely treatment of lung disease. Surveillance of lung function in HIV-infected 
adolescents from early adulthood and throughout adulthood is necessary to detect disease 
early.  
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22Table 1a: Characteristics of participants tested at both baseline and 24 months by HIV status 
 HIV+  
(n=503) 
HIV- 
(n=106) 
P-value HIV+  
(n=435) 
HIV- 
(n=94) 
P-value^ 
 Baseline  24 months  
Age, years (mean/SD) 12.0 (1.6) 11.9 (1.8) 0.533 14.1 (1.6) 13.8 (1.8) 0.171 
Male, n (%) 261 (51.9) 48 (45.2) 0.216 217 (49.9) 42 (44.7) 0.360 
Age (years) at ART 
initiation (median/IQR) 
4.3 (1.9-7.6)   4.3 (2.0-7.6)   
ART duration, years 
median (IQR) 
7.7 (4.6-9.3)   9.8 (6.8-11.3)   
CD4 count, cells/mm3 
median (IQR) 
712 (556-959)   695.5 (529.5-887.5)   
Viral load CAT, n (%)       
<50 copies/ml 383 (76.1)   260 (59.8)   
50-1000 copies/ml 55 (10.9)   108 (24.8)   
1001-10000 copies/ml 37 (7.4)   24 (5.5)   
>10000 copies/ml 27 (5.4)   27 (6.2)   
Missing  1 (0.2)   16 (3.7)   
Poor ART adherence, n (%) 116 (23.0)   41 (9.4)   
ART regimen       
2xNRTI + NNRTI 307 (61.2)    249 (57.2)   
2xNRTI + PI 166 (33.1)    151 (34.7)   
Other 29 (5.8)    35 (8.1)   
Tobacco smoke exposure, 
n (%)* 
      
passive 127 (25.3) 21 (19.8) 0.236 86 (19.8) 14 (14.9) 0.274 
active 2 (0.4)   5 (1.2)   
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History of LRTI requiring 
hospitalisation before 
baseline visit, n (%) 
145 (28.8) 1(0.9) <0.001 - -  
Past history of PTB prior 
to baseline visit, n (%) 
303 (60.2) 2 (1.9) <0.001 - -  
History of asthma, n (%) 
(ever) (self-reported)* 
62 (12.3) 6 (5.7) 0.048 32 (7.4) 7 (7.5) 0.976 
Family history of asthma 78 (15.5) 13 (12.3) 0.395     
Isoniazid prophylaxis 115 (22.9) 4 (3.8) <0.001 33 (7.6) 0 0.006 
Inhaled corticosteroids  13 (2.6) 2 (1.9) 0.674 11 (2.5) 4 (4.3) 0.360 
Short course steroids 13 (2.6) - - 6 (1.4) - - 
Inhaled Salbutamol 33 (6.6) 2 (1.9) 0.060 28 (6.4) 2 (2.1) 0.104 
Oral salbutamol 12 (2.4) - - 6 (1.4) - - 
Cotrimoxazole prophylaxis 50 (9.9) 0 - 33 (7.6) 0 - 
Intercurrent events, n (%) 
during the cumulative two 
years (n=609) 
      
Hospitalisation       
Non-TB LRTI, n (%) - -  5 (0.8) 1 (0.2) <0.001 
Unconfirmed TB, n (%) - -  13 (2.1) 0 - 
Asthma - -  1 (0.2) 1 (0.2) 1.000 
Ambulatory LRTI - -  13 (2.1) 4 (0.7) <0.001 
Culture positive M.tb    19 (3.1) 0 - 
^ P-value t-test or chi-square; * self-reported smoking history;  
ART: antiretroviral therapy; LRTI: lower respiratory tract infection; PTB: pulmonary tuberculosis; M.tb: mycobacteria tuberculosis; NRTI: 
nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor, PI: protease inhibitor; CAT: category 
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23Table 1b: Clinical characteristics of participants tested at both baseline and 24 months  
 HIV+ 
(n=503) 
HIV- 
(n=106) 
P-value 
HIV+ 
(n=435) 
HIV- 
(n=94) 
P-value^ 
 Baseline  24 months  
Height, cm (mean/SD) 140.0 
(10.3) 
144.6 
(11.9) 
0.001 150.6 (9.8) 153.0 (9.7) 0.030 
BMI, kg/m2 (mean/SD) 17.7 (3.2) 19.5 (4.2) <0.001 19.4 (3.5) 21.1 (4.6) <0.001 
Current history of cough 
on most days* 
74 (14.7) 8 (7.6) 0.050 51 (11.7) 11 (11.7) 0.995 
History of ever wheeze*  55 (10.9) 6 (5.7) 0.100 31 (7.1) 7 (7.5) 0.913 
Wheeze in the last 12 
months* 
31 (6.2) 3 (2.8) 0.174 19 (4.4) 4 (4.3) 0.961 
SOB in the last 12 months* 3 (0.6) 2 (1.9) 0.181 6 (1.4) 3 (3.2) 0.218 
Digital clubbing  18 (3.6) 0 (0) 0.048 18 (4.1) 0 (0) 0.045 
Respiratory rate, 
breaths/min 
21.5 (3.5) 20.9 (5.2) 0.142 21.0 (1.1) 20.9 (0.9) 0.565 
Oxygen saturation (%) 98.6 (0.9) 98.8 (0.4) 0.036 98.3 (1.7) 98.5 (0.7) 0.199 
Tanner staging       
I 242 (48.1) 34 (32.1) 0.003 62 (14.3) 11 (11.7) 0.516 
II 123 (24.5) 30 (28.3) 0.406 81 (18.6) 15 (16.0) 0.544 
III 69 (13.7) 18 (17.0) 0.383 87 (20.0) 23 (24.5) 0.333 
IV 39 (7.8) 17 (16.0) 0.007 110 (25.3) 26 (27.7) 0.633 
V 23 (4.6) 6 (5.7) 0.633 83 (19.1) 16 (17.0) 0.643 
Missing 7 (1.4) 1 (0.9) 0.713 12 (2.8) 3 (3.2) 0.819 
^ P-value t-test or chi-square; * symptoms are self-reported at each time point 
SOB: shortness of breath; BMI: body mass index 
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24Table 2: Summary of lung function at baseline, 12 and 24 months 
Variable Baseline 12 months 24 months 
mean (SD) HIV+ 
n=503 
HIV-
n=106 
P-value 
HIV+ 
n=472 
HIV- 
n=96 
P-value 
HIV+ 
n=435 
HIV- 
n=94 
P-value 
zFEV1 
 
-1.0 (1.3) -0.5 (1.0) <0.001 -0.9 (1.3) -0.3 (1.0) <0.001 -0.8 (1.3) -0.3 (1.0) <0.001 
zFVC -1.1 (1.3) -0.8 (1.0) 0.060 -0.9 (1.2) -0.3 (1.0) <0.001 -0.7 (1.2) -0.3 (0.9) 0.003 
zFEF25-75 -0.4 (1.4) 0.1 (1.0) <0.001 -0.5 (1.4) -0.1 (1.1) 0.015 -0.5 (1.4) -0.0 (1.1) 0.004 
zFEV1/FVC 0.2 (1.4) 0.9 (1.2) <0.001 -0.2 (1.3) 0.0 (1.1) 0.231 -0.3 (1.2) 0.0 (1.0) 0.008 
BDR n=483 n=88  n=437 n=91  n=402 n=88  
BDR (yes), n (%) 78 (16.1) 10 (11.4) 0.253 45 (10.3) 5 (5.5) 0.155 25 (6.2) 5 (5.7) 0.849 
P-values from two sample T-test, z-scores derived from GLI African -American reference values, BDR: bronchodilator responsiveness, positive if 
change in FEV1≥12% 
FVC: forced vital capacity, FEV1: forced expiratory volume in 1 second, FEF25-75: forced expiratory flow at 25% and 75% of FVC; SD: standard 
deviation 
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25Table 3: Effect of HIV on lung function over two years (n=609) 
 Coefficient 95% CI P value^ 
z-FEV1  -0.52* -0.76 to -0.27 <0.001 
z-FVC  -0.37* -0.60 to -0.14 0.001 
z-FEF2575 -0.42* -0.68 to -0.17 0.001 
z-FEV1/FVC -0.41* -0.64 to -0.19 <0.001 
^ linear mixed-effects model; * Adjusted for age, sex, height, time  
FVC: forced vital capacity; FEV1: forced expiratory volume in 1second; FEF2575: forced expiratory flow at 25% 
and 75% of FVC 
 
26Table 4: Association of z-FEV1, z-FVC and z-FEV1/FVC at 24 months (n=515) 
Variable z-FEV1 z-FVC z-FEV1/FVC 
 Coefficient P-value^ Coefficient P- value^ Coefficient P-value^ 
HIV infection -0.12 0.510 0.01 0.946 -0.34 0.036 
Time at 12 months 0.04 0.296 0.25 <0.001 -0.51 <0.001 
Time at 24 months 0.17 <0.001 0.41 <0.001 -0.61 <0.001 
Tobacco smoke 
exposure* 
0.01 0.931 0.08 0.192 -0.18 0.022 
Previous PTB -0.27 0.024 -0.27 0.015 -0.01 0.904 
Previous LRTI -0.37 0.003 -0.30 0.013 -0.27 0.020 
^ multivariate linear mixed model; * self-reported passive smoke exposure (active smoking had too few 
numbers therefore not reported) 
LRTI: lower respiratory tract infection; PTB: pulmonary tuberculosis; FEV1: forced expiratory volume in 1s, 
FVC: forced vital capacity  
 
27Table 5: Association of abnormal spirometry pattern and respiratory symptoms/signs 
over 24 months 
Respiratory 
symptom/sign* 
n Odd’s ratio P-value^ 95% CI 
History of ever wheeze 
(yes) 
608 2.4 0.009 1.25 to 4.68 
Cough on most days 
(yes) 
607 2.7 <0.001 1.62 to 4.62 
History of asthma ever 
(yes) 
607 3.1 <0.001 1.64 to 5.83 
History of shortness of 
breath ever(yes) 
608 4.7 0.010 1.44 to 15.25 
Digital clubbing (yes) 609 5.6 0.068 0.89 to 35.94 
* All symptoms are self-reported except digital clubbing; ^ mixed-effects logistic regression; adjusted for 
HIV status and time 
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8Figure 1: Description of the study cohort 
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9Figure 2: Line plots of the trend of lung function over two years (HIV+ n=503, HIV-106 at 
baseline, HIV+472, HIV-96 at 12 months, HIV+435, HIV-94 at 24 months) 
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Variable 
mean (SD) 
Baseline 12 months 24 months 
 LRTI+ 
n=145 
LRTI-
n=329 
P-
value 
LRTI+  
n=134 
LRTI- 
n=312 
P-
value 
LRTI+ 
n=123 
LRTI- 
n=289 
P-
value 
zFEV1 
 
-1.2 
(1.5) 
-0.9 
(1.3) 
0.004 -1.1 
(1.5) 
-0.8 
(1.2) 
0.034 -1.1 
(1.5) 
-0.7 
(1.2) 
0.002 
zFVC -1.3 
(1.4) 
-1.0 
(1.2) 
0.005 -1.0 
(1.5) 
-0.8 
(1.1) 
0.056 -0.9 
(1.3) 
-0.6 
(1.1) 
0.010 
* T-test;  
^missing LRTI data: 29 (5.8%) at baseline, 26 (5.5%) at 12 months, 23 (5.3%) at 24 months; 
LRTI: lower respiratory tract infection 
 
10Figure 3: Lung function at baseline, 12 and 24 months by past severe LRTI status in the 
HIV-infected adolescents 
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11Figure 4: Spirometry pattern by HIV status at baseline, 12 and 24 months 
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28Table 1S: Effect of HIV on lung function (n=609) 
Variable Coefficient P-value 95% CI 
zFEV1 
Time at one year 
 
0.10 
 
0.261 
 
-0.08 to 0.28 
Time at two years 0.16 0.081 -0.02 to 0.34 
HIV -0.52 <0.001 -0.78 to -0.25 
HIV# time at one year -0.03 0.793 -0.22 to 0.17 
HIV#time at two years -0.03 0.764 -0.17 to 0.23 
zFVC    
Time at one year 0.49 <0.001 0.31 to 0.66 
Time at two years 0.54 <0.001 0.36 to 0.72 
HIV -0.25 0.050 -0.50 to 0.00 
HIV#time at one year -0.26 0.009 -0.46 to -0.06 
HIV#time at two year -0.14 0.154 -0.34 to 0.05 
z-FEV1/FVC    
Time at one year -0.93 <0.001 -1.16 to -0.71 
Time at two years -0.91 <0.001 -1.13 to -0.68 
HIV -0.71 <0.001 -0.97 to -0.45 
HIV#time at one year 0.56 <0.001 0.32 to 0.81 
HIV#time at two year 0.40 0.002 0.15 to 0.65 
^ Random intercept mixed-effect model, adjusted for time and the effect of interaction (#) between time 
and HIV status; z-score derived from GLI 2012 African-American reference 
FVC: forced vital capacity, FEV1: forced expiratory volume in 1 second;  
 
 
29Table 2S: Comparison of spirometry patterns by HIV status at baseline,12 and 24 months 
Spirometry Baseline 12 months 24 months 
pattern 
n (%) 
HIV+ 
n=503 
HIV-
n=106 
P-
value 
HIV+ 
n=472 
HIV-
n=96 
P-
value 
HIV+ 
n=435 
HIV-
n=94 
P-
value* 
Obstructive  24 (4.8) 4 (3.8) 0.656 33 (7.0) 6 (6.2) 0.793 35 (8.1) 6 (6.4) 0.584 
Restrictive  118 (23.5) 24 (22.6) 0.856 74 (15.7) 2 (2.1) <0.001 61 (14.0) 6 (6.4) 0.043 
Mixed  25 (5.0) 0 0.019 28 (5.9) 1 (1.0) 0.047 26 (6.0) 0  0.015 
Normal  336 (66.8) 78 (73.6) 0.174 337 (71.4) 87 (89.7) <0.001 313 (72.0) 82 (87.2) 0.002 
* Chi square test; HIV: human immunodeficiency virus 
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30Table 3S: Determinants of bronchodilator positivity over 24 months (n=538) 
Variable Odds ratio 95% CI P value^ 
Age, years 1.05 0.86 to 1.27 0.645 
Height, cm 1.00 0.97 to 1.03 0.959 
Time at 12 months 0.52 0.32 to 0.84 0.007 
Time at 24 months 0.27 0.15 to 0.50 <0.001 
HIV status (infected) 1.46 0.60 to 3.52 0.402 
Sex (male) 1.11 0.69 to 1.79 0.666 
History of wheeze ever (yes) 1.70 0.86 to 3.38 0.130 
History of doctor diagnosed asthma (yes) 1.96 1.02 to 3.77 0.043 
History of cough on most days (yes) 1.30 0.72 to 2.33 0.389 
History of past LRTI requiring hospitalisation 1.72 1.02 to 2.91 0.042 
History of past PTB  1.15 0.68 to 1.93 0.598 
* Mixed-effects logistic regression  
LRTI: lower respiratory tract infection; PTB: pulmonary tuberculosis  
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31Table 4Sa: Associations of z-FEV1 at two years  
Variable  Univariate Multivariate 
 n Coefficient 95% CI P-value Coefficient 95% CI P-value^ 
HIV status 515 -0.50 -0.76 to -0.23 <0.001 -0.12 -0.46 to 0.23 0.510 
Time at 12 months 515 0.07 -0.01 to 0.14 0.086 0.04 -0.04 to 0.13 0.296 
Time at 24 months 515 0.18 0.10 to 0.25 <0.001 0.17 0.08 to 0.25 <0.001 
Smoke exposure 515 0.01 -0.14 to 0.11 0.818 -0.01 -0.13 to 0.12 0.931 
Previous PTB 504 -0.41 -0.61 to -0.20 <0.001 -0.27 -0.50 to -0.03 0.024 
Previous LRTI 463 -0.47 -0.71 to -0.23 <0.001 -0.37 -0.62 to -0.13 0.003 
^ linear mixed models 
FEV1: forced expiratory volume in 1 second; PTB: pulmonary tuberculosis; LRTI: lower respiratory tract infection 
 
32Table 4Sb: Associations of z-FVC over two years 
Variable  Univariate Multivariate 
 n Coefficient 95% CI P-value Coefficient 95% CI P-value^ 
HIV status 515 -0.34 -0.59 to -0.09 0.007 0.01 -0.31 to 0.33 0.946 
Time at 12 months 515 0.26 0.18 to 0.34 <0.001 0.25 0.17 to 0.33 <0.001 
Time at 24 months 515 0. 42 0.34 to 0.49 <0.001 0.41 0.33 to 0.50 <0.001 
Smoke exposure 515 0.02 -0.11 to 0.14 0.795 0.08 -0.04 to 0.21 0.192 
Previous PTB 504 -0.35 -0.54 to -0.15 <0.001 -0.27 -0.49 to -0.05 0.015 
Previous LRTI 463 -0.37 -0.60 to -0.15 <0.001 -0.30 -0.53 to -0.06 0.013 
^linear mixed models 
FVC: forced vital capacity; CI: confidence interval; PTB: pulmonary tuberculosis; LRTI: lower respiratory tract infection 
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33Table 5S: Spirometry outcomes at baseline, 12 and 24 months by category of age at 
antiretroviral therapy initiation  
ART initiated before age 3 years ART initiated after age 3 years  
Baseline  n mean  n mean P value 
z-FEV1 185 -0.9  309 -1.0 0.347 
z-FVC 185 -1.1  309 -1.1 0.837 
z-FEV1/FVC 185 0.4  309 0.1 0.053 
12 months       
z-FEV1 173 -0.8  290 -1.0 0.115 
z-FVC 173 -0.8  290 -0.9 0.206 
z-FEV1/FVC 173 -0.1  290 -0.2 0.497 
24 months       
z-FEV1 158 -0.8  268 -0.9 0.422 
z-FVC 158 -0.6  268 -0.8 0.279 
z-FEV1/FVC 158 -0.3  268 -0.3 0.767 
FEV1 forced expiratory volume in 1 sec; FVC forced vital capacity; z-scores from GLI 2012 African-American 
reference; ART antiretroviral therapy 
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12Figure 1S: Directed Acyclic Graph to determine minimum covariates in the model 
 
13Figure 2S: Trend of lung function (z-FEV1/FVC) over two years 
FEV1 forced expiratory volume in 1 sec; FVC forced vital capacity; z-scores from GLI 2012 African-
American reference 
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14Figure 3S: Z-FEV1/FVC by past severe LRTI status 
FEV1 forced expiratory volume in 1 sec; FVC forced vital capacity; z-scores from GLI 2012 African-
American reference, LRTI lower respiratory tract infection, lb lower 95% confidence interval, ub 
upper 95% confidence interval 
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15Figure 4S: Trend of z-FEV1, z-FVC and z-FEV1/FVC over 2 months by age category at ART 
initiation 
FEV1 forced expiratory volume in 1 sec; FVC forced vital capacity; z-scores from GLI 2012 African-
American reference; lb lower 95% confidence interval, ub upper 95% confidence interval 
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Chapter 6:  
Summary and Recommendations 
6.1 Summary 
In this study, we investigated the spectrum and determinants of lung function in perinatally 
HIV-infected adolescents on antiretroviral therapy (ART) including longitudinal changes. 
The following key findings were reported: - 
1. HIV-infected adolescents, well established on ART had lower lung function (volume, 
flow, compliance and diffusion capacity) and increased airway resistance and lung 
clearance index at baseline compared to HIV-uninfected adolescents. The low lung 
function could have been caused by the impact of HIV and opportunistic infections. 
Further, stunted growth may have contributed to low lung volumes due to 
suboptimal lung growth as HIV-infected adolescents were shorter than HIV-infected 
at all time points. 
2. Spirometry outcomes tracked over two years. Z-FEV1, z-FVC and z-FEV1/FVC tracked 
lower over two years in HIV-infected adolescents compared to the uninfected. This 
may have been attributable to the early effect of HIV or opportunistic infections on 
the developing lung. Adolescents who had ART initiated before 3 years of age had 
higher z-FVC, Z-FEV1 and z-FEV1/FVC over time compared to those who had ART 
initiated above 3 years. Further, those who began ART before 3 years of age had 
significantly lower rates of history of severe LRTI compared to those who began ART 
after 3 years. This emphasises the need for early initiation of ART to optimise lung 
health. Furthermore, it highlights the need for lung function surveillance in children 
and adolescents with HIV to diagnose cases of early COPD or accelerated decline in 
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lung function after the period of physiological lung growth in early childhood up to 
early adulthood. 
3. A lower rate of bronchodilator responsiveness was reported in the HIV-infected 
adolescents at two years (6.4%) compared to baseline (16.4%), supporting the 
development of irreversible airway obstruction; this has been reported in similar 
cohorts in sub-Saharan Africa. [1-4] In previous studies, [2, 3] mosaic attenuation 
on chest computed tomography (CT) scan was reported, most likely caused by post-
infectious bronchiolitis obliterans, as the predominant finding, which is 
characterised by irreversible lower airway obstruction.  
4. There was no difference in six-minute walk test outcomes between HIV-infected 
adolescents on ART and the HIV-uninfected participants, probably reflecting that 
the HIV-infected cohort in our study was generally well and showing the impact of 
ART on preserving exercise tolerance, or cardiopulmonary function in general. 
Published studies with high rates of exercise intolerance were done in cohorts not 
established on ART. [5, 6]  
5. Participants reported minimal chronic respiratory symptoms in our study cohort, 
compared to other similar age cohorts in sub-Saharan Africa, [1-2, 7] probably 
because participants under-reported symptoms. However, this may be on account 
of a more severe spectrum of chronic lung disease and lung function in the other 
cohorts who were not established on ART. These differences may also be as a result 
of cohort selection; our cohort had a mean ART duration of nine years, with ART 
initiated on average by the age of five years, in comparison to the other cohorts 
whose ART duration ranged from a few months to six years and age of ART initiation 
was in later childhood, affirming the importance of early initiation of ART.  
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6. Although lung function was lower in our HIV-infected adolescents than HIV-
negative matched controls at enrolment, HIV-infected adolescents lung function 
was still within normal limits, unlike other adolescent cohorts that reported a higher 
rate of respiratory symptoms and impaired lung function. More than 65% of HIV-
infected adolescents in our study cohort had a normal spirometry pattern at 
baseline, 12 and 24 months. Again, this reflects that our participants were generally 
well and had a long duration on ART. 
7. Previous PTB and previous hospitalisation for LRTI were common in HIV-infected 
adolescents and were associated with lower lung function. High rates of PTB and 
LRTIs have also been reported in HIV-infected children and adolescents. [1, 2] This 
highlights the impact of early LRTI and PTB on the developing lung and the need to 
strengthen prevention strategies. 
8. Lower respiratory tract infection requiring hospitalisation was associated with 
increased lung clearance index (LCI) and low diffusion capacity for carbon monoxide 
(DLCO); showing the impact of HIV and LRTI on small airways and alveolar-capillary 
interface. 
9. Impaired cardiopulmonary function was detected in 13% of HIV-infected 
adolescents and 8% of HIV-uninfected adolescents, p=0.136. The lack of reference 
values for cardiac function assessment in African population may have 
overestimated the cardiopulmonary dysfunction. Previous severe LRTI and body 
mass index were predictors of impaired cardiopulmonary function. 
6.2 Strengths and limitations 
Study strengths include a large cohort of HIV-infected adolescents well established on ART, 
and with high cohort retention and close follow-up. We also included an age-matched 
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comparator group of HIV-uninfected adolescents. Further, comprehensive lung function 
testing including diffusion capacity testing, compliance and resistance testing with forced 
oscillation technique, six-minute walk test, volume measurements with nitrogen multiple 
breath washout tests and spirometry and bronchodilator testing, were used to describe the 
spectrum of lung function patterns. Longitudinal measurement of lung function over two 
years also strengthened the study by showing the trajectory of lung function in HIV-infected 
adolescents. in this study population, we highlighted areas to prevent and manage lung 
disease. 
Limitations include that these findings may not be generalisable in populations with low 
ART coverage, however, ART coverage is increasing globally and in Africa. [8] Other study 
limitations include that smoking data was self-reported rather than a quantitive 
measurement of nicotine. This may have underestimated the impact of passive and active 
smoking on lung function in our cohort. Respiratory symptoms were also self-reported, 
hence recall bias may have been a factor, but the same question was repeated in 
subsequent visits. Computed tomography chest scans were not done on all participants to 
limit cost and radiation exposure; thus, this study does not show the structural pathology 
associated with impaired lung function in HIV-infected adolescents. Further, 
cardiopulmonary function testing using independent assessment of lung and cardiac 
function by spirometry, six-minute walk test and echocardiography may not have been as 
sensitive as a combined measure of cardiopulmonary function such as formal 
cardiopulmonary exercise testing that would measure oxygen consumption and carbon 
dioxide excretion by sampling inspired and expired gas during exercise. [9] This however is 
expensive and not widely available.  
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6.3 Recommendations 
1. Longer studies continuing through late adulthood are needed to characterise the 
progression of lung function in HIV-infected adolescents. Such longitudinal studies 
would investigate the impact of lower lung function in HIV-infected adolescents on 
respiratory health into adulthood and would also delineate if accelerated decline of 
airflow and volume or COPD occurs earlier in this population compared to the 
uninfected population. 
2. Longitudinal studies involving HIV-exposed uninfected children, HIV-infected children 
on ART and HIV-unexposed uninfected children are needed to delineate the impact of 
HIV prenatally on the lung. With the scaling up of prevention of mother to child 
treatment (PMTCT) programmes and the increasing population of HIV-exposed 
uninfected children, these are likely to be important studies with the three comparator 
groups. 
3. Chest CT, lung biopsy and histopathology of lung specimens would be useful to better 
understand the pathology of low lung function phenotype in HIV-infected adolescents 
on ART. Studies on lung microbiome in HIV-infected and uninfected adolescents are 
needed to delineate the effect of airway colonisation by microbes on lung function. 
4. Longitudinal use of lung function spanning to adulthood may offer an objective 
measure of lung health in HIV-infected adolescents and identify abnormalities that 
may be amenable to treatment. 
5. Cardiac magnetic resonance imaging (MRI) may provide a more sensitive assessment 
for right ventricle function and pulmonary hypertension than echocardiography. 
Similarly, arterial gas analysis and cardiac output index measurement and 
cardiopulmonary exercise technology may better assess cardiopulmonary function. 
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6. Public health interventions to prevent PTB or LRTI such as immunisation or 
antimicrobial prophylaxis and promoting optimal nutrition may be important 
interventions to prevent development of low lung function or preserve lung function 
in HIV-infected children and adolescents. Such practices would include cotrimoxazole 
and isoniazid prophylaxis, avoidance of passive or active tobacco smoke, better 
nutrition and accessible quality health care for pregnant mothers and children. In 
addition, optimising childhood immunisation and specific immunisation strategies for 
HIV-infected adolescents (such as booster pneumococcal conjugate vaccine) need 
further study. All these strategies must be strengthened for HIV-infected children and 
adolescents.  
7. With the increasing population of perinatally HIV-infected children surviving into 
adolescence, health systems to provide integrated care to this vulnerable group must 
be strengthened to provide comprehensive care beginning from early infancy. 
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APPENDICES 
Appendix 1: Respiratory Questionnaire  
(Please ask the participant) 
PAST RESPIRATORY ILLNESS 
1. Has any doctor, nurse or caregiver EVER told you that you have any of the following: 
 Chest infection/pneumonia 
 Bronchitis 
 Asthma 
 TB 
 None of the above 
2. How many times in the past 12 months have you been admitted to hospital with a chest 
infection? 
 (write in number) 
3. How many times in the past 12 months have you been treated at your clinic for a chest 
infection? 
 (write in number) 
 
WHEEZE AND TIGHTNESS IN CHEST 
1. Have you ever had a whistling or wheezing noise in the chest at 
any time in the past? 
Yes 
No (if no, skip to Q 6) 
2. Have you had wheezing or whistling in the chest in the past 12 
months? 
Yes 
No (if no, skip to Q 6) 
3. How many attacks of wheezing have you had in the past 12 
months? 
None 
1 to 3 
4 to 12 
More than 12 
4. In the past 12 months, how often, on average, has your sleep 
been disturbed due to wheezing? 
Never 
Less than 1 night per 
week 
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One or more nights 
per week 
5. In the past 12 months, has wheezing ever been severe enough 
to limit your speech to only one or two words at a time 
between breaths? 
Yes 
No 
6. Have you ever had asthma? Yes 
No 
7. In the past 12 months, has your chest sounded wheezy during 
or after exercise? 
Yes 
No 
8. In the past 12 months, have you had a dry cough at night, apart 
from a cough associated with a cold or chest infection? 
Yes 
No 
 
ALL QUESTIONS ARE ABOUT PROBLEMS WHEN YOU DO NOT HAVE A COLD OR FLU 
9. Have you ever had a problem with sneezing, or a runny, or 
blocked nose when you DID NOT have a cold or the flu? 
Yes 
No (if no, skip to Q 14) 
10. In the past 12 months, have you had a problem with 
sneezing, or a runny, or blocked nose when you DID NOT 
have a cold or the flu? 
Yes 
No (if no, skip to Q 14) 
11. In the past 12 months, has this nose problem been 
accompanied by itchy-watery eyes? 
Yes 
No 
12. In which of the past 12 months did this nose problem 
occur? (Please tick any which apply) 
 
January        February 
March           April 
May              June 
July               August 
September    October 
November     December 
13. In the past 12 months, how much did this nose problem 
interfere with your daily activities? 
Not at all 
A little 
A moderate amount 
A lot 
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ALLERGY SYMPTOMS 
14. Have you ever had hay fever? Yes 
No 
15. Have you ever had an itchy rash which was coming 
and going for at least six months? 
Yes 
No(if no, skip to Q20) 
16. Have you had this itchy rash at any time in the past 
12 months? 
Yes 
No(if no, skip to Q20) 
17. Has this itchy rash at any time affected any of the 
following places: 
the folds of the elbows, behind the knees, in front of 
the ankles, under the buttocks, or around the neck, 
ears or eyes? 
Yes 
No 
18. Has this rash cleared completely at any time during 
the past 12 months? 
Yes 
No 
19. In the past 12 months, how often, on average, have 
you been kept awake at night by this itchy rash? 
Never 
Less than 1 night per week 
One or more nights per week 
20. Have you ever had eczema? 
 
Yes 
No 
 
SHORTNESS OF BREATH 
21. Have you ever had an attack of shortness of breath 
when you were at rest? 
 Yes 
 No (if no, skip to Q25) 
22. If Yes, has this occurred in the last 12 months?  Yes 
 No 
23. Are you more short of breath when exercising 
compared to other people your age? 
 Yes 
 No 
24. How many times a week do you do enough exercise 
or physical effort to make you breathe hard? 
Never or occasionally 
Once or twice per week 
 Three or more times per week 
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COUGH AND PHLEGM 
25. Do you currently have a cough on most days?  Yes 
 No (if no, skip to Q29) 
26. When you cough, do you usually bring up phlegm from your 
chest? 
 Yes 
 No (if no, skip to Q29) 
27. Have you brought up phlegm every day for at least three 
months during the last year? 
 Yes 
 No (if no, skip to Q29) 
28. How many years have you brought up phlegm in this way?  
Years: ____________ 
29. Have you been woken by an attack of coughing in the last 12 
months? 
 Yes 
 No 
30. Do you usually cough when you get up in the morning?  Yes 
 No (if no, skip to Q33) 
31. If Yes, does this occur on most mornings for at least three 
months in a row each year? 
 Yes 
 No 
32. Do you easily bring up phlegm from your chest when you 
get up in the morning? 
 Yes 
 No 
33. Have you been woken by an attack of coughing when you 
did not have a cold in the last 12 months? 
 Yes 
 No 
34. Have you ever coughed up blood?  Yes 
 No (if no, skip to Q37) 
35. If Yes, how much blood did you cough up?  More than a cup 
 Teaspoon 
 Speckles of blood  
 Not sure 
36. If Yes, when last did you cough up blood?  Within the last week 
 Within the last month 
 Within the last year 
 More than a year ago 
 Can’t remember 
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BREATHING 
37. Do you ever have trouble breathing?  Yes 
 No (if no, skip to Q43) 
38. If Yes, how often do you have this trouble?  Continuously (your 
breathing is never quite right) 
 Repeatedly (but it always 
gets completely better between 
episodes) 
 Rarely (less than once a 
month) 
39. Are you troubled by shortness of breath when walking 
fast or walking up a hill? 
 Yes 
 No 
40. Have you ever been troubled by coughing a lot when 
you run or just after you have stopped running? 
 Yes 
 No 
41. Does cold air make you cough a lot?  Yes 
 No 
42. Do you sometimes cough in bed at night when you do 
not have a cold? 
 Yes 
 No 
43. Does anyone ever complain that you snore at night?  Yes 
 No 
44. If Yes, how often does this happen?  Most night 
 Some nights 
 Hardly ever 
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Appendix 2: Human Research Ethics Committee, University of Cape Town (REC Ref: 
051/2013) 
signature
removed
149 
signature removed
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Appendix 3: Consent Form 
Parent /Legal Guardian/Caregiver Information Sheet and Consent Form  
Cape Town Adolescent Antiretroviral Cohort (CTAAC) 
Your child is being invited to take part in this clinical research study because he/she is an 
HIV-infected adolescent receiving antiretroviral therapy (ART). This study that is being 
done at Red Cross Children’s Hospital in the School of Child and Adolescent Health, 
University of Cape Town. Before you decide if you want to be a part of this study, we 
want you and your child to know more about the study.  
 
This form gives you information about your child’s participation in this study. The 
research staff will talk with you and your child about this information. You are free to ask 
questions about this study and discuss any concerns with the staff. If you agree to take 
part in this study, you will be asked to sign this consent form and your child may be asked 
to sign a separate assent form. You will be given copies of these forms. 
 
WHY IS THIS STUDY BEING DONE? 
We want to know how the Human Immunodeficiency Virus (HIV) and antiretroviral 
therapy (ART) affect HIV-infected adolescents over time. The study will take place over 3 
years during which we will follow-up your child and monitor his/her health.  At any time 
during this study, if we find that your child has a specific health issue that needs 
treatment (such as tuberculosis, TB); we will refer you to an appropriate health facility for 
treatment and care. 
 
WHO CAN TAKE PART IN THE STUDY? 
To participate, adolescents must be between the ages of 9 and 14 years, and must have 
been on ART for at least 6 months and must live in Cape Town. Approximately 600 
adolescents will take part in this study. 
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WHAT DO I HAVE TO DO IF I TAKE PART? 
Your child will need to attend study visits held at Red Cross War Memorial Children’s 
Hospital every 6 months for the next 3 years.  
 
Enrolment and annual (yearly) visits 
The first study visit at Red Cross War Memorial Children’s Hospital will last 4-5 hours. At 
the first visit and once a year, your child will be asked to undergo the following 
measurements: 
 
1. You and your child will be asked to complete a questionnaire. The questionnaire 
asks about personal and family circumstances, medical history, HIV treatment 
history, and other aspects of health, both in the past and at present. 
 
2. Your child will be asked to undergo a clinical examination. A study doctor or nurse 
will examine your child, lasting 10 minutes approximately, to assess his/her 
general health. This is similar to an examination whenever your child goes to the 
clinic. 
 
3. Your child will be asked to give blood. We will collect about 15 milliliters (3 
teaspoons) of blood once a year. This blood will be used to test for HIV in the body 
(viral load), the body’s response to HIV infection (CD4 cell count), the fats in the 
blood (lipogram), the body’s degree of health or general inflammation (Full blood 
count, Liver and Kidney function, C-reactive protein, Calcium, Magnesium 
Phosphate, Albumin), TB infection and autoantibodies like ANA, anti-cardiolipin 
antibody and anti-dsDNA.  Antibodies are made by the body to help fight 
infection.  Sometimes rather than fighting infection these antibodies attack the 
body and are called autoantibodies. There are specific autoantibodies that cause 
specific diseases like Lupus.  It is possible to have these autoantibodies even 
before one gets sick with a disease and these antibodies can sometimes be 
present without actually causing any disease. If permission is given some of this 
blood may be stored for future tests and studies. 
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4. Your child will be asked to undergo echocardiography. This is a video of the child’s 
heart. This video is called an echocardiogram or “echo”. For this, we will put some 
gel and a probe on your child’s chest. The doctor will see your child’s heart move 
on a screen. A short video of this movement will be recorded. We will also check 
your heart rate and rhythm (the way in which your heart is beating). We will also 
look at the arteries in your child’s neck to see if they are harder or thicker than 
usual. This will take less than 5 minutes. We will only do this test at the first visit, 
at the two year visit and the last study visit. 
 
5. Your child will be asked to undergo endothelial pulse amplitude tonometry (Endo-
PAT). This is a painless procedure very similar to having blood pressure measured, 
using a special machine. This will measure the thickness of your child’s veins and 
how easily the blood flows through the veins. This test will be done at the first visit 
and then yearly. 
 
6. Your child will be asked to have a chest x-ray. This is a painless procedure to take a 
picture of your child’s lungs. This helps to check if your child has a lung problem 
which needs treatment. An X-ray will be done at the first visit and yearly. 
 
7. Your child will be asked to provide a urine sample to test for kidney function and 
to test for substances that may affect his/ her health and if permission is given a 
sample will be stored for future testing. Urine will be tested for commonly abused 
drugs and exposure to smoking. If any of these are detected in the urine we will 
inform you and your child of these results, you will both receive counselling and 
you will be referred to the Cape Town Drug Counselling Centre for treatment. 
 
8. Your child will be asked to give us some stool (kaka) that we will collect in a 
container.  The stool (kaka) is being collected so that we can study it to see what it 
is made up of and to see if the medicines your child has taken has any effects on 
the stool (kaka).  This can help us to understand how your child is growing and 
also understand any illnesses that they may have.  To collect the stool, we will put 
a container in the toilet.  Your child will sit on the toilet as they usually do to 
 153 
 
provide the stool.  They will leave it in the bathroom and the study nurse will 
collect it afterwards. 
 
9. Your child will be asked to undergo lung function testing. This involves breathing 
into a special machine to see how the lungs are working. Your child will do 3 
different blowing tests. One test measures inflammation in the lungs and takes 
only 1 or 2 minutes. A second test measures the size of the lungs and how well 
they are working and involves breathing oxygen for the middle part of the test. 
The third test measures the flow of air out of the lungs when your child blows as 
hard and fast as she/he can. If your child cannot blow air well out of their lungs we 
will give your child an asthma medicine (bronchodilator) to open their chest. After 
5 minutes we will repeat the blowing test, to see if this treatment helps your child 
and what kind of lung problem your child might have. 
 
10. Your child will be asked to do a 6 minute walk test to measure their ability to do 
exercise. This involves your child walking back and forth on a flat surface such as a 
hallway for 6 minutes. We will monitor their oxygen level and blood pressure 
before and after the test. 
 
11. Your child may be asked to undergo sputum induction to test for TB and other 
infections. This involves having a nebuliser treatment to open your child’s chest 
and make him / her cough. We will then ask your child to cough some phlegm up 
into a container or suction him/ her to get phlegm if he/ she cannot cough this up. 
The phlegm will be sent to the laboratory for tests for TB and other germs. 
 
12. Your child will be asked to have a nasal swab done. This procedure involves 
putting a small stick with cotton wool at the tip into your child’s nose to collect 
mucus. We will test this for bacteria and infection. 
 
13. Your child will be asked to undergo a bedside ultrasound, it involves putting a little 
bit of gel on your child’s stomach and chest and a probe that will take a video of 
your child’s organs, and this is similar to the ultrasound that is done when you are 
pregnant and is quick and painless.  
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14. Your child will be asked to undergo another ultrasound of the joints with a bit of 
gel and the probe on their knuckles, wrist and the heel of their foot.  It is also 
quick and painless though the gel may be cold. 
 
15. Your child will be asked to have a hearing test done. This involves your child 
putting in earphones and listening to beeping sounds at different volumes and 
telling us when he/she hears the sounds. This will help us to test whether or not 
your child has a hearing problem. This is a quick and painless test. 
 
Six-monthly visits 
Between the yearly study visits your child will be asked to participate in a shorter study 
visit. This visit will last approximately 1-2 hours and will include the following: 
 
1. You and your child will be asked to complete a questionnaire. The questionnaire 
asks about personal and family circumstances, medical history, HIV treatment 
history, and other aspects of health. 
 
2. Your child will be asked to undergo a clinical examination. A study doctor or nurse 
will examine your child, lasting about 10 minutes, to assess his/her general health. 
This is similar to an examination whenever your child goes to the clinic. 
 
We will also ask for permission to look at information from your child’s health care 
records at the clinic he/ she currently attends, and other facilities he/she may have 
attended. We will get information about your child’s past health in the past, including 
whether they attended a clinic or hospital, the treatment received, and laboratory results 
over time. This information is important to help us understand the results of the tests 
done as part of this study. 
 
We are not taking over your child’s routine health care or ART; he/she should still attend 
all their regular follow up visits at your local health facility. We will inform your child’s 
doctor of any abnormal results we may find during the study. 
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We may also ask you to participate in other studies that are related to this research. 
Participation in this additional research will have a separate consent process and another 
form, similar to this one.  
 
WHAT ARE THE RISKS OF TAKING PART IN THE STUDY? 
Some of the questions asked in the questionnaire may make you or your child feel 
uncomfortable; this may include questions on smoking, alcohol and drug use and sexual 
behaviour. Our interviewers are trained in asking sensitive questions and you or your 
child can choose not to answer any questions if you don’t want to. 
 
The clinical examination may make your child feel uncomfortable. The examination will 
be in a private room, and if your child prefers you or another caregiver can be present. 
  
Some of the study measurements are associated with slight discomfort. Specifically: 
1. Blood drawing: Your child will experience discomfort from the needle when blood 
is taken. Where possible this blood test will be done at the same time as other 
blood tests and using an anaesthetic cream to dull the pain from the needle. Only 
a small amount of blood will be taken. 
2. Endo-PAT: This will be similar to having a blood pressure done- that is for 5 
minutes, a tight bandage will be placed on the upper part of both arms while 
measurements are done on the fingers. This is slightly uncomfortable but not 
painful. 
3. Echocardiography: It is not painful, but will need your child to lie still for about 15 
minutes. Gel will be used to help make the pictures clearer and this will be slightly 
cold. 
4. Lung function testing: Lung function testing is not painful. Your child may feel a 
little dizzy for a short time when they blow out hard and fast. All the testing will be 
done by a trained technologist who is experienced in guiding young people in 
these tests. Breathing oxygen feels similar to breathing room air and is safe. 
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5. 6 minute Walk Test: The object of this test is to walk as far as possible in 6minutes. 
This is a painless test but your child may feel short of breath. We will monitor their 
oxygen level and blood pressure before and after the test and if your child feels 
tired they can stop to rest. 
6. Chest X-ray: This is painless but may cause your child some discomfort as it 
requires sitting still for less than 5 minutes. An X-ray will be done at the start and 
at the end of the study, unless your child has an illness for which an X-ray is 
needed. 
7. Induced Sputum: Your child may experience minor side effects such as increased 
coughing, vomiting, wheezing or mild bleeding from the nose. A trained nurse will 
do this in a special room.   
8. Nasal swab: This is a painless procedure but may cause some sneezing that will 
stop quickly. 
9. Bedside ultrasound: The gel might be slightly cold but it won’t hurt. 
 
WHAT ARE THE BENEFITS OF TAKING PART IN THE STUDY? 
Your child’s health will be carefully monitored during the study so any new health 
problems may be picked up early. If we find your child has a problem that needs to be 
treated, we will refer him/her to an appropriate facility. The information we learn 
through this study may help to improve the management of HIV-infected children in the 
future. 
 
WILL I RECEIVE ANY PAYMENT? 
You will receive R80 for the shorter visits and R200 for the longer visits when you and 
your child visit the study to compensate you for transport costs and time associated with 
the study. 
 
CAN I AND/OR MY CHILD REFUSE TO TAKE PART IN THE STUDY? 
If you or your child do not wish to participate, you or your child can refuse now or at any 
time in the future. Your child may also refuse to participate despite you having given 
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consent for him/her participation. Even if you and your child decide not to take part, your 
child will receive the same health care, including ART, through your local health facility.  
 
CONFIDENTIALITY 
Every effort will be made to ensure that your child’s information is protected. The study 
team will keep your child’s study information confidential. Your child will be given a study 
number. The questionnaire and study specimens will be labelled with this study number 
and not with his/ her name. As a participant in this study it is very important to be able to 
contact you and therefore we will need to collect detailed tracing information like your 
address and at least two phone numbers where we might get hold of you. Please take 
note that even when contacting friends or neighbours we will never give them the reason 
that we are looking for you. 
 
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
 
If you have any questions about this study you may ask the study staff or you may 
contact: 
 
Professor Heather Zar at (021) 658 5111 or the study Medical Officer at (021) 658 5520 
 
If you have any questions about your rights as a research participant, you may contact the 
following member of the Human Research Ethics Committee in the Faculty of Health 
Sciences at the University of Cape Town: 
 
Prof Marc Blockman at (021) 406 6338 
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STORAGE OF SAMPLES 
 
If any of the blood, sputum, nasal swabs or urine samples my child has provided for this 
research project are unused or leftover when the project is completed  
 
􀂆 I give my permission for my child’s samples to be stored indefinitely and used in future 
research of any type which has been properly approved by the Human Research Ethics 
Committee including genetic testing and other research. 
 
􀂆 I give permission for my child’s samples to be stored indefinitely and used in future 
research but only for research on HIV. 
 
􀂆 I give permission for my child’s samples to be stored indefinitely and used in future 
research except for research about _______________________________________.  
 
OR       􀂆 I wish for my child’s samples to be destroyed immediately.  
 
I have read this consent form (or have had it explained to me), all my questions have been 
answered, and I agree for my child to take part in this study. 
 
___________________________ ________________________DD/MMM/YYYY at - -H - - 
Parent/Legal Guardian/Caregiver          Parent/Legal Guardian/Caregiver       Date and Time 
(Print)                                                 signature/Thumbprint)  
 
___________________    _______________________                 DD/MMM/YYY at - -H- -        
Study Staff (Print)          Study Staff’s Signature                              Date and Time 
 
Please complete the Witness page if the participant’s Parent/Legal Guardian/Caregiver is 
unable to read or write. 
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________________________      ___________________                DD/MMM/YYYY at - -H- -           
Witness’ Name (Print)                        Witness’ Signature                                     Date and Time                   
   
Participant Enrolment number: _________________ 
 
Please complete the following: 
􀂆 The caregiver of this child confirms that the biological mother / father (please circle) of this 
child is alive but does not take ANY responsibility for the care of or decision-making for this 
child.  
 
  Not applicable - neither of the child’s biological parents are alive. 
 
  Not applicable - the child’s biological parent signed consent. 
 
Parent / Legal Guardian/ Caregiver Information Sheet and Consent Form  
HIV negative controls 
Lung function sub-study of Cape Town Adolescent Antiretroviral Cohort 
 
Your child is being invited to take part in a clinical research study that is being done at Red 
Cross Children’s Hospital in the School of Child and Adolescent Health, University of Cape 
Town. Before you decide if you want to be a part of this study, we want you and your 
child to know more about the study.  
 
This form gives you information about your child’s participation in this study. The 
research staff will talk with you and your child about this information. You are free to ask 
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questions about this study and discuss any concerns with the staff. If you agree to take 
part in this study, you will be asked to sign this consent form and your child may be asked 
to sign a separate assent form. You will be given copies of these forms. 
WHY IS THIS STUDY BEING DONE? 
We want to know how the Human Immunodeficiency Virus (HIV) and antiretroviral 
therapy (ART) affect HIV-infected adolescents over time. When collecting this type of 
information about HIV, it is important to compare the findings of the HIV positive group 
with a control group that are HIV negative, like your child. The study will take place over 3 
years during which we will follow-up your child and monitor his/her health.  At any time 
during this study, if we find that your child has a specific health issue that needs 
treatment (such as tuberculosis, TB); we will refer you to an appropriate health facility for 
treatment and care. 
WHO MAY TAKE PART IN THIS STUDY? 
You may participate in this study if your child is between the ages of 9 and 14years old, 
HIV negative and living in Cape Town. Approximately 600 adolescents will take part in this 
study. 
HIV testing procedure: 
Since your child is a HIV negative participant in this study, with your permission we 
would like to do a simple HIV screening test to make sure we are comparing data from 
HIV positive children to HIV negative children like your child. It is also important for you 
and your child to know your HIV status to ensure early treatment if you test positive. This 
test will be done at your first study visit, prior to doing any other investigations. 
If your child is confirmed HIV negative, he/she will be enrolled into this study with your 
permission as parent/legal guardian/ caregiver. If as a result of your participation in this 
research study your child is initially diagnosed as positive, the results will be given to your 
child privately if your child is older than 12 years; they may choose to share this result 
with you. If your child is less than 12 years, the results will be revealed to you. Your child 
will then be referred by the study doctor to the appropriate health facility for immediate 
counselling and appropriate treatment. 
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Having an HIV test done can cause feelings of anxiety and worry. These kinds of feelings 
are normal. We will take every step possible to ensure that you are comfortable with 
having your child take the HIV test. We will perform an HIV rapid test, which will require 
your child to have a finger prick for a drop of blood. The test results are immediately 
available. 
 As part of this procedure, you and your child will be counselled both prior to taking the 
test and afterwards, regardless of the test outcome.  
If your child has already had a recent HIV test, he/she will not need to redo the test to 
participate in this study, but with your permission, we will have to get this information 
from the clinic at which he/she was tested. 
WHAT DO I HAVE TO DO IF I TAKE PART? 
Your child will need to attend study visits at Red Cross War Memorial Children’s Hospital 
every 6 months for the next 3 years.  
Enrolment and annual (yearly) visits 
The first study visit at Red Cross War Memorial Children’s Hospital will last 4-5 hours. At 
the first visit (enrolment) and once a year, your child will be asked to undergo the 
following measurements: 
16. You and your child will be asked to complete a questionnaire. The questionnaire 
asks about personal and family circumstances, medical history, and other aspects 
of health, both in the past and at present. 
17. Your child will be asked to undergo a clinical examination. A study doctor or nurse 
will examine your child, lasting 10 minutes approximately, to assess his/her 
general health. This is similar to an examination whenever your child goes to the 
clinic. 
18. Your child will be asked to give blood. We will collect about 15 millilitres (3 
teaspoons) of blood once a year. This blood will be used to test for the body’s 
degree of health or general inflammation (Full blood count).  
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19. Your child will be asked to undergo echocardiography. This is a video of the child’s 
heart. This video is called an echocardiogram or “echo”. For this, we will put some 
gel and a probe on your child’s chest. The doctor will see your heart move on a 
screen. A short video of this movement will be recorded. We will also check your 
heart rate and rhythm (the way in which your heart is beating). We will also look 
at the arteries in your child’s neck to see if they are harder or thicker than usual. 
This will take less than 5 minutes. We will only do this test at the first visit, at the 
two year visit and the last study visit. 
20. Your child will be asked to have a chest x-ray. This is a painless procedure that involves 
taking a picture of your child’s lungs.  This helps to check if your child has a lung problem 
which needs treatment. An X-ray will be done at the start of the study and  and yearly. 
 
21. Your child will be asked to undergo lung function testing. This involves breathing into a 
special machine to see how the lungs are working. Your child will do 3 different blowing 
tests. One test measures inflammation in the lungs and takes only 1 or 2 minutes. A 
second test measures the size of the lungs and how well they are working and involves 
breathing oxygen for the middle part of the test. The third test measures the flow of air 
out of the lungs when your child blows as hard and fast as she/he can. If your child cannot 
blow air well out of their lungs we will give your child an asthma medicine 
(bronchodilator) to open their chest. After 5 minutes we will repeat the blowing test, to 
see if this treatment helps your child and what kind of lung problem your child might 
have. 
22. Your child will be asked to do a 6 minute walk test to measure their ability to do 
exercise. This involves your child walking back and forth on a flat surface such as a 
hallway for 6 minutes. We will monitor their oxygen level and blood pressure 
before and after the test. 
 
Six- monthly visits 
Between the yearly study visits your child will be asked to participate in a shorter study 
visit. This visit will last approximately 1-2 hours and will include the following: 
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3. You and your child will be asked to complete a questionnaire. The questionnaire 
asks about personal and family circumstances, medical history, and other aspects 
of health. 
4. Your child will be asked to undergo a clinical examination. A study doctor or nurse 
will examine your child, lasting about 10 minutes, to assess his/her general health. 
This is similar to an examination whenever your child goes to the clinic. 
We will also ask for permission to look at information from your child’s health care 
records at the clinic he/ she currently attends, and other facilities he/she may have 
attended. We will get information about your child’s past health, including whether they 
attended a clinic or hospital, the treatment received, and laboratory results over time. 
This information is important to help us understand the results of the tests done as part 
of this study. 
We are not taking over your child’s routine health care; he/she should still attend all their 
regular follow up visits at your local health facility. We will inform your child’s doctor of 
any abnormal results we may find during the study. 
 
We may also ask you to participate in other studies that are related to this research. 
Participation in this additional research will have a separate consent process and another 
form, similar to this one. 
WHAT ARE THE RISKS OF TAKING PART IN THE STUDY? 
Some of the questions asked in the questionnaire may make you or your child feel 
uncomfortable; this may include questions on smoking. Our interviewers are trained in 
asking sensitive questions and you or your child can choose not to answer any questions if 
you don’t want to. 
The clinical examination may make your child feel uncomfortable. The examination will 
be in a private room, and if your child prefers you or another caregiver can be present. 
 Some of the study measurements are associated with slight discomfort. Specifically: 
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10. Blood drawing: Your child will experience discomfort from the needle when blood 
is taken. Where possible this blood test will be done at the same time as other 
blood tests and using an anaesthetic cream to dull the pain from the needle. Only 
a small amount of blood will be taken. 
11. Echocardiography: It is not painful, but will need your child to lie still for about 15 
minutes. Gel will be used to help make the pictures clearer and this will be slightly 
cold. 
12. Lung function testing: Lung function testing is not painful. Your child may feel a 
little dizzy for a short time when they blow out hard and fast. All the testing will be 
done by a trained technologist who is experienced in guiding young people in 
these tests. Breathing oxygen feels similar to breathing room air and is safe. 
13. 6 minute Walk Test: The object of this test is to walk as far as possible in 6minutes. 
This is a painless test but your child may feel short of breath. We will monitor their 
oxygen level and blood pressure before and after the test and if your child feels 
tired they can stop to rest. 
14. Chest X-ray: This is painless but may cause your child some discomfort as it 
requires sitting still for less than 5 minutes. An X-ray will be done at the start and 
at the end of the study, unless your child has an illness for which an additional X-
ray is needed. 
 
WHAT ARE THE BENEFITS OF TAKING PART IN THE STUDY? 
 Your child’s health will be carefully monitored during the study so any new health 
problems may be picked up early. If we find your child has a problem that needs to be 
treated, we will refer him/her to an appropriate facility. The information we learn 
through this study may help to improve the management of HIV-infected children in the 
future. 
WILL I RECEIVE ANY PAYMENT? 
You will receive R80 for the shorter visits and R200 for the longer visits when you and 
your child come to visit the study to compensate you for transport costs and time 
associated with the study. 
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CAN I AND/OR MY CHILD REFUSE TO TAKE PART IN THE STUDY? 
If you or your child do not wish to participate, you or your child can refuse now or at any 
time in the future. Your child may also refuse to participate despite you having given 
consent for their participation. Regardless of whether or not you and your child 
participate, your child will receive the same health care through your local health facility.  
CONFIDENTIALITY 
Every effort will be made to ensure that your child’s information is protected. The study 
team will keep your child’s study information confidential. Your child will be given a study 
number. The questionnaire and study specimens will be labelled with this study number 
and not with his/ her name. As a participant in this study it is very important to be able to 
contact you and therefore we will need to collect detailed tracing information like your 
address and at least two phone numbers where we might get hold of you. Please take 
note that even when contacting friends or neighbours we will never give them the reason 
that we are looking for you. 
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
If you have any questions about this study you may ask the study staff or you may 
contact: 
 
Professor Heather Zar at (021) 658 5111 or the study Medical Officer at (021) 658 5520 
If you have any questions about your rights as a research participant, you may contact the 
following member of the Human Research Ethics Committee in the Faculty of Health 
Sciences at the University of Cape Town: 
Prof Marc Blockman at (021) 406 6338 
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I have read this consent form (or have had it explained to me), all my questions have been 
answered, and I agree for my child to take part in this study. 
 
__________________________   ______________________      DD/MMM/YYYY at - -H - -
Parent/Legal Guardian/Caregiver        Parent/Legal Guardian/ Caregiver       Date and Time 
(Print)                                                    Signature/Thumbprint 
 
___________________    _______________________            DD/MMM/YYY at - -H- -        
 Study Staff (Print)                Study Staff’s Signature                           Date and Time 
 
Please complete the Witness page if the participant’s Parent/Legal Guardian/Caregiver is 
unable to read or write.  
 
_____________________      ___________________                       DD/MM/YYYY at - -H- -           
Witness’ Name (Print)                  Witness’ Signature                                         Date and Time                   
   
 
 
Participant Enrolment number: _________________ 
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Appendix 4: Lung Function CRF 
 
Study Details 
1 Time arrived (24 hour clock) HH : HH 
2 Time finished (24 hour clock) HH : HH 
3 Date of Birth DD/MMM/YYYY 
4 Height                                            
cm 
5 Weight                                           
kg 
6 Room temperature                                                                
0C 
7 Pressure                                          
hPa 
8 Humidity  % 
8 Position  Sitting 
 Standing 
9 Additional information:  
 
 
Equipment Calibration – EasyOnePro         
Date Time Within 3 % File Reference 
 DD/MMM/YYYY HH : HH  yes  no See Cal Log 
 
Spirometry - Pre 
 
 Test FVC  
FEV1 
 
FEV1/FVC  
 
FEF25-75% 
 
 Time 
 HH : HH 
 
Comments 
 
  
Total number of attempts:  _________________ 
 
 
See attached results for values 
Quality 
 
Comment 
Effort 15  Maximal 
 Submaximal 
16  
Acceptable* 
*meets SOP criteria: start and 
end of test, free from artefact 
17  Yes  
 No 
18  
Repeatable 
<150ml difference best two 
FVC and FEV1 
19  Yes 
 No 
20  
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Bronchodilator 
 Time given  
(24 hour clock) HH : HH 
 Dose of bronchodilator                                                                             
mcg 
Spirometry - Post 
 Test FVC  
FEV1 
 
FEV1/FVC 
 
FEF25-
75% 
 Time 
 HH : HH 
 
Comments 
 
  
Total number of attempts:  _________________ 
 
See attached results for values 
Quality 
 
Comment 
Effort   Maximal 
 Submaximal 
  
Acceptable* 
*meets SOP criteria: start and 
end of test, free from artefact 
  Yes 
 No 
  
Repeatable 
<150ml difference best two 
FVC and FEV1 
  Yes 
 No 
  
 
 
Date CRF completed DD /  MMM  /  YYYY 
Name of person completing CRF  
Signature  
 
CO Diffusion Capacity 
Test DLCO 
[ml/min/mmHg] 
DLadj 
[ml/min/mmHg] 
DLCO/VA (KCO) 
[ml/min/mmHg/L] 
TLC sb  
    Time HH : HH Comments  
Hb (Actual)   
 
Total number of attempts: _______________________________ 
 
Multiple Breath Washout 
Test 
 
FRC litres LCI M0 M1 VT litres 
   Time 
 HH : HH 
Comments  
 
Total number of attempts: _______________________________ 
 
See attached results for values 
